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ABSTRACT 
 
Diabetes mellitus is a metabolic disease characterised by hyperglycaemia resulting from de-
fects in insulin secretion, insulin action, or both. The leaf extract of Leonotis leonurus and its 
active compound marrubiin, have been shown to possess anti-diabetic, antiplatelet, anti-in-
flammatory and anti-coagulation activity. In the present study, the mechanism by which L. 
leonurus and marrubiin exert their anti-diabetic properties, the cross-talk between the periph-
eral tissues and a nano drug delivery system were investigated.  
Marrubiin in the plant extract was effectively quantified by an optimised reversed phase high-
performance liquid chromatography (HPLC) protocol using a pentafluorophenyl (PFP) col-
umn with water and acetonitrile (50:50) as mobile phase, and a flow rate of 1ml/min. The 
chemical structure was determined using liquid chromatography-tandem mass spectroscopy 
LC-MS/MS. Real-time quantitative polymerase chain reaction (RT-qPCR) gene expression of 
selected adipokines and proteins implicated in Type-2 diabetes (T2D) were investigated in 
specific peripheral tissues isolated from an in vivo obese rat model. An in vitro cell culture 
model was used to determine the crosstalk between the peripheral tissues and pancreatic 
(INS-1E) β-cells. Various nanoformulations of L. leonurus extract were prepared and their ef-
fect on cytotoxicity (in Chang liver and INS-1 cells), insulin-mediated glucose uptake (Chang 
liver cells) and insulin secretion (INS-1) were investigated. 
The average yield of marrubiin from the plant extract was 10% (n=3), with a molecular mass 
of 333.20Da and a molecular formula of C20H29O4
+
. Results from the in vivo study showed 
that the L. leonurus extract significantly (p<0.05) enhanced the gene expression of adiponect-
in, peroxisome proliferator-activated receptor gamma (PPAR-γ), glucokinase (GK),  
uncoupling protein-2 (UCP-2) and reduced leptin in adipose tissue, but resistin, glucose 
transporters (GLUT), fatty acid synthase (FAS), insulin receptor substrate -1 (IRS-1) and 
phosphoenolpyruvate carboxykinase (PEPCK) gene expression were not affected. Marrubiin 
decreased gene expression of leptin and resistin, and increased IRS-1 and glucokinase in 
adipose tissue. In liver and muscle tissues, marrubiin and the L. leonurus extract reduced 
gene expression of PPAR-γ, IRS-1, glucokinase and PEPCK. In the in vitro crosstalk study 
(under normoglycaemic and hyperglycaemic conditions), conditioned medium from 3T3-L1 
cells significantly (p<0.01) enhanced insulin secretion. This was not observed in INS-1E cells 
exposed to muscle- and liver-conditioned medium, respectively. The in vitro studies using a 
nanostructured lipid formulation (NLC) of the plant extract was not cytotoxic to either INS-1 
xiii 
 
and Chang liver cells. The NLC formulation significantly (p<0.05) enhanced glucose uptake 
in Chang liver cells and improved chronic insulin release in INS-1 cells (p<0.05).  Based on 
the above findings from the in vivo and in vitro studies, both L. leonurus and marrubiin 
exerted an insulinotropic effect via adipose tissue on pancreatic β-cells.  The findings in the 
in vivo study showed that marrubiin and the L. leonurus extract were employing their major 
anti-diabetic action via the adipose tissue. 
1 
 
1 CHAPTER 1: LITERATURE REVIEW 
1.1 Diabetes prevalence  
Diabetes mellitus is a metabolic disease characterised by hyperglycaemia resulting from de-
fects in insulin secretion, insulin action, or both. Type-1 diabetes (T1D) is immune-mediated 
and accounts for only 5% to 10% of diabetes cases. It is a condition of absolute insulin defici-
ency due to autoimmune destruction of pancreatic β-cells. T2D, on the other hand, accounts 
for 90% to 95% of people with diabetes. In 2011 it was reported that an estimated 285 million 
people worldwide had diabetes, with this figure set to rise to 595 million in the year 2035 or 
roughly 10% of the world population (IDF, 2013). In 2013, 382 million people had diabetes 
and in developing countries, a 69% increase in adult diabetes cases is predicted for the year 
2035 (Guariguata et al., 2014). Unlike in T1D, insulin is produced by the β-cells of the 
pancreas in T2D, but insufficient amounts are produced or the body is unable to utilise the 
insulin provided. This phenomenon is often referred to as insulin resistance and is associated 
with obesity, ageing and inactivity (Donath and Shoelson, 2011; Kahn, 2003). In the early 
stages of the disease, insulin resistance is countered by an increase in pancreatic β-cell mass 
and function (Chang-Chen et al., 2008). Hyperglycaemia develops in patients when insulin 
secretion by β-cells is too low to cause cells to take up glucose. The insulin secretory defect 
involves both an initial decline in the capacity of β-cells to secrete insulin in response to high 
glucose levels, followed by a reduction in β-cell mass (Thorens, 2011). The β-cells respond to 
insulin resistance by increasing their cell mass and insulin secretory activity and failure of the 
β-cell to compensate for this anomaly leads to T2D.  
 
Long-term consequences of T2D include, among others, macrovascular complications (e.g. 
atherosclerosis) and microvascular complications (e.g. retinopathy, neuropathy and nephropa-
thy) (Wilmot and Idris, 2014). It is known, however, that many insulin-resistant individuals 
do not become diabetic because their β-cells are able to compensate for the increased demand 
for insulin. Some major hypothesised mechanisms explaining insulin resistance and β-cell 
dysfunction have been oxidative stress, endoplasmic reticulum (ER) stress, amyloid 
deposition in the pancreas, ectopic lipid deposition in the muscle, liver and pancreas, 
lipotoxicity and glucotoxicity. All these stressful conditions are caused by over-nutrition 
(Donath and Shoelson, 2011; Prentki and Nolan, 2006).  
 
2 
 
A sedentary lifestyle and feeding behaviour with increased access to high-fat diets are known 
to be major causes of the current epidemic of obesity and  early onset T2D, in conjunction 
with rapid social and cultural changes, ageing in populations, urbanisation and dietary 
changes (Wilmot and Idris, 2014). This is accompanied with an increased risk of several 
cancers (pancreatic, hepatic, colorectal, breast, urinary tract and endometrial) observed in 
diabetic patients (Shikata et al., 2013). Thus, interventions that reverse or improve these 
factors have shown to have beneficial effects in the control of T2D. Also, continual 
medication and ongoing patient self-management education are also necessary to reduce the 
risk of further complications (Thorens, 2011; Nathan et al., 2009). The focus of this review 
will be predominantly on T2D as the present study is based on it.  
 
1.1.1 Type-2 diabetes and insulin resistance 
Insulin resistance, in general, occurs when cells fail to respond to the normal action of insulin 
(Lin et al., 2013; Bailey, 1999). It is associated with endothelial dysfunction and a reduced 
insulin delivery across the endothelium (Mather et al., 2013). It is mainly driven by obesity of 
which the total fat present is not important, but rather its distribution (Wilmot and Idris, 
2014). The major site of impaired insulin-stimulated glucose usage is the skeletal muscle, 
which shows a reduction in glucose uptake, glycogenesis and glucose oxidation. Insulin-sti-
mulated glucose uptake is also impaired in adipocytes in T2D  (Groop et al., 1989). The sup-
pression of lipolysis in adipocytes is also observed in T2D patients. Insulin resistance is often 
observed as an early feature in T2D patients (Guillausseau et al., 2008). This is initially com-
pensated for by an increase in insulin concentration so that glucose homœostasis remains nor-
mal. The ability of the insulin-resistant individual to avoid having T2D will depend on the 
ability of the β-cells to adapt to an increase in insulin concentration (Kaiser and Leibowitz, 
2009; Medina-Gomez et al., 2009). At the onset of T2D, insulin resistance is very prominent, 
but hyperglycaemia continues to prevail due to β-cell dysfunction, which eventually leads to 
β-cell death. This can occur in non-obese individuals as well. However, there is a strong cor-
relation that obesity promotes both insulin resistance and hyperglycaemia (Bailey, 1999).  
 
Insulin resistance studies are normally performed in muscle, liver and adipose tissue, where 
insulin exerts its main metabolic action (Olefsky and Glass, 2010). The insulin receptor (IR) 
is structurally normal in T2D; however, the impaired action of insulin in states of insulin re-
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sistance suggests that there is a rate-limiting step that occurs early in the signal transduction 
process before the different pathways are separated (Zhao and Townsend, 2009). Thus, it is 
noted in T2D that there is decreased the activity of phosphatidylinositol 3-kinase (PI3K), 
decreased phosphorylation of IRS-1 (Shibata et al., 2013) and decreased phosphorylation of 
tyrosine kinase activator (TKA) of the IR β-subunit (Bailey, 1999).  
 
The effect of insulin resistance on the cardiovascular system is generally linked indirectly to 
hyperinsulinaemia, dyslipidaemia, glucose intolerance and the atherothrombotic effects 
(Aihara et al., 2010). Vascular smooth muscle and the endothelium possess an insulin signal-
ling system, and insulin causes an acute vasodilatory effect via the IR pathway (Feener and 
King, 1997). 
 
1.1.2 Type 2 diabetes and inflammation  
It has been suggested that T2D is a manifestation of an unending low-grade chronic inflam-
mation (Abdul-Ghani, 2013; Ma et al., 2012; Mazzola, 2012; Donath and Shoelson, 2011). 
Inflammation is defined as a cascade of phenomena induced in response to different patho-
logical stimuli and tissue injury. Elevated levels of interleukin-1β (IL-1β), interleukin-6 (IL-
6) and cytokine reactive protein (CRP) are predictive of T2D  (Wang et al., 2013a; Donath 
and Shoelson, 2011). Markers of inflammation include: low leucocyte count, erythrocyte 
sedimentation rate, interleukin by-products, tumour necrosis factor alpha (TNF-α), CRP, 
fibrinogen and seromucoid  as well as coagulation and kinin cascades (Zozulinska and 
Wierusz-Wysocka, 2006). Inflammatory markers such as IL-6, CRP and TNF-α are 
positively associated with insulin resistance (Yudkin et al., 1999).  
 
Islets from patients with T2D have typical features of inflammation, including the expression 
of cytokines and chemokines, immune cell infiltration, decreased insulin content, β-cell apop-
tosis and fibrosis-containing amyloid polypeptides (Ehses et al., 2007). Hyperglycaemia and 
elevated free fatty acid (FFA) levels activate the inflammasome in β-cells. Assembly of the 
inflammasome activates caspase-1 that cleaves pro-IL-1β into active IL-1β. The cytokine 
then binds to its membrane receptor and activates the transcription factor nuclear factor kappa 
beta (NF-κβ), resulting in the release of a broad array of cytokines, including IL-1β itself, and 
chemokines such as IL-8, followed by recruitment of immune cells including macrophages. 
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This inflammatory process may contribute to defective insulin secretion in patients with T2D. 
However, the immune system may also contribute to β-cell adaptation during periods of in-
creased insulin demand (Donath, 2013).  
 
Hepatic insulin resistance in the onset of obesity is associated with increased expression of 
inflammatory mediators and massive accumulation of intracellular lipid within hepatocytes, 
also known as steatosis (Schenk et al., 2008). The major bone marrow-derived macrophage 
cell type in the liver is the Kupffer cell, which resides in the liver sinusoids and is poised to 
communicate with hepatocytes (Olefsky and Glass, 2010). They contribute to the production 
of inflammatory mediators that promote insulin resistance in hepatocytes. In high-fat diet- 
(HFD)-induced obesity, increased macrophage accumulation occurs in skeletal muscle. These 
macrophages are primarily localised to the intermuscular adipose depots, which accumulate 
within skeletal muscle in obesity (Olefsky and Glass, 2010).  
 
1.1.2.1 Tumour necrosis factor alpha 
TNF-α is released by adipose tissue and macrophages and its circulating plasma level is in-
creased in obesity, insulin resistance, hypertension and T2D (Olefsky and Glass, 2010). It is a 
pro-inflammatory cytokine which has a major role in down-stream signal transduction cas-
cades that affect insulin signalling. High circulating levels of TNF-α in obesity has been asso-
ciated with the pathogenesis of insulin resistance (Dunmore and Brown, 2013; Boni-
Schnetzler and Donath, 2011). Neutralisation of TNF-α in obese rodents improves insulin 
sensitivity (Hotamisligil et al., 1995). In the early stage of the disease, macrophages and 
lymphocytes infiltrate into islets and secrete cytokines such as TNF-α, IL1-β and IL-6, 
resulting in high concentrations within the islets. Chronic exposure of the cytokines to the β-
cells induces islet dysfunction and β-cell apoptosis. Based on animal and in vitro data, TNF-α 
has been proposed to reduce all of the following: endothelial nitric oxide (NO) production, 
insulin-stimulated glucose uptake in skeletal muscle, capillary recruitment, insulin-mediated 
vasodilation in muscle resistance arteries, and NO production in aortic endothelial cells 
(Bakker et al., 2009). TNF-α induces Ser phosphorylation of IRS-1 in vitro and Ser-
phosphorylated IRS-1 acts as an inhibitor of IR kinase activity and downstream signalling 
including PI3K activation, induces lipolysis, down-regulates IRS-1 and the insulin-sensitive 
glucose transporter-4 (GLUT-4) (Fasshauer and Paschke, 2003). Membrane-associated TNF-
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α, which is up-regulated in obesity, can act in an autocrine manner, thereby altering adipose 
biology. In humans, TNF-α’s messenger ribonucleic acid (mRNA) and protein expression in 
fat are low but correlate positively with body adiposity and is decreased in obese subjects 
after weight loss (Rotter et al., 2003).  
 
1.1.2.2 Interleukin-6 and IL-1β 
IL-6 was originally cloned as a leucocyte-derived pro-inflammatory protein. Because 30% of 
systemic IL-6 is secreted by adipose tissue, this protein is also considered an adipokine 
(Kristiansen and Mandrup-Poulsen, 2005). IL-6, derived from omentum fat depots, flows di-
rectly into the liver and stimulates hepatic triglyceride secretion. IL-6 influences insulin sen-
sitivity via distinct mechanisms. It directly impairs insulin signalling in primary mouse hepa-
tocytes and 3T3-L1 adipocytes with decreased activation of IRS-1 and PI3K, and an impaired 
insulin-induced glycogenesis in liver cells (Senn et al., 2002). Administration of recombinant 
IL-6 in rodent models and humans induces hepatic gluconeogenesis, which leads to hypergly-
caemia and compensatory hyperinsulinaemia. IL-6 plasma concentrations are significantly 
up-regulated in murine and human insulin resistance and obese cases. There have not been 
any studies indicating that thiazolidinediones (TZDs) used in clinical practice directly in-
fluence IL-6 gene expression in adipocytes (Catta-Preta et al., 2012). Subsequently, one study 
showed that 26 weeks of rosiglitazone treatment did not affect IL-6 serum concentrations 
(Fasshauer et al., 2003).  
 
β-adrenergic activation stimulates IL-6 mRNA expression in 3T3-L1 adipocytes and this ef-
fect is mediated via a classic Gs-protein-coupled pathway (Fasshauer et al., 2003). In accord-
ance with these findings, IL-6 protein secretion was increased in human adipocytes in vitro 
and in vivo in volunteers after treatment with the β-adrenoceptor agonist, isoprenaline (Kern 
et al., 2001). Furthermore, insulin stimulates while glucocorticoids suppress IL-6 mRNA and 
protein expression in 3T3-L1 and human adipocytes (Fasshauer and Paschke, 2003). In 
support of these in vitro results, diminished exercise-induced IL-6 plasma concentrations 
have been found after treatment with hydrocortisone or dexamethasone in vivo (Wallberg et 
al., 2011). These results are consistent with the anti-inflammatory effect of glucocorticoids 
used in clinical medicine and indicate that IL-6 is not a candidate to mediate glucocorticoid-
induced insulin resistance.  
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Elevated levels of IL-1β are predictive of T2D. Also, the serum concentration of IL-1 re-
ceptor antagonist (IL-1RA) is elevated in obesity and prediabetes (Meier et al., 2002). The 
expression of IL-1RA is induced by IL-1β and reflects the body’s response to counterbalance 
increased IL-1β activity. Most proinflammatory factors that are present at high levels in the 
blood of patients with T2D are IL-1β dependent, and blocking IL-1β activity has been shown 
to reduce their concentrations (Dinarello, 2000). Elevated levels of circulating IL-1β, IL-6 
and acute phase proteins in T2D may reflect the activation of innate immune cells by in-
creased nutrient concentrations, but the levels of these inflammatory markers may not neces-
sarily reflect the degree of inflammation in individual tissues (Donath and Shoelson, 2011).  
 
Hyperglycaemia induces β-cell apoptosis by inducing the expression of the pro-apoptotic re-
ceptor FAS (also known as CD95) on β-cells, which is further upregulated by glucose-in-
duced IL-1β production by β-cells. Thus, IL-1β and FAS both contribute to the glucose-in-
duced impairment of β-cell secretory function as well as apoptosis (Maedler et al., 2002). A 
combination of moderately increased glucose level as well as FFAs (such as oleate, palmitate 
and stearate) stimulate IL-1β secretion and the production of IL-1β dependent pro-inflamma-
tory molecules in cultured human and rodent islets (Ehses et al., 2010).  
 
In the activation of the IL-1β complex, FFAs stimulate the production of pro-inflammatory 
molecules by direct activation of Toll‑like receptor 2 (TLR2) and TLR4, which can sense 
lipids. Glucose-induced IL-1β production involves the non-obese diabetic (NOD)-, leucine-
rich repeat- and pyrin domain-containing 3 (NLRP3; also known as NALP3) inflammasome. 
High concentrations of glucose induce the dissociation of thioredoxin-interacting protein 
(TXNIP) from thioredoxin under the influence of reactive oxygen species (ROS), allowing 
binding of TXNIP to the NLRP3 inflammasome. This leads to the activation of caspase-1 and 
the subsequent processing of pro-IL-1β and release of mature IL-1β. IL-1β induces the 
production of a wide range of cytokines and chemokines such as CC‑chemokine ligand 2 
(CCL2), CCL3 and CXC-chemokine ligand 8 (CXCL8) through NF-κβ activation. This is 
enhanced by FFA-induced activation of TLR2 or TLR4 and leads to the recruitment of 
macrophages (Boni-Schnetzler and Donath, 2011; Donath and Shoelson, 2011).  
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IL-1RA is highly expressed in the endocrine pancreas of non-diabetic individuals but it is de-
creased in the islets of patients with T2D, and this enhances the susceptibility of the β-cells to 
IL-1β. The precise mechanisms responsible for this decrease remain to be explained but the 
adipose tissue-derived hormone, leptin, might be involved, as it decreases IL-1RA expression 
in human islets in vitro (Maedler et al., 2004).  
 
1.2 β-Cell function and dysfunction 
1.2.1 Insulin secretion  
Insulin is a polypeptide hormone secreted by pancreatic β-cells in response to elevated glu-
cose concentrations, aiding in the control of blood glucose levels. The β-cell is the only adult 
cell making pro-insulin which is processed into mature insulin. Pancreatic and duodenal ho-
meobox 1 (PDX-1) is the most extensively studied transcription factor of insulin. It binds to 
the A-box motif of the insulin promoter and it is involved in glucose and glucagon-like pept-
ide-1- (GLP-1)-mediated up-regulation of the insulin gene. Glucose induces translocation of 
PDX-1 to the nucleus. Elevation of second messengers’ cyclic adenosine monophosphate 
(cAMP) and Ca
2+
, can enhance insulin transcription by the activation of two separate sites on 
the insulin gene promoter. The human insulin promoter contains two cAMP response ele-
ments (CRE and TGACGTCA), both of which are responsible for cAMP being induced 
(Inagaki et al., 1992). Activation at this site is through a protein kinase-A (PKA)-dependent 
phosphorylation which then binds the co-activator cAMP response element-binding protein, 
resulting in the activation of transcription of the insulin gene (Komatsu et al., 2013; Manu et 
al., 2013; Lam et al., 2011a).  
 
Within the nucleus of the β-cell, the preproinsulin mRNA is modified by the addition of a 5’-
methylguanine cap, the RNA is cleaved to signal the addition of a poly-A tail, and the non-
coding introns are excised. The now mature mRNA is translocated to the cytoplasm where 
translation to preproinsulin begins on membrane-bound ribosomes. The cytoplasm of the β-
cell contains large amounts of preproinsulin mRNA (10-15% of the total mRNA) that are 
dormant in glucose concentrations of >3.3mM. The initiation of translation ultimately leads 
to insulin biosynthesis that is acutely regulated by glucose. It is in the ER that the translation 
of proinsulin mRNA is completed and the conversion to proinsulin occurs. Preproinsulin, 
once synthesised in the ER, exists for about 30 to 60 seconds before the pre-portion is 
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removed enzymatically and proinsulin is then transported along the microtubule network in 
transport vesicles to the cis part of the Golgi apparatus. Once in the cisternae of the Golgi 
apparatus, insulin is packaged into secretory vesicles ready for export to the plasma 
membrane (Cheng et al., 2013; Komatsu et al., 2013). 
 
1.2.2 Glucose-stimulated insulin secretion 
The components of the insulin secretory pathway include the potassium channels, the volt-
age-dependant Ca
2+
 channels, adenylyl cyclase system, calcium/phosphatidylinositol system 
and G-protein-coupled receptors on the β-cell (Doyle and Egan, 2003). The mechanism for 
glucose-induced insulin secretion is depicted in Figure 1.1. This action is triggered by blood 
glucose that is very tightly controlled by rapid pulsatile release of insulin from β-cells. 
Grodsky (1972) showed that glucose-stimulated insulin secretion (GSIS) is biphasic when the 
extracellular glucose concentration is increased from 3.3mM to 16.7mM to 22.2mM. The first 
phase terminates five to six minutes after stimulation, and a gradual increase in insulin is 
released over a 60-minute period (second phase). This biphasic nature of GSIS is robust in rat 
and human islets, weak in mouse islets and absent in most tumour β-cell lines (Thorens, 
2011).  
 
Glucose equilibrates through the glucose transporter-2 (GLUT-2) across the plasma mem-
brane of the β-cell and is rapidly phosphorylated to G6P by glucokinase (GK), which 
thereafter determines the rate of glycolysis. The resultant increase in the adenosine 
triphosphate/adenosine diphosphate (ATP/ADP) ratio in the cytosol causes depolarisation of 
the plasma membrane by the closure of the ATP-sensitive K
+
 channels. This permits opening 
of voltage-dependent Ca
2+
 channels and an increase in cytosolic Ca
2+
, which then triggers 
fusion of insulin-containing secretory vesicles to the plasma membrane, and exocytosis of 
insulin follows rapidly. Besides activating K
+
 channels, ATP appears to be a major permis-
sive factor for movement of insulin vesicles toward the plasma membrane and for priming of 
exocytosis (Eliasson et al., 1997).   
 
Noradrenaline binds to the β2-adrenergic receptor and activates the heterotrimeric G protein. 
Somatostatin, which is secreted from pancreatic δ-cells, suppresses insulin secretion by bind-
ing to the specific heterotrimeric G protein-coupled receptor as well (Figure 1.1). These in-
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hibitory hormones activate the initial growth phase (Gi) and/or the resting phase (Go), and 
inhibit insulin exocytosis at multiple sites. It is likely that changes in the inhibitory signals are 
intimately involved in the physiology of insulin secretion in vivo (Komatsu et al., 2013). 
 
Figure 1.1. An illustration of the mechanism of glucose-stimulated insulin secretion in β-cells. 1) 
Glucose enters the plasma membrane via glucose transporters; 2) it is phosphorylated to G6P by GK 
to generate pyruvate for the trichloroacetic acid (TCA) cycle; 3) ATP is generated from the TCA 
cycle and exported to the cytoplasm; 4) ATP/ADP ratio increase causes depolarisation of the plasma 
membrane due to the closure of the KATP channels, causing the voltage-gated Ca
2+
 channels to open 
and an influx of Ca
2+
 to trigger the exocytosis of insulin. AKAP, A-kinase anchor proteins; PPi, 
pyrophosphate; DAG, diacylglycerol; PKC, protein kinase C; PLC, phospholipase C, PIP2, 
phosphatidyl 4,5-bisphosphate; Pyr, pyridine; GIP, glucose-dependent insulinotropic factor; GLP-1, 
glucagon-like peptide 1; IP3, 1,4,5-trisphosphate; SUR, sulfonylurea receptor. The figure is an 
adaptation from Doyle and Egan (2003).  
 
Intracellular calcium [Ca
2+
]i levels can also increase because of Ca
2+ 
being released from or-
ganelles. Activation of Gα leads to hydrolysis of phosphatidylinositol bisphosphate to pro-
duce diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) (Figure 1.1). IP3, in turn, in-
creases [Ca
2+
]i by mobilising ER calcium stores. DAG activates protein kinase C (PKC), at 
1 
2 
3 
4 
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least partly by sensitising it to Ca
2+
. Activation of the Ca
2+
/calmodulin kinases also occurs 
with the rise of [Ca
2+
]i. Many drugs may interact with the ion channels or with the G-protein-
coupled family of receptors on the β-cell. The Gs protein is coupled to the subfamily B G-
protein-coupled receptors and β2-adrenergic receptors. Binding to the Gs protein leads to 
activation of adenyl cyclase and subsequently of PKA, while the somatostatin, purinergic and 
α2-adrenergic receptors are coupled to Gi, leading to inhibition of adenyl cyclase. Activated 
Ca
2+
/calmodulin kinases, (PKC), and PKA can lead to phosphorylation of a myriad of 
proteins throughout the β-cell associated with the insulin secretory vesicles, the ion channels 
and the cytoskeletal structure. Phosphorylation and dephosphorylation reactions initiated 
through these G-coupled pathways also ultimately regulate transcription of genes involved in 
the regulation of insulin secretion (Doyle and Egan, 2003).  
 
Figure 1.2. Insulin binding to its receptor and signalling cascade showing the intracellular downstream 
receptors involved. Adapted from Anderson et al. (2005).  
 
Insulin binding to its receptor further activates an array of intracellular pathways (Figure 1.2). 
It binds to the α-subunit of the IR, causing a conformational change in the β-subunit. This 
exposes the ATP binding domain and activates protein kinase B (AKT) and 
autophosphorylation of the β-subunit. Tyrosine is then phosphorylated on a range of protein 
substrates such as IR substrate-1 and 2 (IRS-1 and IRS-2), sarcoma homology 2 protein 
domain containing (SHC) and various others. Phosphotyrosine of these proteins binds to the 
sarcoma homology 2 protein domain (SH2) on other signalling kinases, activating 
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downstream pathways for insulin action. The PI3K pathway, which signals through AKT, is 
important for the acute metabolic effect of insulin, stimulating the translocation of GLUT-4 
into the plasma membrane. The PI3K pathway also participates in glycogenesis, lipogenesis 
and protein synthesis (Bailey, 1999).  
 
The insulin receptor regulates cell growth and gene expression via the MAP-kinase pathway, 
and Shc serves as a substrate for MAP-kinase activation. Activation of the MAP-kinase, in 
turn, activates the kinase Raf, the dual specificity kinase MEK, MAP-kinase/ERK1/2 and 
further downstream kinases (Siddle, 2011). The downstream mammalian target of rapamycin 
(mTOR) is vital in promoting growth-related intracellular activities such as protein synthesis 
and ribosome biogenesis (Ozoe et al., 2013). 
 
1.2.3 β-cell regulation 
Effective β-cell survival and function are vital for the normal functioning of glucose metabo-
lism and insulin sensitivity. Pancreatic β-cells grow by replication of existing β-cell and β-
cell neogenesis. The neogenesis is believed to be activated by β-cell transcription factors such 
as PDX-1 (Bonner-Weir, 2000). Glucose is one of the major nutrients required for β-cell 
growth. Growth factors such as insulin-like growth factor 1(IGF-1), GLP-1 and growth hor-
mone are all glucose-dependent. Glucose is not directly involved in the signal transduction 
pathway of β-cell growth but it assists in the activation of downstream receptors such as IRS-
2. The mechanism by which growth hormone acts is via the Janus kinase-2/ signal transducer 
and activator of transcription (JAK2/STAT) signalling pathway (Lingohr et al., 2002a). IGF-
1 and its signal transducers are expressed in the pancreatic β-cells and mediated by IRS sig-
nalling which is important for β-cell growth and survival (Lingohr et al., 2002b).  
 
The regulation of pancreatic β-cell mass occurs via the interplay of multiple proteins. The 
major classes of cell cycle proteins known as cyclin proteins include the cyclin-dependent ki-
nases (CDKs) and cyclin-dependent kinase inhibitors (CKIs). Cyclin D1 and cyclin D2 are 
both expressed in β-cells. Cyclin D1 knockout mice exhibit normal islet cell size and number. 
However, cyclin D1 overexpression in mice has been found to increase β-cell proliferation 
and mass in vivo. Cyclin D2 is essential for the regulation of β-cell mass; cyclin D2 knockout 
mice are known to have a decreased β-cell mass and decreased insulin levels. CDK4 and 
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CDK2 are expressed in β-cells. CDK4 knockout mice exhibit normal islets at birth, but devel-
op diabetes early in life (Chang-Chen et al., 2008).  
 
IGF-I and IGF-II increase β-cell proliferation in rat islets and insulinoma cell lines in vitro. 
Overexpression of IGF-I in β-cells is associated with increased β-cell proliferation, but not β-
cell mass. Insulin infusion in mice induces β-cell proliferation and increases β-cell mass and 
this effect is augmented by associated glucose infusion (Paris et al., 2003). Mice deficient in 
IRs in β-cells exhibit hyperglycaemia and reduced β-cell mass with age. 
 
Numerous growth factors have been shown to regulate β-cell proliferation. These include the 
lactogens, namely prolactin, placental lactogen and growth hormones. They are known to in-
crease β-cell mass in response to increased insulin demand. Transgenic mice with overex-
pression of hepatocyte growth factor have increased β-cell mass and proliferation and display 
improved glucose tolerance (Chang-Chen et al., 2008).  
 
1.2.4  Selected factors associated with type-2 diabetes affecting β-cell function and dys-
function 
1.2.4.1  Hyperglycaemia 
Hyperglycaemia is responsible for the unresponsiveness of β-cells in the secretion of insulin 
(Leahy, 1992). Glucotoxicity of the islets can be defined as non-physiological and potentially 
irreversible β-cell damage, caused by chronic exposure to supraphysiological glucose concen-
trations, along with the characteristic decreases in insulin synthesis and secretion caused by 
decreased insulin gene expression. It implies the gradual, time-dependent formation of irre-
versible damage to cellular components of insulin production and consequently to insulin 
content and secretion (Wajchenberg, 2007). Chronic hyperglycaemia could also lead to long-
term increases in cytosolic Ca
2+
 that could be pro-apoptotic. Long-term hyperglycaemia also 
induces the generation of ROS, leading to chronic oxidative stress since the islets express 
very low levels of antioxidant enzymes and activity. ROS, particularly hydroxyl radicals, 
interfere with normal processing of PDX-1 mRNA, a necessary transcription factor for 
insulin gene expression and glucose-induced insulin secretion besides being a critical 
regulator of β-cell survival. ROS activate stress-induced pathways such as NF-κβ, stress 
kinases and hexosamines to manipulate cell fate (Wajchenberg, 2007). 
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Any abnormalities in β-cell mass, growth and function lead to glucotoxicity, insulin resist-
ance and the onset of T2D (Talchai et al., 2012). Leahy et al. (1992) made normal rats hyper-
glycaemic with intravenous glucose infusions and observed that selective β-cells were unre-
sponsive to glucose. It is important in the prevention of T2D for the body to maintain both 
pancreatic β-cell mass and function during insulin resistance and hyperglycaemic conditions. 
Glucose regulates the long-term adaptation of insulin production by regulating β-cell turnover 
and is capable of inducing β-cell apoptosis in most human islets (Donath et al., 2010).  
 
1.2.4.2 Dyslipidæmia 
Dyslipidæmia is characterised by hypertriglyceridaemia, a decrease in high-density 
lipoproteins (HDLs) and a multitude of small, dense low-density lipoprotein (LDL) particles; 
features typically observed in T2D.  Elevation of FFA in healthy individuals has stimulatory 
effects on insulin secretion, but may contribute to progressive β-cell failure in some individu-
als with a genetic predisposition to diabetes (Boden and Shulman, 2002). Chronic dyslipi-
dæmia (lipotoxicity) also affects β-cell function and growth. Prolonged exposure to elevated 
levels of fatty acids is associated with inhibition of glucose-induced insulin secretion (Zhou 
and Grill, 1994). In combination with glucotoxicity, glucolipotoxicity also refers to the com-
bined, deleterious effects of elevated glucose and fatty acid levels on pancreatic β-cell func-
tion and survival (Poitout et al., 2010). In patients with dyslipidæmia, peroxisome prolifer-
ator-activated receptor gamma (PPAR-γ) agonists reduce the levels of inflammatory markers 
such as IL-6, fibrinogen, CRP, serum amyloid A, plasminogen, α2-macroglobulin, interferon-
γ, IL-2, TNF-α and IL-1β (Libby and Plutzky, 2007).  
 
Long-chain fatty acyl-coenzyme A (fatty acyl-CoA) might be involved in the mechanism by 
which dyslipidæmia affects the β-cells after prolonged exposure to FFAs, mediating its harm-
ful effects. The simultaneous presence of elevated glucose and fatty acids results from 
glucose as an oxidative fuel, in accumulation of cytosolic citrate, the precursor of malonyl-
CoA, which in turn inhibits carnitine-palmitoyl-transferase-1, the enzyme responsible for 
transport of fatty acids into the mitochondria, blocking their oxidation and energy production, 
resulting in cytosolic accumulation of long-chain fatty acyl-CoAs (Prentki and Corkey, 
1996). 
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1.2.4.3 Nitric oxide production and oxidative stress  
Nitric oxide (NO) has a biological function as a gaseous messenger acting on the relaxation 
of vascular endothelial cells. Because of this effect, it was named endothelium-derived relax-
ing factor (Joffin et al., 2012). It is synthesised from L-Arg in a process mediated by three 
isoforms of NO that belong to the homeoprotein family, and the name is based on tissue 
localisation; they are neuronal NO (or NO I), inducible NO (or NO II) and endothelial NO or 
(NO III). Neuronal and endothelial NO are also found in skeletal and cardiac muscles. 
Inducible NO is primarily found in macrophages. NO I and II are constitutive and calcium-
calmodulin-dependent and are regulated in a post-translational manner by phosphorylation, 
palmitoylation and myristoylation to produce a rapid and transient NO flux. NO is produced 
in vascular endothelial cells and acts in smooth muscle cells where it activates the soluble 
guanylyl-cyclase and forms cyclic guanosine monophosphate (cGMP) leading to 
vasodilation. It has a short life of three to five seconds, suggesting a rapid and local role 
(Pitocco et al., 2010).  
 
In pathological conditions such as obesity, inflammation and insulin resistance, the concen-
trations of nitrites in the plasma are in the micromolar range and oxidants and cytotoxic ef-
fects of NO are evident (Stamler et al., 1992). It is also observed that when present in high 
amounts, NO reacts with O2
-
, a potent oxidant, to form ONOO
-
, and this dominates the action 
of natural antioxidants and scavengers. Large quantities of NO released into the cell inacti-
vate proteins, leading to their degradation and eventually to cell death (Stamler et al., 1992). 
The action of NO depends also on how long it is exposed to the cells. Short-term exposure 
(<12h) of endothelial cells to NO donors, down-regulates the expression of PPAR-γ co-
activator 1 alpha. In contrast, a long-term exposure (four days) induces PPAR-γ co-activator 
1 alpha in a human thyroid cell line, or in cultured brown adipocytes or L6 myocytes. 
Mitochondria biogenesis and oxidative phosphorylation are increased by NO during the long-
term exposure (Lira et al., 2010).  
 
It has been shown that leptin increases NOS II protein expression in vascular smooth muscle 
cells and that the resulting increases in NO prevent the vasoconstrictor effects of angiotensin 
II (Rodríguez et al., 2007). NOS II has also been linked to insulin resistance, but not to hy-
pertension or oxidative stress. In the muscle, 5' adenosine monophosphate-activated protein 
15 
 
kinase (AMPK) prevents NO II induction and reduces NO production, leading to a reduced 
effect of insulin. AMPK activation also suppresses the expression of the NO II protein in cy-
tokine-treated adipocytes, suggesting a counterbalancing role for the pathogenic induction in 
atherosclerosis- and obesity-linked diabetes (Pilon et al., 2004). Studies have shown that NO 
is required for FA-induced attenuation of insulin secretion in pre-diabetic rat islets in vitro 
(Shimabukuro et al., 1997). Rat adipocytes express NO II and NO III, and NO donors induce 
lipolysis (Ribiere et al., 1996). NO could also impair lipolysis in cytokine/lipopolysaccha-
ride-activated adipocytes, possibly via oxidative modifications of key lipolytic proteins 
(Penfornis and Marette, 2005). NO III knockout mice show increased abdominal fat mass and 
dyslipidæmia, and are insulin-resistant (Joffin et al., 2012; Nisoli et al., 2003). 
 
Cells are protected against the harmful effects of ROS by antioxidant enzymes (e.g., Cu/Zn-
superoxide dismutase, vitamin C, vitamin E and glutathione). When ROS generation over-
whelms antioxidant capacity, ROS accumulates, being recognised as oxidative stress, and 
contributes to the development of many pathological conditions such as T2D (Matsuda and 
Shimomura, 2013). There are many sources of ROS production in T2D including mitochon-
drial and non-mitochondrial origins: reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, xanthine oxidase, uncoupled endothelial nitric oxide synthase (eNOS), 
lipoxygenase, cyclooxygenase, cytochrome P450 enzymes, and other hæmoproteins. The 
mitochondria are thought to be the main ROS generation site in T2D (Liu et al., 2013). 
 
ROS appears to be produced in larger amounts by islets from T2D patients than by those 
from non-diabetics. The β-cell mitochondria in islets from T2D subjects have been found to 
exhibit morphologic abnormalities such as hypertrophy, a rounded rather than elliptical 
shape, and a higher density compared with β-cell mitochondria in islets from control subjects 
(Ma et al., 2012). β-Cell mitochondrial membrane potential can be regulated by uncoupling 
protein-2 (UCP-2). UCP-2 negatively regulates insulin secretion and is a major link between 
obesity, β-cell dysfunction and T2D. Obesity and chronic hyperglycaemia increase 
mitochondrial superoxide (O2
•−
) production, and this causes activation of UCP-2 and results 
in pancreatic islet β-cell dysfunction. ER stress is one of the main causes of β-cell dys-
function and death (Back et al., 2012). 
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1.3 Selected marker changes in peripheral tissues associated with type-2 diabetes 
1.3.1 Peroxisome proliferator-activated receptors (PPAR) 
Peroxisomes are subcellular organelles found in most plant and animal cells. They are known 
to perform functions such as H2O2-based respiration, β-oxidation of FFAs and cholesterol 
metabolism (Tyagi et al., 2011). PPARs belong to a large nuclear hormone receptor super-
family that includes the steroid hormone and thyroid hormone receptors. PPARs bind specific 
ligands and in response, PPARs bind to retinoid X receptors (RXRs) to form active 
transcription factors that activate target genes with PPAR response elements in their promoter 
regions. PPARs can also repress the expression of other target genes (Maeda et al., 2001). 
Their isotypes are ligand-activated nuclear transcription factors, which have been identified 
as playing a critical physiological role as lipid sensors and regulators of lipid metabolism 
(Chen et al., 2014). PPARs function as heterodimers in association with co-activator 
complexes that bind to deoxyribonucleic acid (DNA) sequences, termed peroxisome pro-
liferator response elements present in the promoter of target genes, which lead to 
transactivation and transrepression of various genes. In the absence of the ligands, these het-
erodimers are associated with co-repressor complexes which block gene transcription (Ahma-
dian et al., 2013). 
 
The family of PPARs is represented by three members: PPAR-α, PPAR-δ and PPAR-γ. They 
play an essential role in energy metabolism; however, they differ in the spectrum of their act-
ivity. With regard to tissue expression, PPAR-α is expressed predominantly in the liver and, 
to a lesser extent, in muscle, heart and in bone tissue. PPAR-δ is ubiquitously expressed in 
the whole body and is known to regulate energy expenditure. PPAR-γ is expressed in endo-
thelial cells and vascular smooth muscle cells and it regulates energy storage. PPAR-γ is fur-
ther subdivided in four isoforms; γ1 is expressed in virtually all tissues, including heart, 
muscle, colon, kidney, pancreas and spleen, γ2 (30 amino acids longer) is expressed mainly 
in adipose tissue (white and brown), γ4 is expressed in endothelial cells and γ3 is expressed 
in macrophages, large intestine and white adipose tissue (Evans et al., 2004). While PPAR-γ 
isoforms have distinct tissue distributions, there are no known functional differences between 
the isoforms (Tyagi et al., 2011).  
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PPAR-α expression is relatively high in hepatocytes, enterocytes, vascular and immune cell 
types such as monocytes/macrophages, endothelial cells, smooth muscle cells, lymphocytes, 
non-neuronal cells like microglia and astroglia (Heneka and Landreth, 2007). In the liver, it 
plays a crucial role in FFA oxidation, which provides energy for peripheral tissues, elevated 
mitochondrial and peroxisomal fatty acid β-oxidation rates in the liver, heart muscle, kidney, 
skeletal muscle, retina and brown adipose tissues. It also has a potential role in the 
oxidant/antioxidant pathway (Rigamonti et al., 2008). PPAR-α activators have been shown to 
regulate obesity in rodents by both increasing hepatic FFA oxidation as well as decreasing the 
levels of circulating triglyceride levels responsible for adipose cell hypertrophy and 
hyperplasia (Planavila et al., 2005). PPAR-δ/β is expressed in skeletal muscle, adipocytes, 
macrophages, lungs, brain and skin, promoting fatty acid metabolism and suppressing 
macrophage-derived inflammation (Barish et al., 2006). In the section to follow PPAR-γ will 
be discussed in more detail. 
 
1.3.1.1 Peroxisome proliferator-activated receptor gamma 
PPAR-γ is one of a family of receptors that is responsible for regulating the burning or stor-
ing of fat as well as adipocyte differentiation. PPAR-γ is expressed mainly in adipose tissue 
and is a key transcriptional mediator of adipogenesis, lipid metabolism and glucose homœo-
stasis (Grygiel-Górniak, 2014). It is known to be a positive regulator of adiponectin gene ex-
pression (Shehzad et al., 2012). PPAR-γ knockout mice fail to generate adipose tissue when 
fed a high-fat diet (Jones et al., 2005). Adipose PPAR-γ protects non-adipose tissues against 
excessive lipid overload and maintains normal organ function (liver and skeletal muscle). Ac-
tivated PPAR-γ in adipocytes guarantees a balanced and adequate secretion of adipokines 
(adiponectin and leptin) that are mediators of insulin action in peripheral tissues (Kintscher 
and Law, 2005).  
 
With reference to adipogenesis, PPAR-γ regulates the expression of numerous genes involved 
in lipid metabolism, including adipocyte fatty acid binding protein aP2, phosphœnol pyru-
vate-carboxylase kinase (PPCK) gene, acyl-CoA synthase and lipoprotein lipase (LPL). It 
controls the expression of fatty acid transport protein 1 (FATP-1) and CD36, which are both 
involved in lipid uptake into adipocytes. Studies have shown that in the presence of standard 
differentiation medium, PPAR-γ is required for maximal adipocyte differentiation, since 
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PPAR-γ null adipocytes have been shown to have significantly impaired lipid accumulation 
and expression of adipose differentiation marker mRNAs (Tyagi et al., 2011). Mice with 
adipose-specific ablation of PPAR-γ show insulin resistance in adipose tissue and liver but 
not skeletal muscle (He et al., 2003). In these mice, TZDs improved insulin sensitivity in the 
skeletal muscle and liver but not adipose tissue, indicating a direct action of TZDs in skeletal 
muscle and liver, as well as adipose tissue (He et al., 2003).  
 
In skeletal muscle, liver and adipocytes, PPAR-γ is known to increase fatty acid oxidation, 
increase UCP expression, decrease triglyceride content as well as increase HDL (Grygiel-
Górniak, 2014). PPAR-γ is expressed in blood vessels, specifically in vascular smooth 
muscle cells and endothelium. In endothelial cells, it regulates targets relevant to 
inflammation and atherosclerosis (Marx et al., 1999). In T2D long-term activation of PPAR-γ 
by TZDs not only reduces glycaemia and insulinaemia but also decreases vascular 
dysfunction (Grygiel-Górniak, 2014; Caballero et al., 2003). A study suggested that the 
insulin-sensitizing effects of TZDs on muscle are indirect and age-dependent, and that 
skeletal muscle PPAR-γ may have a role in the regulation of whole-body insulin sensitivity, 
perhaps through tissue crosstalk (Kintscher and Law, 2005). The liver is also a proposed site 
of TZD action; however, the effects of PPAR-γ agonism on the liver promotes hepatic 
steatosis through the up-regulation of genes involved in lipid uptake and storage and it 
prevents hepatic steatosis and fibrosis, possibility by sequestering fatty acids in adipose tissue 
and preventing hepatic stellate cell activation (Musso et al., 2012).  
 
Treatment with PPAR-γ agonists also decreases the expression of genes involved in gluco-
neogenesis, and liver-specific disruption of PPAR-γ in mice results in increased adiposity, 
hyperlipidaemia and insulin resistance, yet these mice remain responsive to TZD treatment 
(Gavrilova et al., 2003). However, on a lipodystrophic background, liver-specific ablation of 
PPAR-γ renders these mice resistant to TZD treatment, indicating that in the absence of adi-
pose tissue, the liver becomes a major site of TZD action (Ahmadian et al., 2013; Gavrilova 
et al., 2003).  
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1.3.2 Glucokinase 
Glucokinase (GK) is a hexokinase isoenzyme. It is also known as hexokinase-IV and is a 
monomeric enzyme with a molecular mass of 50 kDa (Matschinsky et al., 2011; Agius, 2009; 
Sarabu et al., 2007). GK differs from the other members of the hexokinase gene family in 
that it has a much lower affinity for glucose and is not subject to product inhibition by glu-
cose-6-phosphate (G6P) (Iynedjian, 1993). It has a half saturation glucose concentration of 
7.0 mmol/l. The enzyme shows a sigmoidal glucose dependency and is, therefore, sensitive to 
glucose changes at 4.0 mmol/l. High glucose induces GK expression in the β-cell and sensiti-
zes them to glucose stimulation of insulin biosynthesis and release. 
 
GK is the predominant enzyme involved in glucose phosphorylation in β-cells and hepato-
cytes. It is also known to play an important role as a glucose sensor in β-cells, a regulator of 
β-cell mass and as a regulator of glucose metabolism in the liver (Matschinsky et al., 2011). 
GK is also found in a few other cells of the gut and brain. In excess of 99% of the body’s GK 
complement resides in the liver, hence its post-prandial role in high-capacity glucose clear-
ance from the bloodstream is coupled with an enhanced glycogen synthesis and glucose cata-
bolism (Matschinsky et al., 2011). Transgenic mice overexpressing GK in the liver gain 
weight more easily, suggesting a role for hepatic glucose metabolism in energy homeostasis 
(Tsukita et al., 2012). 
 
In hepatocytes, GK is regulated by GK regulatory protein, a 68 kDa nuclear protein that in-
activates and facilitates the repossession of GK in the nucleus when glucose levels are low. 
High glucose and fructose-1-phosphate levels dissociate the GK/GK regulatory protein com-
plex, resulting in translocation of active GK to the cytosol. Hepatic GK regulates glycolysis, 
the pentose-phosphate shunt and glucose oxidation, and associated oxidative phosphorylation 
and ATP production (Matschinsky et al., 2011; Sarabu et al., 2007). 
 
When blood glucose levels are higher than normal, GK binds to and phosphorylates glucose, 
allowing it to maintain constant blood glucose levels (Nakamura et al., 2012; Kassem et al., 
2010). Therefore, glucokinase has been considered an anti-diabetic drug target. This is be-
cause it effectively maintains glucose homeostasis in pancreatic β-cells and in the liver, and 
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controls the rate of glucose clearance as well as glycogen synthesis (Matschinsky, 2009; 
Gomis et al., 2000). These processes are impaired in T2D. 
 
An increase in glucose phosphorylation by GK gene expression in skeletal muscle results in 
an increased energy expenditure that counteracts weight gain and mimics a situation of insu-
lin sensitivity. Muscle tissue usually expresses the hexokinase-II enzyme (Baqué et al., 
1998). The increased expression of UCP-3 in skeletal muscle of high-fat fed transgenic mice 
expressing GK, reflects an increase in energy expenditure that prevents the development of 
obesity and insulin resistance, suggesting that modulation of skeletal muscle phosphorylation 
through the expression of the GK gene in skeletal muscle may be a therapeutic approach to 
improve insulin sensitivity in T2D (Otaegui et al., 2003). 
 
1.3.3 Glucose transporters 
Glucose uptake in virtually all cell types is facilitated by glucose transporter proteins located 
in the plasma membrane. These proteins allow for bi-directional facilitative diffusion of glu-
cose. The first glucose transporter was cloned by screening cDNA expression libraries from 
Hep G2 cells (Fukumoto et al., 1988). This was glucose transporter subtype-1 (GLUT-1) and 
it is highly expressed in the blood-brain barrier, placenta and erythrocytes, and is also found 
to a lesser degree in adipocytes, most other tissues and virtually all eukaryotic cultured cell 
lines (Garvey, 1992). GLUT-3 mRNA is detected in various human tissues. It was cloned 
from a human fœtal muscle cDNA library. It mediates glucose transport in central nervous 
system (CNS) neurons (Yano et al., 1991). GLUT-4 is expressed exclusively in peripheral 
insulin target tissues such as fat, skeletal and cardiac muscle, and the protein is increased 10-
fold in adipocyte plasma membranes upon acute insulin stimulation (Garvey, 1992). GLUT-5 
was cloned from human jejunum and is only highly expressed in the small intestine (Kayano 
et al., 1990). 
 
 
Adipocytes express both GLUT-1 and GLUT-4 transporter isoforms. GLUT-4 comprises 
90% to 95% of rat adipocyte glucose transporters. Under basal conditions, it was found that 
the ratio of GLUT-4 to GLUT-1 was 2:1. In rat adipocyte plasma membrane, insulin causes a 
3- to 5- fold increase in GLUT-1 and a 15- to 20-fold increase in GLUT-4, such that the ratio 
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of GLUT-4 to GLUT-1 is 10:1 (Holman et al., 1990). Insulin-stimulated glucose uptake and 
GLUT-4 gene expression are enhanced in differentiated 3T3-L1 cells (Nugent et al., 2001). 
Thus, it is observed that insulin resistance at the level of the glucose transport effector system 
is likely to involve altered function and/or expression of GLUT-4. In obesity, cellular 
depletion of GLUT-4 was quantified at 40%, compared with lean control individuals. In T2D 
patients, the reduction in cellular GLUT-4 was more profound (85% vs lean control 
individuals). 
 
GLUT-4 is also the major glucose transporter isoform expressed in skeletal muscle. Most 
studies indicate that insulin stimulates glucose transport in skeletal muscle with an increase in 
Vmax and little change in Km. It has been reported that insulin-stimulated glucose transport 
rates are markedly decreased in the muscle of diabetic patients. Diminished glucose transport 
activity in adipocytes correlated well with in vivo insulin resistance measured during glucose 
clamps, which primarily reflects muscle glucose uptake, suggesting that insulin resistance in 
fat and muscle may arise via parallel mechanisms. It is also known that pre-translational sup-
pression of GLUT-4 in both fat and muscle causes insulin resistance in streptozotocin (STZ)-
induced diabetic rats (Zorzano et al., 2005). 
 
The GLUT-2 gene was cloned from human, rat and mouse liver and it facilitates glucose 
transport in the liver, pancreas, small intestine, kidney and brain (Leturque et al., 2009). The 
protein is able to process very high concentrations of glucose effectively due to its high Vmax 
and low Km for glucose (Gould et al., 1991). It has a Km of between 17 and 20 mM in 
hepatocytes, and in β-cells, it has a Km of 17 mM (Garvey, 1992). GLUT-2 is found in the 
basolateral and brush-border membrane of the small intestine and basolateral membrane of 
renal tubular cells. It is the main transport machinery for glucose between the liver and blood 
(Thorens, 2001).  
 
GLUT-2 is known to facilitate glucose transport in the liver, pancreas, small intestine, kidney 
and brain and it plays a role in the metabolism of dietary sugars in these tissues (Thorens, 
2001). Low levels of GLUT-2 gene expression have been found in the pancreas and liver of 
T2D subjects (Leturque et al., 2009). In humans, mutations in the GLUT-2 gene result in the 
Fanconi-Bickel syndrome, an autosomal recessive disorder in carbohydrate metabolism and 
patients with this condition suffer from hepatomegaly, nephropathy, fasting hypoglycaemia, 
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sugar intolerance and growth retardation (Leturque et al., 2009). GLUT-2 in the liver is 
known to have bi-directional transport capabilities, thus transporting glucose molecules in 
and out of the cell (Wood and Trayhurn, 2003).  
 
Low insulin and high glucose levels in STZ-induced diabetic rodents increase GLUT-2 
expression in the intestine and liver, suggesting that glycaemia and insulinaemia control its 
expression. A reduction in the expression of GLUT-2 has been found in the diabetic pancreas 
and the liver, suggesting that other factors, in addition to glucose and insulin, regulate GLUT-
2 expression (Leturque et al., 2009).  
 
 
1.3.4 Phosphœnolpyruvate carboxykinase 
One of the key enzymes of gluconeogenesis is phosphœnolpyruvate carboxykinase (PEPCK). 
Its activity is distributed in both the cytosol and mitochondria as a result of two enzymatically 
indistinct isozymes, PEPCK-cytosolic and PEPCK-mitochondrial (PEPCK-C and PEPCK-
M), selectively encoded by different nuclear genes (Pck1 and Pck2, respectively) (Gómez-
Valadés et al., 2008). PEPCK-C is restricted to differentiated liver, small intestine, kidney 
cortex and adipose tissue, whereas PEPCK-M appears not to be constrained to those tissues 
as it is expressed in a variety of cell types, including T- and B-cells, pancreatic β-cells or neu-
rons (Méndez-Lucas et al., 2014). In the liver of most mammals (including humans), 50% of 
the PEPCK activity is PEPCK-M. However, only PEPCK-C is studied in detail in mammals 
and glucose production is most commonly ascribed to this isoform (Stark and Kibbey, 2014). 
The cytosolic isoform accounts for all gluconeogenesis from mitochondrial-dependent pre-
cursors. PEPCK catalyses the following reaction in the cytosol: 
Oxalacetate + GTP         Phosphoenolpyruvate + GDP + CO2 
The mouse liver almost exclusively expresses PEPCK-C and humans express both isoforms 
(Méndez-Lucas et al., 2014). PEPCK has been shown to be the key regulatory enzyme in glu-
coneogenesis as well as glyceroneogenesis, Ser synthesis and amino acid metabolism (Xiong 
et al., 2011). The gene for PEPCK is mainly expressed in the liver and kidney cortex and in 
white adipose tissue, with lesser amounts in the skeletal muscle, colon, lungs and certain 
smooth muscles (Zimmer and Magnuson, 1990). It has been shown that DNA sequences in-
volved in the specific expression of PEPCK in the liver, kidney and small intestine are lo-
23 
 
cated in the same proximal region of the promoter (–600bp to 69bp). In contrast, white and 
brown fat-specific sequences are located distally (–2 088bp to –888bp) (Short et al., 1992).  
 
Fasting hyperglycaemia in patients with T2D is attributed to increased hepatic gluconeogene-
sis, which has been attributed to increased transcriptional expression of PEPCK and catalytic 
glucose-6-phosphatase (Samuel et al., 2009). Glycogen phosphorylase, glucose-6-
phosphatase and PEPCK are inhibited by insulin and activated by glucagon (Choukem and 
Gautier, 2008). Suppression of G6Pase and PEPCK inhibits glycogenolysis and gluconeogen-
esis. AMPK is known to lower liver G6Pase and PEPCK mRNA expression (Combs and 
Marliss, 2014). In white adipose tissue, it could be involved in the supply of glyceraldehyde-
3-phosphate for triglyceride synthesis. The glycerogenesis pathway is required for the re-
esterification of FFA to maintain an active level of triglyceride synthesis (Reshef et al., 
1970). Glucocorticoid inhibits the transcript of the PEPCK gene in adipocytes (Short et al., 
1992). PEPCK is rapidly induced in adipose tissue during exercise and this effect may be me-
diated, at least in part, by catecholamines (Wan et al., 2013; Wan et al., 2012). This results in 
lipolysis and the release of FA into circulation to be used as a fuel source in the peripheral tis-
sues. There is, however, some re-esterification of FFAs into triglycerides. Thus, examining 
the processes regulating the expression of PEPCK in adipose tissue is of importance, due to 
its control of lipolysis and re-esterification (Wan et al., 2013). It has been shown that silen-
cing the gene for PEPCK-M in rats, using anti-sense oligonucleotides, reduces white adipose 
tissue mass (Stark et al., 2014). 
 
PEPCK-C has been widely studied and is considered a key pathway for hepatic gluconeogen-
esis and overlaps with many other biosynthetic and oxidative pathways (Yang et al., 2009). 
Its gene transcription is up-regulated in response to hormones during fasting and is dynamic-
ally down-regulated by insulin and glucose (Hanson et al., 1973). Global ablation of the 
PEPCK-C gene causes hypoglycaemia and an acute reduction of PEPCK-C in the liver of 
db/db mice was sufficient to improve glycaemia (Gómez-Valadés et al., 2008). The PEPCK 
gene is regulated by cAMP, glucocorticoid and thyroid hormone in the liver. 
 
Skeletal muscle has a small but significant level of PEPCK-C activity where the enzyme pro-
vides pyruvate from phosphœnolpyruvate for the synthesis of Ala by Ala aminotransferase. 
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Ala is required by the skeletal muscle as it constitutes the majority of amino acids released by 
the muscle during fasting (Yang et al., 2009). Another possible metabolic role of PEPCK-C 
in skeletal muscle is glyceroneogenesis. Skeletal muscle contains triglyceride, and glycero-
neogenesis is the major source of carbon for glyceride-glycerol in triglycerides in this tissue 
(Nye et al., 2008). PEPCK-C also has a cataplerotic function in skeletal muscle as it plays an 
important role in removing citric acid cycle anions for either the biosynthetic process or the 
subsequent complete oxidation to carbon dioxide in the citric acid cycle. Thus, the 
downstream pathways in which PEPCK-C participates are linked to cataplerosis. PEPCK-C 
plays a key role in gluconeogenesis, glyceroneogenesis, the synthesis of serine and the 
conversion of carbon skeletons of amino acids, such as glutamine and glutamate, to 
phosphoenolpyruvate (via PEPCK) and then to pyruvate (via pyruvate kinase) for subsequent 
oxidation in the citric acid cycle (Yang et al., 2009). The cataplerotic effect of PEPCK links 
it to glucose synthesis and it has been shown that deletion of the gene for PEPCK-C in mouse 
liver ablates gluconeogenesis in that tissue (Chakravarty et al., 2005).  
 
In the study by Novak et al., (2009), transgenic mice had roughly 100 times the activity of the 
enzyme in their skeletal muscle using the cDNA for PEPCK-C. These mice were hyperactive 
(eight times more active than the control rats). They ate twice as much as the control rats but 
weighed half as much (Novak et al., 2009). The reason for this is possibly an increased num-
ber of mitochondria, as well as elevated levels of triglycerides observed in their skeletal mus-
cle. The rats had less insulin in their blood, in comparison with control rats, suggesting the ef-
fect of hyperactivity on glucose utilisation and reduced adipose tissue in these rats. The in-
creased concentration of triglycerides is caused by elevated PEPCK-C activity increasing the 
rate of glyceroneogenesis (Yang et al., 2009). 
 
1.3.5  Fatty acid synthase 
Fatty acid synthase (FAS) is the enzyme that catalyses de novo synthesis of FAs and was tra-
ditionally thought of as a housekeeping protein, producing FAs to be used for energy storage, 
membrane assembly and repair, and secretion in the form of lipoprotein triglycerides (Jensen-
Urstad and Semenkovich, 2012). FAS, a soluble protein, is thought to be localised in the cy-
toplasm, although the specifics of its subcellular localisation remains largely unexplored. Its 
tissue distribution is broad with highest levels in the liver, adipose tissue and lungs 
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(Jayakumar et al., 1995). Changes in FAS activity are due primarily to alterations in the 
transcription rate of the FAS gene (Wang et al., 2004). The FAS protein exists as a 
homodimer with 273 kDa subunits (Jensen-Urstad and Semenkovich, 2012). Each monomer 
contains seven protein domains required for FA synthesis. The domains include acyl carrier, 
acyl transferase, β-ketoacyl synthase, β-ketoacyl reductase, β-hydroxylacyl dehydratase, 
enoyl reductase and thioesterase (Chirala and Wakil, 2004). However, it is only active in the 
dimeric form existing as a head-head orientation of the monomers, intertwined in the middle 
to form an X-shape (Maier et al., 2008). The primary product of the FAS reaction is 
palmitate, but stearate and shorter FAs may be produced. The substrates for FAS are acetyl-
CoA, malonyl-CoA and NADPH. 
 
The contribution of human adipose tissue to whole-body lipogenesis is considered to be low 
and less than that of the liver’s contribution. However, adipose tissue remains an important 
site of endogenous FA synthesis. In humans, increased FAS gene expression in adipose tissue 
is linked to visceral fat accumulation, impaired insulin sensitivity and increased circulating 
fasting insulin, IL-6 and leptin (Berndt et al., 2007). It has been shown that inhibiting FAS 
could serve as a treatment for T2D and related metabolic disorders. This was evident in a 
study where a FAS inhibitor reduced liver triglyceride levels and improved insulin sensitivity 
in db/db mice fed a high-fructose diet (Wu et al., 2011). The FAS gene is over transcripted in 
the adipose tissue of genetically obese rats (Guichard et al., 1992). FAS gene expression in 
adipose tissue is known to be linked to visceral fat accumulation (Berndt et al., 2007). Both 
visceral and subcutaneous FAS mRNA expressions were recently demonstrated to be closely 
correlated with FAS protein levels in both depots, impaired insulin sensitivity and the adipo-
kine profile. The decrease of FAS gene expression in adipose tissue contrasts with enhanced 
hepatic lipogenesis. TNF-α, whose expression and secretion by adipocytes are increased in 
obesity, could also explain the decrease in FAS mRNA levels because it reduces the expres-
sion of several genes including FAS in adipocytes (Menendez et al., 2009). 
 
FAS can affect FA oxidation through PPAR-α, the main mediator of the fasting response in 
the liver. Hepatic FAS is known to be regulated by insulin, glucagon, cyclic AMP, fructose, 
glucose, and dietary fat (Jensen-Urstad and Semenkovich, 2012). Insulin acutely decreases 
FAS activity. Hepatic FAS synthesises lipids that are stored as lipid droplets or secreted in 
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very low-density lipoprotein (VLDL) in the fed state. On diets low in fat and high in 
carbohydrate (10% of calories as fat and 75% as carbohydrate), de novo lipogenesis makes a 
significant contribution to circulating lipids as almost half of VLDL triglyceride is derived 
from de novo lipogenesis under these conditions. In rats fed a chow diet, 11% ± 1% of 
hepatic triglycerides are derived from de novo lipogenesis (Delgado et al., 2009). On a high-
fat diet, de novo lipogenesis is suppressed and only 1.0% ± 0.2% of hepatic triglycerides are 
derived from FAS. Thus, the contribution of de novo lipogenesis to stored triglycerides is 
small in the healthy liver (Iizuka et al., 2006), but in a fatty liver, the contribution of FAS to 
intrahepatic triglycerides may be more. Ob/ob mice have increased hepatic FAS gene 
expression as well as increased hepatic FAS activity compared with lean mice (Donnelly et 
al., 2005). The modulation of FAS in the liver could be relevant to our understanding of non-
alcoholic fatty liver disease, which is associated with obesity and insulin resistance, as well as 
T2D (Menendez et al., 2009). 
 
The amount of triglyceride in skeletal muscle, although quite small relative to that in adipose 
tissue, is nevertheless significantly associated with insulin resistance and thus, FA flux gener-
ated by skeletal muscle FAS could promote insulin resistance through activation of PPAR-α. 
Inactivation of FAS in the skeletal muscle protected mice from insulin resistance without alt-
ering adiposity, specific inflammatory mediators of insulin signalling, or skeletal muscle lev-
els of DAG or ceramide. Increased insulin sensitivity despite high-fat feeding was driven by 
activation of AMPK without affecting AMP content or the AMP/ATP ratio in resting skeletal 
muscle (Funai et al., 2013). Thus, inhibition of skeletal muscle FAS prevents obesity-
associated diabetes in mice. 
 
1.3.6 Insulin receptor substrates (IRSs) 
Insulin signalling involves the phosphorylation of tyrosines on a range of protein substrates 
known as the insulin receptor substrate (IRS) proteins; IRS-1, IRS-2, IRS-3 and IRS-4. The 
IRS proteins are indispensable for propagating insulin action from the IR to final cellular 
effects, such as glucose uptake and protein synthesis (Koh et al., 2013). Skeletal muscle 
accounts for roughly 75% of whole-body glucose uptake. Glucose uptake is under the control 
of the IRS-1-associated PI3K activity. Therefore, defects in IRS-1-associated PI3K activity in 
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skeletal muscle contribute to impaired glucose metabolism (Koh et al., 2013; Leng et al., 
2004).  
 
The main targets for insulin are skeletal muscle, adipose tissue, and the liver, all expressing 
IRs (Thorens, 2011). The first step in the activation of the insulin pathway is the binding of 
insulin to the IR. The IR is a tyrosine kinase comprising two extracellular α-subunits and two 
transmembrane β-subunits. The binding of insulin leads to the autophosphorylation of 
tyrosine residues in the intracellular subunits and activation of tyrosine kinase. Once 
activated, the IR phosphorylates several intracellular proteins, including members of the IRS 
family and the SHC adaptor protein-1. Binding of an IRS to the IR activates PI3K, which in 
turn activates the AKT pathway. Binding of SHC adaptor protein-1 to the IR activates the 
extracellular signal regulated kinase (ERK) cascade, one of the mitogen-activated protein 
kinase (MAPK) pathways (Figure 1.3).  
 
Figure 1.3. Insulin receptor signalling mechanism and its activation of several downstream pathways. 
The insulin signalling mechanism is largely through IRS proteins but also involves the SHC adaptor 
protein-1. Phosphorylation of the IRS controls various pathways such as the p70S6K, MAP kinase, 
MEK and GLUT-4, to produce their relevant signals. Adapted from White (1997).  
 
Cell-based experimentation with immortalised hepatocytes suggests that IRS-2 is the major 
effector of both the metabolic and the growth-promoting actions of insulin. Studies 
PI3K 
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performed on transgenic mice revealed that many insulin responses, especially those 
associated with somatic growth and carbohydrate metabolism, are mediated largely through 
IRS-1 and IRS-2. Knockout of the IRS-2 gene in mouse pancreas β-cells and parts of the 
brain, including the hypothalamus, increases appetite, body mass, linear growth and insulin 
resistance that progresses to diabetes (Lin et al., 2004). Strategies to enhance the IRS-2 
branch of the insulin/IGF signalling pathway in β-cells and the hypothalamus could be a ra-
tional approach to prevent obesity and diabetes. IRS-2 is the major effector of both the 
metabolic and the growth-promoting actions of insulin. Gene knockout studies in mice have 
established that the IR is essential for survival, whereas IRS-1 knockout causes insulin 
resistance and reduced growth, but not severe T2D. IRS-2 knockout causes insulin resistance 
and reduced β-cell mass, resulting in severe T2D (Bailey, 1999). Phosphorylation of IRS-1 
results in recruitment of several signalling proteins, including PI3K, into a multicomponent 
complex via interaction between their phosphotyrosine-containing motifs and the Src 
homology 2 domains of downstream signalling molecules (Figure 1.3). PI3K activation in 
response to the association with IRS-1 or IRS-2 is considered to play a critical role in insulin-
induced glucose metabolism in muscle, fat and liver tissues. Insulin controls major critical 
energy functions such as glucose and lipid metabolism. When insulin binds to its receptor, it 
activates its receptor proteins. Tyr phosphorylated IRS serves as a binding site for many other 
signalling intermediates (Zolotnik et al., 2012). IRS-1 will be discussed in more detail in the 
following section as this will be further investigated in this study.  
 
1.3.6.1  Insulin receptor substrate subtype-1 
IRS-1 is a family member of IRSs, which were firstly characterised as typical cytosolic 
adaptor proteins both in IR and insulin-like growth factor I receptor (IGF1R) signalling 
(Zhou et al., 2013). It has a vital role in the insulin-stimulated signal transduction pathway 
and thus the IRS-1 gene has been studied extensively as a candidate gene for T2D.  
 
IRS-1 is involved in insulin signalling and insulin-stimulated glucose uptake of glucose trans-
porter vesicles. It is Tyr-phosphorylated on several sites and serves as a binding scaffold for 
several adaptor proteins, leading to a downstream signalling cascade in the signal trans-
duction pathway (Stumvoll et al., 2005). There are 50 to 70 potential phosphorylation sites in 
IRS-1, some of which up- and down-regulate insulin signalling (Lu et al., 2013).   
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In an insulin-resistant state, there is a mechanism blocking insulin signalling. Ser/Thr phos-
phorylation of IRS-1 reduces its activity to act as a substrate for Tyr kinase activity of the IR, 
inhibiting its coupling to downstream effectors. Signal down-regulation can also occur by the 
degradation of IRS proteins. This degradation involves the suppressor of cytokine signalling 
(SOCS) family of proteins (Dietze et al., 2002). 
 
Before differentiation of 3T3-L1 adipocytes, IRS-1 are barely detectable by immunoblotting. 
After differentiation, the amount of IRS-1 increases dramatically and insulin strongly stimu-
lates its Tyr phosphorylation. Consistent with this observation, IRS-1 is the predominant 
phosphorylated IRS-protein in isolated rat adipocytes during insulin stimulation (Ozoe et al., 
2013). 
 
A study by Ma et al. (2013) revealed that in myotubes, genipin promoted glucose transporter 
4 (GLUT-4) translocation to the cell surface, which was observed by analysing their distribu-
tion in subcellular membrane fractions, increasing the phosphorylation of IRS-1, AKT and 
Glycogen synthase kinase 3 beta. Both glucose uptake and muscle mass are under the control 
of IRS-1-associated PI3K activity. Therefore, defects in IRS-1-associated PI3K activity in 
skeletal muscle contribute to impaired glucose metabolism and loss of muscle mass, known 
as muscle atrophy (Koh et al., 2013). It was observed that the suppressor of cytokine 
signalling – isoform 3 (SOCS-3) protein concentration was elevated in skeletal muscle of 
high-fat-fed animals and that there were significantly more co-immunoprecipitation of 
SOCS-3 with the IR-β subunit and IRS-1 in the high-fat-fed skeletal muscle, possibly 
resulting in a physical barrier that impaired IRS-1 from interacting with the IR-β subunit 
(Zolotnik et al., 2012). The effect of the uncoupling proteins on the peripheral tissues in T2D 
is reviewed in the next section.  
 
1.3.7 Uncoupling proteins  
Mitochondrial uncoupling proteins, UCPs 1, 2, 3, 4, and 5, are members of an anion-carrier 
protein family and are located in the inner mitochondrial membrane. They are the critical pro-
teins mediating proton leak across the inner mitochondrial membrane (Margareto et al., 
2001). The uncoupling proteins are about 300 amino acids long and have a molecular mass of 
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30 kDa. UCP-2 and UCP-3 have the highest predicted amino acid sequence homology to 
UCP-1.  
 
The uncoupling effect leads to homologue-specific and tissue-specific functions, such as ther-
mogenesis and energy expenditure (UCP-1), regulation of FFA metabolism (UCP-2 and 
UCP-3), reduction in ROS formation (UCP-1, 2, 3 & 5), and regulation of ATP-dependent 
processes (UCP-2) (Souza et al., 2011).  
 
UCP-1 is detected only in brown adipocytes. UCP-2 is ubiquitous and present in many organs 
and cell types of humans and rodents and UCP-3 is primarily expressed in skeletal muscle 
and brown adipose tissue (Rousset et al., 2004). UCP-2 and UCP-3 are known to uncouple 
respiration from ATP synthesis, however, only when they are over-expressed in tissues (Boss 
et al., 1998). UCP-4 and UCP-5 are mainly expressed in the brain (Souza et al., 2011). 
Unlike UCP-1, UCP-2 and UCP-3 are not involved in cold-induced thermogenesis; however, 
the possibility that these novel UCPs participate in basal thermogenesis was supported by 
human genetic studies (Bouchard et al., 1997). UCP-3 mRNA and protein levels are 
decreased in skeletal muscle of patients with T2D, compared with healthy control subjects. 
UCP-3 protein content is reduced in prediabetic subjects and T2D, and eight weeks of rosigli-
tazone treatment restores skeletal muscle UCP-3 (Schrauwen et al., 2006).  
 
The rate of mitochondrial oxidative metabolism is vital in T2D. It is possible that the recent 
discovery of uncoupling proteins could serve as targets for anti-obesity and anti-diabetic 
drugs. It is observed that in brown adipose tissue, UCP-1 mRNA expression is generally low 
(Brondani et al., 2012). UCP-2 and UCP-3 are known to be involved in energy dissipation, 
thus they could possibly play a role in weight regulation and any mutations in their gene 
could play a role in the development of obesity and T2D (Boss et al., 2000). UCP-2 will be 
discussed in more detail in the following section as it is the focus of this study. 
 
1.3.7.1 Uncoupling protein 2 
UCP-2 is a member of the mitochondrial anion carrier protein family. It is a fatty acid-
responsive mitochondrial inner membrane carrier protein, showing wide tissue distribution 
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with a substantially increased presence in fatty liver. Other tissue distribution includes the 
spleen, kidney, immune system, pancreas and CNS (Almanza-Perez et al., 2010). Cold 
induces UCP-2 expression in brown adipose tissue (Diano and Horvath, 2012). 
 
The respiratory chain generates free radicals that, when diffusing in the mitochondrial inner 
membrane, will attack membrane phospholipids to produce lipid hydroperoxides. These lipid 
hydroperoxides will activate UCP-2 and increase proton leak. Increased proton leak will, in 
turn, reduce the membrane potential, increasing electron flux through the respiratory chain 
and decreasing the concentration of reduced electron carriers, which are responsible for the 
production of superoxide. Thus, a proton leak via UCP-2, decreases ROS production, 
protecting against oxidative stress (Diano and Horvath, 2012). In β-cells, ROSs activate 
UCP-2, which results in a proton leak across the mitochondrial inner membrane, leading to 
the reduction of β-cell ATP synthesis and content (Ma et al., 2012). Treadmill exercise in low 
and moderate intensities has been found to improve the control of glycogen metabolism and 
fat oxidation by up-regulating UCP-2 expression specifically in the brown adipose tissue of 
Zucker rats (Kim et al., 2013).  
 
UCP-2 is responsible for the dissemination of the proton motive force which uncouples oxi-
dative phosphorylation (Affourtit et al., 2011; Esteves and Brand, 2005). Its activity is known 
to attenuate GSIS (Ma et al., 2012). It negatively regulates insulin secretion and is a major 
link between obesity, β-cell dysfunction and T2D (Ma et al., 2012; Polonsky and 
Semenkovich, 2001). Its uncoupling results in a reduction of blood glucose and fat mass, im-
proving glucose tolerance (Li et al., 2000). UCP-2 genetically knocked-out mice resulted in 
greatly improved GSIS in comparison to normal mice (Pi et al., 2009; Boss et al., 1998). The 
uncoupling of the metabolism also causes an increase in glycolysis and the synthesis and 
translocation of GLUT-4, as well as the breakdown of fatty acids.  
 
1.3.8 The interplay between adipokines and selected protein markers 
Adipose tissue is the major organ for energy storage in mammals and also has an important 
endocrine function. It releases a variety of cytokines called adipokines, which are involved in 
the regulation of glucose and lipid homeostasis and also plays a role in immunity. The list of 
molecules confirmed as adipokines have expanded as new ones are discovered. Most but not 
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all adipokines are peptide/proteins with hormone-like properties (Dunmore and Brown, 
2013).  
 
The adipokines secreted by adipose tissue include leptin, adiponectin, resistin (also known as 
adipose tissue-specific secretory factor), visfatin (also known as pre β-cell colony-enhancing 
factor), vaspin (visceral adipose tissue derived serpin) and omentin in addition to pro-
inflammatory cytokines, such as TNF-α, IL-6, and MCP-1 (Figure 1.4) (Catta-Preta et al., 
2012; Antuna-Puente et al., 2008). Adiponectin is a 244-amino acid protein and is 
exclusively secreted by adipose tissue into the bloodstream, thus making it an adipokine. It is 
sometimes referred to as apM1, AdipoQ, Acrp30 or GBP-28 (Beales et al., 2014; Wang et 
al., 2013a). Apelin, a peptide found in adipose tissue, is known to inhibit insulin secretion. 
(Dunmore and Brown, 2013). Adipokines mainly serve as regulators of insulin sensitivity and 
many effects on both the function and survival of β-cells (Figure 1.4). In subsequent sections, 
a selected number of these adipokines will be discussed in more detail.  
 
Figure 1.4. Crosstalk between adipose tissue and pancreatic β-cells. Positive regulations include the 
stimulation of insulin synthesis and secretion, as well as cell proliferation. Negative regulation results 
in the inhibition of insulin synthesis, secretion and increased apoptosis and necrosis of β-cells. NEFA, 
non-esterified fatty acid; IGF-1, insulin-like growth factor. Image adapted from Dunmore and Brown 
(2013). 
 
TNF-α 
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1.3.8.1 Leptin  
Leptin is a protein of 167 amino acid residues (Ahima and Osei, 2004; Ahima and Flier, 
2000). It is derived from white adipocytes and its circulating level is directly proportional to 
the total amount of adiposity in the body. This 16 kDa adipokine is found in various tissues 
such as the stomach, placenta, bone, mammary gland, liver and muscle, but in much lower 
quantities compared with adipose tissue (Joffin et al., 2012). This hormone was originally 
cloned in 1994 as the protein product of the ob gene mutation and leads to an increase in 
obesity in ob/ob mice (mice homozygous for the spontaneous obese mutation). It was the first 
endocrine product of adipose tissue to be identified (Zhang et al., 2005). Leptin inhibits 
appetite and weight gain by decreasing orexigenic and increasing anorexigenic peptide 
expression in the hypothalamus (Ahima and Flier, 2000).  Consistent with its appetite-
suppressive effect, leptin expression is stimulated upon feeding and suppressed during 
starvation. TZDs consistently suppresses leptin expression in rodent fat in vivo and in vitro. 
Furthermore, β-adrenergic activation rapidly decreases leptin expression and secretion in 
primary adipocytes in vitro and in mice in vivo (Ahima and Flier, 2000).  
 
The action of leptin is initiated when leptin binds and activates its receptor, i.e. the obese-re-
lated leptin receptor (OB-R), which is a class I cytokine receptor with a single trans-
membrane domain and six isoforms generated by alternative splicing. These isoforms differ 
in the length of their intracellular domains but share identical extracellular ligand binding 
domains. The long isoform OB-Rb contains a fully active intracellular signalling domain and 
is responsible for most of the known effects of leptin. OB-Rb has the ability to activate 
different signalling pathways, such as JAK2/STAT3 and the mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways (Peelman et al., 2006). 
OB-Ra is proposed to participate in leptin transport through the blood-brain barrier (Vauthier 
et al., 2013; Golden et al., 1997). Leptin acts via the CNS to modulate glucose metabolism in 
muscle and liver. Intra-cerebro-ventricular (ICV) or intravenous (IV) injection of leptin in-
creases glucose uptake and gluconeogenesis in the liver, along with an increase in glucose-6-
phosphatase activity. Both central and direct effects of leptin on muscle glucose uptake have 
been demonstrated (Burcelin et al., 1999; Kamohara et al., 1997). In the Caco-2 (a human co-
lon carcinoma cell line) intestinal model, leptin rapidly inhibits glucose uptake and reduces 
the number of amino acid transporters (Fanjul et al., 2012; Joffin et al., 2012).  
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Leptin has a dual effect on the immune system, where it plays a protective role against 
infections by regulating T-cell proliferation and activation while also functioning as a pro-
inflammatory cytokine (Procaccini et al., 2012). It is involved in the pathogenesis of 
inflammatory and autoimmune diseases like rheumatoid arthritis.   
 
Insulin is a potent activator of leptin mRNA expression and protein secretion. It is plausible 
that insulin is the major mediator of increased post-prandial leptin concentration 
(Kolaczynski et al., 1996). In a synergistic manner, leptin and insulin have been shown to 
enhance NO production by phosphorylation of eNOS at Ser 1177 (Vendrell et al., 2004). It 
also increases sympathetic nerve activity and enhances endothelin-1 release from vascular 
endothelium (Dardeno et al., 2010). Circulating leptin levels are elevated in obesity, 
contradicting the beneficial effects of leptin previously described (Ahima and Osei, 2004; 
Lee et al., 2002). To explain this, studies have shown the impairment of leptin’s metabolic 
effects and leptin-induced NO production, i.e. “leptin resistance”, in obesity and human 
hypertension. Leptin resistance may be caused by inflammatory mechanisms, as CRP impairs 
intracellular leptin signalling (Chen et al., 2006). Therefore, resistance to the vasodilatory 
effects of leptin may contribute to vascular dysfunction in obesity (Bakker et al., 2009). 
 
In adipose tissue, factors that are known to increase the concentration and expression of lep-
tin include overfeeding, obesity, insulin, glucocorticoids, acute infection and the proinflam-
matory cytokines TNF-α and IL-1β. Fasting and the exposure to cold are known to cause a 
decrease in leptin expression (Ahima and Osei, 2004). Leptin is also known to increase insu-
lin sensitivity in normal and hyperglycaemic rodents (Sivitz et al., 1997). Leptin has many 
important functions for the general function of the body, such as linking the nutritional status 
with neuroendocrine and immune functions, thereby acting as an immune-modulator 
(Procaccini et al., 2012).  
 
Pancreatic β-cells express the leptin receptor (OB-R) in rat islets and murine-derived β-TC3 
cells, and deletion of the leptin receptor in the β-cells and hypothalamus develop obesity, 
fasting hyperinsulinaemia, impaired glucose-stimulated insulin release and glucose 
intolerance (Wang et al., 2010). Chronic exposure of human islets to leptin leads to β-cell 
apoptosis via increasing the release of IL-1β and decreasing the release of IL-1RA in the 
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islets (Wajchenberg, 2007). Leptin plays a protective role in pancreatic β-cell function by ex-
erting its anti-apoptotic effects by reducing triglyceride accumulation and inhibiting NO pro-
duction (Dunmore and Brown, 2013). Leptin can activate multiple signalling pathways in the 
pancreatic β-cells. The classical pathway associated with leptin binding to its receptor is 
activation of the JAK/STAT pathway where receptor-associated kinase JAK2 phosphorylates 
Tyr residues on the leptin receptor, which subsequently recruits and phosphorylates STAT 
family members that can then translocate to the nucleus and regulate gene transcription 
(Dunmore and Brown, 2013).  
 
Leptin has been implicated in causing peripheral insulin resistance by attenuating insulin ac-
tion, and signalling, in various insulin-responsive cell types. Glucose uptake into the cells is 
stimulated by insulin and leptin activating the JAK2/IRS/PI3K/AKT signalling pathway and 
triggering the translocation of the GLUT-4 from the cytosol to the cell surface. Down-
regulation of PI3K/AKT indicates an insufficiency of insulin to maintain the normal 
signalling of this pathway. This results in a reduced intake of glucose through GLUT-4 vesi-
cles in the muscles, which results in hyperglycaemia (Al-Suhaimi and Shehzad, 2013). The 
PI3K pathway is also affected by leptin. Leptin is known to inhibit the protein and lipid phos-
phatase, which acts downstream of PI3K to dephosphorylate phosphatidylinositol (3,4,5) 
trisphosphate and decrease its levels. Thus, it is possible for leptin to increase phospha-
tidylinositol (3,4,5) trisphosphate, which in turn leads to increased activation of ATP-
dependent potassium channels, hyperpolarisation of the β-cell membrane and hence inhibi-
tion of GSIS (Dunmore and Brown, 2013). Leptin also impairs insulin secretion of human isl-
ets via inhibition of UPC-2 expression (Wang et al., 2010). AMPK is an essential enzyme in 
leptin signalling which is related to the PI3K pathway. Both PI3K/AKT and AMPK are 
involved in regulating glucose homeostasis. Under normal conditions, AMPK stimulates ca-
tabolism and obstructs anabolic pathways. Leptin deficiencies decrease the AMPK activity in 
the liver but increase its activity in the hypothalamus of the diabetic rat, thereby resulting in 
diabetic hyperphagia (Al-Suhaimi and Shehzad, 2013). 
 
1.3.8.2 Adiponectin 
Adiponectin is known to regulate metabolism, inflammation, immune response and vascular 
homeostasis, glucose regulation and the breakdown of FAs (Shetty et al., 2009). The level of 
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adiponectin is inversely correlated to body adipose tissue in adults, possibly because 
hypertrophic adipocytes release less of the adipokine (Dunmore and Brown, 2013; Shehzad et 
al., 2012). This makes adiponectin a negative marker of the metabolic syndrome (Shehzad et 
al., 2012). 
 
Most physiological actions of adiponectin are mediated by activation of AMPK via phosphor-
ylation at Thr 172 yielding phosphorylated AMPK (pAMPK). This signalling pathway re-
quires an endosomal adaptor protein, an adaptor protein with phosphotyrosine-binding, 
pleckstrin homology domains and a leucine zipper motif. It circulates primarily as a multime-
ric (trimeric, hexameric and high molecular weight) association of full-length adiponectin and 
is locally cleaved by proteases to a globular (trimeric) form in which the collagen-like amino-
terminal domain is released (Mao et al., 2006).  
 
Adiponectin acts by binding to its receptors, adiponectin receptor type 1 (AdipoR1) and type 
2 (AdipoR2).  The receptors are composed of seven transmembrane spanning regions and 
have external carboxyl-terminus and cytoplasmic amino-terminus. AdipoR1 is found in many 
tissues, being particularly abundant in skeletal muscle, whereas AdipoR2 is most commonly 
found in the liver. The expression of these receptors in insulin target organs significantly 
increases in fasted mice and decreases in re-fed mice. In vitro studies have shown the 
expression of AdipoR1/R2 is reduced by insulin via the PI3K/FOXO1-dependent pathway. 
AdipoR1 and AdipoR2 levels are significantly decreased in the muscle and adipose tissue of 
insulin-resistant ob/ob mice (Yamauchi et al., 2014). Adiponectin-induced activation of 
AMPK is reduced in skeletal muscle of ob/ob mice, suggesting that the reduced expression of 
AdipoR1 and AdipoR2 seen in the ob/ob mice is associated with insulin resistance, indicating 
that obesity not only decreases plasma adiponectin levels but also AdipoR1/R2 expression, 
thereby reducing adiponectin sensitivity and leading to insulin resistance (Tsuchida et al., 
2004).  
 
Adiponectin has been shown to have beneficial effects in improving insulin sensitivity and 
vascular function with both anti-diabetic and anti-atherogenic activity (Das, 2010; Pajvani 
and Scherer, 2003). It has anti-inflammatory and anti-oxidant properties (Kadowaki et al., 
2006). Weight loss has a positive effect on adipose tissue as it causes an increase in 
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adiponectin and a decrease in adipose tissue inflammation (Mazza et al., 2011). Adiponectin 
has a protective effect against many major obesity-related pathologies, including hyper-
tension, atherosclerosis, non-alcoholic fatty liver, heart failure, airway inflammation and 
some cancers (Mao et al., 2006).  
 
The globular C-terminal fragment of adiponectin is able to reduce plasma glucose concentra-
tions (Kadowaki and Yamauchi, 2005). The globular fragment, as compared with full-length 
adiponectin, increases fatty acid combustion in muscle cells much more effectively, thereby 
reducing plasma glucose concentrations. Activation of AMPK followed by inhibition of ace-
tyl CoA carboxylase (ACC) by adiponectin might be a mechanism by which this effect is me-
diated (Yamauchi et al., 2001). Research data indicate that low serum adiponectin concentra-
tions at basal level independently predict the future risk of developing T2D in humans 
(Shibata et al., 2013; Koenig et al., 2006). Adiponectin mRNA expression in adipose tissue 
and plasma concentrations are decreased in insulin resistance and obesity. Its expression 
increases with improved insulin sensitivity and weight loss. As an exception, exercise does 
not appear to influence adiponectin expression despite its profound insulin-sensitising effect 
(Cheng et al., 2013; Pajvani and Scherer, 2003). Adiponectin mRNA synthesis and secretion 
are increased by treatment with TZDs in vitro and in vivo (Fasshauer and Paschke, 2003). 
Adiponectin has been shown partly to restore insulin content and PDX-1 gene expression. 
TZDs have been shown to increase the expression and circulating levels of adiponectin 
(Maeda et al., 2001).  
 
Adiponectin is involved in the regulation of pancreatic β-cell function and survival, and the 
adiponectin receptors (ADIPOR1 and ADIPOR2) are expressed in primary as well as clonal 
β-cells (Dunmore and Brown, 2013), with AdipoR1 generally being found to be expressed at 
higher levels than AdipoR2 (Fantuzzi, 2013). Adiponectin has anti-apoptotic effects on β-
cells, both in cell culture and islet preparations, and the apoptotic effect is due to the 
activation of ERK1/2 and AKT. Adiponectin is able to alleviate the apoptotic effects of either 
palmitate- or ceramide-induced cell death. The effect is critically dependent on the formation 
of the downstream conversion product of ceramide, sphingosine-1 phosphate (Turer and 
Scherer, 2012).   
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In a T2D Goto-Kakizaki rat model, it was observed that the resulting increase in adiponectin 
levels was associated with a decrease in islet β-cell apoptosis (Chai et al., 2011). Chetboun et 
al. (2012) also showed that adiponectin (and leptin) increased proliferation of clonal β-cells 
(RIN and MIN6) without affecting apoptosis. These effects involve the generation of ROS 
(H2O2) possibly by inhibiting expression of antioxidant enzymes such as superoxide 
dismutase. The oxidant molecules are known to play a physiological role in regulating β-cell 
mass. The overall effect of high levels of adiponectin would be to preserve β-cell mass, 
whereas low levels found in obesity and T2D would contribute to its reduction (Dunmore and 
Brown, 2013). 
 
Skeletal muscle is an important peripheral target tissue for adiponectin to exert its beneficial 
metabolic effects and contribute to anti-diabetic action. Skeletal muscle adiponectin has been 
known to increase glucose uptake. Adiponectin stimulates glucose uptake in muscle, causing 
translocation of GLUT-4 to the cell surface, thereby enhancing insulin sensitivity in the 
muscle. The ability of adiponectin to enhance insulin-stimulated phosphorylation of AKT 
was attenuated upon overexpression of AMPK. Adiponectin also regulates FA metabolism in 
muscle and has been shown to increase FA uptake and oxidation and suppress FA synthesis 
through the activation of AMPK, p38, MAPK and PPAR-α (Liu and Sweeney, 2013).  
 
1.3.8.3 Resistin  
Resistin is a 12.5 kDa cysteine-rich protein encoded by the RETN gene in humans. It was 
identified in 2001 and was shown to potentially induce insulin resistance in rodents (Steppan 
et al., 2001), hence its name, resistin. In humans, resistin is secreted by immune and epitheli-
al cells and has also been detected in tissues like placenta, skeletal muscle, small intestine, 
spleen, stomach, thymus, thyroid gland and uterus (Al-Suhaimi and Shehzad, 2013). In ro-
dents, it is secreted by adipose tissue (Ricci and Bevilacqua, 2012). Serum resistin levels 
increase with an increase in adiposity and is reduced by TZD treatment. The hormone is 
usually overexpressed in rodent models of diet-induced obesity (Al-Salam et al., 2011).  
 
Resistin may be involved in sensing the nutritional status as its mRNA level is low during 
fasting and high after food consumption (Stofkova, 2010). Its main function is maintaining 
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glucose homœostasis and insulin sensitivity. Research data suggests that the mechanism for 
resistin’s pro-diabetic effect involves the inhibition of the intrinsic activity of cell surface glu-
cose transporters, the suppression of GLUT-4 gene expression, the induction of the inhibitor 
of SOCS, blocking of the insulin signal transduction pathway, stimulation of hepatic glucose 
production and the activation of FFA release from adipose tissue (Stofkova, 2010). 
 
Resistin gene expression is up-regulated by glucose and glucocorticoids. It causes liver tissue 
to be less sensitive to insulin. It has been proposed to play an important role in the pathogene-
sis of obesity-related insulin resistance and to inhibit GSIS (Al-Salam et al., 2011). In hu-
mans, insulin resistance is positively correlated with the expression of resistin. An elevated 
expression of resistin in circulation leads to glucose intolerance, hyperinsulinaemia related to 
impaired insulin signalling in skeletal muscle, liver and adipose tissue. Loss of resistin in 
obesity decreases the blood glucose levels and improves insulin sensitivity (Stofkova, 2010). 
The important role of AMPK in the liver is to stimulate FA oxidation, prevent cholesterol 
synthesis and promote insulin secretion by pancreatic β-cells. Resistin inhibits the phosphor-
ylation of the hepatic AMPK pathway that down-regulates β-oxidation resulting in lipid accu-
mulation. Resistin stimulates SOCS-3 in mice adipose tissue resulting in the inhibition of the 
insulin signalling pathway in tissues. Furthermore, resistin affects glycogen metabolism, lea-
ding to T2D (Al-Suhaimi and Shehzad, 2013).  
 
In human peripheral blood mononucleated cells (PBMCs), pro-inflammatory cytokines such 
as IL-1β, IL-6 and TNF-α, and lipopolysaccharides, have strongly induced resistin mRNA ex-
pression. However, in pre-adipocytes and adipocytes, TNF-α administration significantly de-
creased resistin mRNA expression (Fasshauer and Paschke, 2003). Stimulation of human 
PBMCs with recombinant resistin led to a marked up-regulation of the genes for IL-1β, IL-6, 
TNF-α and resistin itself, showing that it induces a positive feedback mechanism on its own 
expression in PBMCs (Bokarewa et al., 2005). Resistin has been demonstrated to  induce 
expression of the vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1) and MCP-1 directly (Kawanami et al., 2004).  
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1.3.9 A summary of metabolic events of the selected proteins and peptides affecting 
T2D in the peripheral tissues 
Various peripheral tissue protein markers are affected by T2D, as reviewed in the previous 
sections. There is an interplay between these proteins and the effect they have on each other. 
In turn, the activation or gene expression of a particular protein or adipokine has an effect on 
other cellular processes, and when there is dysfunction from the normal cellular functioning, 
this could result in T2D with its associated complications such as insulin resistance and 
obesity. As can be seen in figure 1.5, there are several key factors that play a role and will be 
discussed. 
 
Figure 1.5. Crosstalk between peripheral tissue protein markers for a generalised cell as applied to an 
insulin-resistant model. Conditions depicted may vary between muscle, liver and adipose tissue, and 
thus a general concept across the tissues is summarised. The up-regulation   and down-regulation  of 
the various proteins are discussed in the text.    Indicates a positive effect;      indicates a negative 
effect.  
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In diabetics, defects in IRS signalling lead to defects in PI3K signalling and result in impaired 
glucose metabolism (Nathanson and Nystrom, 2009). This is more evident in skeletal muscle, 
however, the IR is found in all peripheral tissues and the defects in IRS signalling could lead 
to insulin resistance (Fatchiyah et al., 2013). The expression and phosphorylation of the IRS 
proteins further results in the translocation of glucose into the cell. This is facilitated by 
glucose transporters. Thus, defects in IRS activity result in a reduction in GLUT expression 
and activity (Thorens, 2011) (Figure 1.5). 
 
The uncoupling proteins control the effect on GSIS since they decrease this process in the 
liver. Thus, a knock-out of the gene greatly improves GSIS and ATP synthesis. Overexpres-
sion of UCP-2 has been linked to obesity, β-cell dysfunction, as well as T2D. The regulation 
of UCP-2 expression has been linked to the activity of PPAR-γ (Aubert et al., 1997). 
 
FAS gene expression, especially in adipose tissue, has been linked to visceral fat accumula-
tion; therefore, inhibition of FAS activity could serve as a treatment for T2D. TNF-α is 
known to control hepatic and adipose tissue FAS activity. Also, skeletal muscle FAS could 
promote insulin resistance through the activation of PPAR-α (Funai et al., 2013).  
 
Increased PEPCK activity leads to the production of glucose and hence could be attributed to 
hepatic gluconeogenesis. The gene for PEPCK is overexpressed in patients with all forms of 
diabetes in which gluconeogenesis is inappropriately high (Stark and Kibbey, 2014). 
Glucokinase, however, plays a major role in glucose phosphorylation as well as being a rate-
controlling enzyme for hepatic glucose clearance. One of the key functions of PPAR-γ is the 
regulation of glucose homeostasis. The cataplerotic effect of PEPCK is also seen in the 
muscle where it plays a major role in removing citric acid cycle intermediates for either the 
biosynthetic process or the subsequent complete oxidation of these compounds to carbon 
dioxide in the citric acid cycle. The cataplerotic process links PEPCK to glucose synthesis 
(Méndez-Lucas et al., 2014).  
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1.4 Treatments for type-2 diabetes 
In the treatment of T2D, the rationale for drug therapy should be to maintain normoglycaemia 
and avoid frequent fluctuations in blood glucose; in this way the cardiovascular system is 
protected from glucotoxicity. Clinical treatment of diabetes targets both insulin deficiency, 
insulin resistance and the prevention of the decline of pancreatic β-cell function (Triggle and 
Ding, 2014). Some of the current treatments for T2D are summarised (Table 1.1).  
 
Conventional anti-diabetic agents can affect several glucose metabolic pathways such as in-
sulin secretion, glucose uptake by target organs as well as nutrient absorption. Incretins and 
transcription factors such as PPARs are targets of modern therapy (Rosenson, 2007; Hansotia 
and Drucker, 2005). IRs and glucose transporters have not been the focus of anti-diabetic 
therapy. Although a few studies using natural products have been published, these 
methodologies may serve as complementary tools to explore findings obtained in in vivo 
models (Iwashima et al., 2001). 
Table 1.1. Some conventional injectable and oral medications for T2D treatment. Adapted from 
(Diabetes.co.uk, 2015). 
Injectable medications 
Medications Action Advantages Possible side effects 
 Amylin mimetics (Mack et al., 
2009)  
 Pramlintide (Symlin) (Ryan et 
al., 2008) 
Stimulates the release of 
insulin; used with insulin 
injections 
May suppress hunger; may 
promote modest weight loss 
Hypoglycaemia; nausea 
or vomiting; headache; 
redness and irritation at 
injection site 
Incretin mimetics  
 Exenatide (Byetta) (Bond, 
2006) 
 Liraglutide (Victoza) (Jackson 
et al., 2010) 
Stimulates the release of 
insulin; used with metform-
in and sulfonylurea 
May suppress hunger; 
may  promote modest 
weight loss 
Nausea or vomiting; 
headache; dizziness; 
kidney damage or failure 
Oral medications 
Meglitinides (Shrishrimal et al., 
2009) 
 Repaglinide (Prandin) 
 Nateglinide (Starlix)  
Stimulates the release of 
insulin 
Works quickly 
Severely low blood sugar 
(hypoglycaemia); weight 
gain; nausea; back pain; 
headache 
Sulfonylureas (Chan and 
Abrahamson, 2003) 
 Glipizide (Glucotrol) 
 Glimepiride (Amaryl) 
 Glyburide (DiaBeta, Glynase) 
Stimulates the release of 
insulin 
Works quickly 
Hypoglycaemia; weight 
gain; nausea; skin rash 
Dipeptidyl peptidase-IV (DPP-4) 
inhibitors  
 Saxagliptin (Onglyza) 
 Sitagliptin (Januvia) 
 Linagliptin (Tradjenta) 
(Scheen, 2010) 
Stimulates the release of 
insulin; inhibit the release 
of glucose from the liver 
Does not cause weight gain 
Upper respiratory tract 
infection; sore throat; 
headache; inflammation 
of the pancreas (sita-
gliptin)  
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Biguanides  
 Metformin (Fortamet, Gluco-
phage, others) (Franciosi et al., 
2013; Mahrouf-Yorgov et al., 
2009) 
Inhibits the release of 
glucose from the liver; 
improve sensitivity to 
insulin 
May promote modest 
weight loss and modest 
decline in LDL, or "bad", 
cholesterol 
Nausea; diarrhœa; rarely, 
the harmful build-up of 
lactic acid (lactic acid-
osis) 
Thiazolidinediones (TZDs) 
 Rosiglitazone (Avandia) 
 Pioglitazone (Actos) 
(Wooltorton, 2002) 
Improves sensitivity to 
insulin; inhibit the release 
of glucose from the liver 
May slightly increase HDL 
Heart failure; heart 
attack; stroke; liver 
disease 
Alpha-glucosidase inhibitors  
 Acarbose (Precose) (Chiasson 
et al., 2002) 
 Miglitol (Glyset) (Campbell et 
al., 2000) 
Slows the breakdown of 
starches and some sugars 
Does not cause weight gain 
Stomach pain; gas; 
diarrhœa 
 
1.4.1 Conventional treatments 
Metformin, a biguanide, is considered to be the first choice of drug for the treatment of pa-
tients with T2D. It is a synthetic oral hypoglycaemic drug with minimal side effects, gastroin-
testinal problems being the most common. It reflects the accumulation of metformin in the 
small intestine (Wilcock and Bailey, 1994). Metformin is known to improve insulin sensitivi-
ty, thus improving glucose utilisation as well as lipid metabolism. It is associated with weight 
loss or is weight neutral. Metformin reduces hepatic gluconeogenesis, decreases gly-
cogenolysis, facilitates glucose disposal into peripheral tissues, reduces fatty acid oxidation 
and protects the cardiovascular system from the negative effects of hyperglycaemia 
(Kirpichnikov et al., 2002). On the cellular basis, metformin enhances AMPK-mediated ex-
pression of hepatic gluconeogenesis and the enhancement of GLUT-4 receptors in muscle 
and adipose tissue (Foretz et al., 2010). In cell-free assays, AMPK is activated by the AMP 
analogue 5-aminoimidazole-4-carboxamide riboside, a known activator of AMPK, but is not 
activated by metformin, thus suggesting that the effects of metformin on AMPK are indirect 
(Hawley et al., 2002). Metformin also has an effect on the cAMP pathway. It causes an in-
crease in AMP, inhibits adenylate cyclase and therefore, suppresses glucagon-mediated glu-
coneogenesis in the liver (Triggle and Ding, 2014; Miller et al., 2013).  
 
The meglitinides, first introduced in 1997 with repaglinide and followed by nateglinide and 
other mitiglinide, are oral hypoglycaemic agents that inhibit KATP channels and thus serve as 
insulin secretagogues. They share comparable side effects, notably hypoglycaemia and 
weight gain, with the sulfonylurea drugs. They differ from the sulfonylureas in having a 
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faster onset and shorter duration of action, thus making them suitable for postprandial control 
of blood glucose (Triggle and Ding, 2014).  
 
PPAR-γ’s synthetic ligands such as glitazones, the derivatives of TZDs, improve insulin and 
glucose sensitivity and increase whole body insulin sensitivity. They indirectly increase insu-
lin-stimulated glucose uptake in adipocytes, hepatocytes and skeletal muscle cells (Deeg and 
Tan, 2008). Activation of PPAR-γ results in an increase in GLUT-4 expression, enhanced 
sensitivity to insulin, reduced hepatic gluconeogenesis and thus, reduced blood glucose and 
glycated haemoglobin (HbA1c) levels. The drugs do not enhance insulin secretion. They 
enhance the expression of PPAR-γ cofactor 1, an important regulator of mitochondrial 
biogenesis, and thus modulate energy homœostasis. The beneficial effects of glitazones can 
be linked to their effects on insulin sensitivity and the reduction of lipotoxicity and 
glucotoxicity with improved β-cell function (Triggle and Ding, 2014; Nathanson and 
Nystrom, 2009).  
 
The effects of pharmacological PPAR-γ activation by TZDs have been attributed, at least in 
part, to decreased FFA levels and increased lipid storage in adipose tissue. As a result of this, 
lipotoxicity in muscle and liver tissue is reduced. PPAR-γ agonists have the ability to redis-
tribute fat from visceral to subcutaneous depots and increase adiponectin and reduce tissue 
necrosis factors (Deeg and Tan, 2008). Rosiglitazone and pioglitazone are used in the treat-
ment of patients with T2D because they decrease hepatic glucose production and prolong β-
cell function by preventing apoptosis of β-cells (Deeg and Tan, 2008). Pioglitazone increases 
HDL cholesterol and decreases triglycerides and fasting plasma FFA without altering the 
total cholesterol and LDL cholesterol levels (Diamant and Heine, 2003). Rosiglitazone 
significantly supplements HDL levels (Krishnaswami et al., 2010), total cholesterol and the 
LDL fraction (Diamant and Heine, 2003).  
 
The sulfonylureas, as hypoglycaemic compounds, inhibit the opening of KATP channels, 
resulting in the depolarisation of β-cells, a subsequent increase in calcium influx and intracel-
lular free calcium levels and, thus, increasing insulin release. The sulfonylureas bind to the 
sulfonylurea receptor, SUR, which in turn regulate the potassium channel (Triggle and Ding, 
2014). The SUR protein is a member of the ATP-binding cassette gene family homologue 
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and it senses the intracellular ATP:ADP ratio. Higher ATP levels close the channel and 
enhance insulin release (Nathanson and Nystrom, 2009).  
 
The glitazars are a combination of PPAR-α and -γ agonists. They have a pharmacological 
profile similar to that of combining a fibrate with a glitazone. Muraglitazar and tesaglitazar 
were introduced into clinical trials but were discontinued in 2006 due to an elevated risk of 
renal function and congestive heart failure (Triggle and Ding, 2014). Despite many beneficial 
features of glitazones (metabolic and anti-arteriosclerotic activity), they exhibit side effects, 
such as weight gain, œdema, bone fractures, heart failure and increased risk of myocardial 
infarctions (Grygiel-Górniak, 2014).  
 
Glucose-dependent insulinotropic polypeptide and GLP-1 are gastrointestinal hormones 
called incretins, which robustly enhance nutrient-induced insulin secretion. Incretins bind to 
G protein-coupled receptors on the β-cell membrane and increase cellular cAMP. When the 
β-cells are exposed to a stimulatory concentration of glucose, cAMP further elevates GSIS. 
Incretin action is resistant to dioxide, and therefore, it is independent of KATP channel closure 
(Ayala et al., 2008). cAMP enhances GSIS through PKA-dependent and -independent 
mechanisms (Yang et al., 2004). With regard to insulin granule dynamics, cAMP increases 
the size of a readily releasable pool in a glucose concentration-dependent manner. This 
finding strongly indicates that incretin primes the β-cells in the presence of stimulatory 
ambient glucose concentration. Incretin priming occurs in a Ca
2+
-independent manner, even 
under stringent Ca
2+
-free conditions (Baggio and Drucker, 2007). In T2D the insulinotropic 
actions of GIP are deficient and therefore only GLP-1 has been pursued as a pharmacological 
target. In 2005, exenatide was the first GLP-1 mimetic approved for the treatment of T2D. 
Similar to exenatide is liraglutide; both are known to slow the emptying of the stomach and 
decrease body weight, but have been found to have a positive inotropic action (Triggle and 
Ding, 2014).  
 
Dipeptidyl peptidase-4 (DPP-IV) is expressed in adipocytes of subjects with obesity and thus 
its release is correlated to adipocyte size (Dunmore and Brown, 2013; Lamers et al., 2011). 
DPP-IV inhibitors are novel oral glucose-lowering agents that modulate fasting plasma 
glucose, postprandial glucose and HbAlc levels by decreasing the inactivation of incretins 
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(GLP-1 and glucose-dependent insulinotropic polypeptide) to stimulate the release of insulin 
in a glucose-dependent manner (Cheng et al., 2014). The Food and Drug Administration 
(FDA) approved the first DPP-IV inhibitor, sitagliptin in 2006. Its main action was to 
increase incretin levels subsequent to the inhibition of DPP-IV. DPP-IV is a multifunctional 
protein and thus its inhibition may have many diverse effects. It is known to impair insulin 
signalling (Lamers et al., 2011). DPP-IV inhibition in both in vitro and in vivo modes has the 
ability to enhance endothelial cell growth; thus, in addition to its action is able to enhance the 
effects of GLP-1, and may have direct actions to reverse the deleterious effects of T2D on 
vascular function (Takasawa et al., 2010).  
 
α-Glucosidase inhibitors such as acarbose and miglitol were approved by the FDA in 1995 
and 1996, respectively. The primary action of these compounds is to inhibit the α-glucosidase 
enzymes (maltase, isomaltase, sucrose and glucoamylase) that hydrolyse oligosaccharides 
and disaccharides to glucose. These enzymes are associated with the small intestine and thus, 
when inhibited, result in the reduction of glucose availability and absorption. In so doing, 
cardiovascular risk, weight loss, blood pressure reduction and triglyceride lowering in T2D 
patients are reduced (Hanefeld and Schaper, 2008). Gastrointestinal side effects include 
flatulence and diarrhoea (Triggle and Ding, 2014; Nathanson and Nystrom, 2009).  
 
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are known to block glucose 
reabsorption by binding to the SGLT2 in the proximal tubule in the kidney. They lower blood 
glucose by increasing urinary glucose excretion. SGLT2 treatment lowers the blood glucose 
load that is filtered by the kidney and further urinary glucose excretion becomes limited. 
Thus, SGLT2 inhibitors can be viewed as having a self-regulating effect on blood glucose 
levels, and have a low intrinsic propensity to cause hypoglycaemia (Moses et al., 2014). 
Phlorizin is an example of such an inhibitor used to correct hyperglycaemia and improve 
insulin sensitivity within an animal model of T2D; however, it has been evaluated in clinical 
trials based on toxicity and non-specificity effects associated with the SGLT transport family 
(Ehrenkranz et al., 2005). SGLT2 inhibitors should be specific in order not to affect glucose 
transporters. Canagliflozin and dapagliflozin, unlike phlorizin, were approved in the US and 
Europe, respectively. These inhibitors are associated with insulin sensitivity, weight loss and 
reduction in blood pressure, but side effects may include dehydration (Merovci et al., 2014). 
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The effectiveness of the flozins depends on adequate renal function and since chronic kidney 
disease is a feature of advanced stages of T2D, caution in their use in patients with renal 
impairment is required (Triggle and Ding, 2014). 
 
Insulin treatment is essential for T1D as well as T2D, to facilitate the storage and synthesis of 
carbohydrates, lipids and proteins. It is pivotal in the maintenance of normal glucose homœo-
stasis by reducing hepatic glucose production via gluconeogenesis and glycogenolysis, and 
by promoting glucose uptake, primarily into skeletal muscle and to a lesser degree into adi-
pose tissue. Administration of high doses of insulin to patients with T2D improves both their 
insulin sensitivity and endothelial function, probably as a consequence of an improvement in 
glycaemia (Triggle and Ding, 2014; Nathanson and Nystrom, 2009). 
 
Targeting inflammatory markers for T2D treatment has been of importance in recent times. 
Islets from diabetic patients display features of inflammation which include the expression of 
cytokines and chemokines, immune cell infiltration, decreased insulin staining, β-cell apopto-
sis and fibrosis. Hyperglycaemia and elevated FFA levels may initiate this process (Donath, 
2013). Unravelling the mechanism of inflammation in T2D paves the way for possible treat-
ment. Currently, two approaches, namely IL-1RA (Sloan-Lancaster et al., 2013) and 
modulation of NF-κβ by salsalate (Goldfine et al., 2013) are treatments that target the 
modulation of inflammation to improve the disease. Both approaches target the same path 
because IL-1 activates NF-κβ. Studies have confirmed the ability of these interventions to 
improve insulin secretion in pre-diabetics and diabetics as well as to improve insulin 
sensitivity, along with a decrease in HbA1c (Donath, 2013). However, this approach is used 
in conjunction with standard care. A phase III study of IL-1A aiming at testing this 
hypothesis in 17 200 patients has been launched (ClinicalTrials.gov NCT01327846), where 
an antibody to IL-1β is used, allowing for dosing every three months, with the aim of 
preventing cardiovascular disease and improving insulin secretion and maintaining glycaemic 
control (Donath, 2013).  
 
1.4.2 Alternative treatments 
In this section, selected known alternative treatments will be highlighted. Small-molecule GK 
activators have also been shown to demonstrate effective glucose lowering and are used for 
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T2D treatment (Pal, 2009). Activators of GK increase the sensitivity of the enzyme to glu-
cose, leading to increased insulin secretion and liver glycogen synthesis, and a decrease in 
liver glucose output. The GK activators have been shown to have potent anti-hyperglycaemic 
actions in rodents, by increasing pancreatic insulin secretion and by enhancing hepatic glu-
cose metabolism. GK activators bind to the allosteric pocket of GK. The binding pocket 
(about 20Å) is situated distant from the glucose binding site. An example of a GK activator is 
a phenylacetamide derivative and a few more are in development (Pal, 2009).  
 
Another study has shown that antioxidants (taurine or tempol) may protect β-cells through the 
attenuation of both islet fibrosis and β-cell apoptosis in T2D (Lee et al., 2011). The authors 
found that after administering the antioxidants in drinking water to Otsuka Long-Evans 
Tokushima fatty rats (an animal model for T2D) for 16 weeks, the blood glucose levels 
decreased, insulin secretion was restored to normal and beta cell mass as well as pancreatic 
insulin content were higher in the diabetic rats when compared with the untreated rats. They 
found that β-cell apoptosis was attenuated (Lee et al., 2011).  
 
Nanocrystal technology has also been engineered for diabetic drugs. A drug like glibencla-
mide is an oral anti-diabetic drug that has been produced through nanotechnology to increase 
its solubility as well as its bioavailability to retain its dissolution properties (Salazar et al., 
2013). The principles of nanotechnology are reviewed in detail in section 1.6.  
 
Medicinal plants have also gained major interest for the treatment of diabetic symptoms. 
Cannabis sativa and the cannabinoids, tetrahydrocannabinol (THC) and cannabinol (CBN), 
display anticoagulant activity and may be useful in the treatment of T2D in which a hyperco-
agulable state exists, or in cases where anticoagulants such as heparin and warfarin are not 
suitable for administration (Coetzee et al., 2007). Another such plant is Leonotis leonurus, 
which has shown promising results to contain an anti-diabetic drug. L. leonurus contains an 
active compound, marrubiin, exhibiting some medicinal properties. Both L. leonurus and 
marrubiin will be reviewed in the following section as they form the basis of the current 
study.  
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1.4.2.1 Leonotis leonurus 
L. leonurus is a plant that belongs to the family Lamiaceae and is widely distributed through-
out South Africa (Figure 1.6D). It is a robust shrub which grows to 2 to 3 m tall and 1.5 m 
wide. The aerial parts of the plant are widely used in oriental medicine (Van Wyk et al., 
2000). The major constituents of this plant are the diterpenoids marrubiin and premarrubiin 
(Figure 1.6 A and B). A dilactone known as compound X is a labdane diterpenoid that has 
been extracted from L. leonurus (Kruger and Rivett, 1988; Rivett, 1964). The plant is 
reported to have anticonvulsant, anti-nociceptive, anti-inflammatory and hypoglycaemic 
activities (Ojewole, 2003). This plant is traditionally smoked for the relief of epilepsy. An 
infusion and decoction of the leaves and stem have been used to treat coughs, colds, 
influenza, bronchitis, high blood pressure and headaches. It has been used externally for relief 
of haemorrhoids, eczema, skin rashes and itching, muscular cramps and boils (Agnihotri et 
al., 2009; Scott et al., 2004; Bienvenu et al., 2002).  
 
Previous phytochemical screenings of L. leonurus revealed that it contains diterpenoid lab-
dane lactones, tannins, quinones, saponins, alkaloids and triterpene steroids (Maphosa et al., 
2008; Bienvenu et al., 2002). One of the diterpenoid labdane lactones, marrubiin (Figure 
1.6A), has been investigated within our research group to be one of the active constituents of 
the organic leaf extract of L. leonurus (Mnonopi, 2010). Mnonopi et al., (2011) found that 
marrubiin increased the gene expression of insulin and GLUT-2 in INS-1 cells. Under in vitro 
conditions, marrubiin and the organic extract of L. leonurus increased the respiration rate of 
INS-1 cells. In addition, it was found that marrubiin increased insulin secretion and decreased 
HDL-cholesterol in an in vivo rat model. The plant extract has also been shown to possess 
anticoagulative activity, antiplatelet activity, anti-inflammation effects (Mnonopi et al., 
2011), antimicrobial activity (Steenkamp et al., 2004) and anti-diabetic properties (Mnonopi 
et al., 2012). 
 
1.4.2.2 Marrubiin  
Marrubiin is reported to have inhibitory activity against α-glucosidase, the key enzyme in the 
treatment of diabetes and also in weight loss. α-Glucosidase is found in the brush borders of 
the intestinal cell wall and is a key enzyme of carbohydrate digestion, producing 
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disaccharides and monosaccharides. It can, therefore, serve as a therapeutic approach for the 
reduction of blood sugar, which usually rises after a meal (El-Mohsen et al., 2014). 
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Figure 1.6. The chemical structure of (A) marrubiin, (B) premarrubiin, (C) leonurun and (D) the 
flowering tops of L. leonurus. Chemical structures were drawn using ChemSketch software. 
 
In addition to marrubiin and premarrubiin, other labdane diterpenoids are contained in L. 
leonurus. Such a compound is leonurun (Figure 1.6C), which has a structure similar to that of 
premarrubiin. The compound was isolated from the plant and its structure was determined 
from spectroscopic data and relative stereochemistry from single-crystal X-ray diffraction 
analysis (McKenzie et al., 2006). An acetone extract provided a yield of 547mg from 1 140g 
of dried leaf material. Mass spectroscopy analysis showed a mass-to-charge ratio (m/z) of 
390.210, agreeing with the calculated m/z for C22H30O6 of 390.20 (Figure 1.7).  
 
Figure 1.7. 
 1
H NMR spectrum of leonurun in CDCl3 (McKenzie et al., 2006). 
 
A B C D 
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Marrubiin and the extract from Marrubium vulgare have been shown to have anti-ulcer 
activity in mice (Paula de Oliveira et al., 2011). The main therapeutic aim in the treatment of 
ulcers is to control acid secretion using antacids, H2 receptor blockers, anticholinergics or 
proton pump blockers. However, most of the drugs currently available show limited efficacy 
and are often associated with severe side-effects, such as hypersensitivity, arrhythmia, 
impotence, gynaecomastia and haematopoietic changes. Thus, a drug with a high efficacy and 
low toxicity is required. After treatment with 25 mg/kg of marrubiin and varying 
concentrations of the M. vulgare extract (25 mg/kg, 50 mg/kg and 100 mg/kg), all the mice 
received 0.5 ml of a 0.3M HCl/60% ethanol solution to induce gastric ulcers, one hour after 
treatment. The animals were sacrificed an hour later and their stomachs analysed for this 
study. The extract of M. vulgare at doses of 50 and 100 mg/kg, marrubiin at a dose of 25 
mg/kg and the positive control (cimetidine, 100 mg/kg) caused an increase in gastric pH and 
decreased the concentration of H
+
 ions, compared with the control group, suggesting that the 
extract and marrubiin interfere with gastric acid secretion. In summary, the study showed that 
the gastroprotection presented by M. vulgare and marrubiin is related to its ability to 
stimulate the synthesis of mucus and to decrease gastric acid secretion. It is dependent on NO 
activity and sulfhydryl groups, which are important gastroprotective factors that have 
vasodilator effects, inhibit gastric acid secretion and are antioxidants in gastric mucosa (Paula 
de Oliveira et al., 2011). 
 
Agnihotri et al. (2009) identified and isolated a compound (compound 1), also known as 1 
(2,3-trihydroxy-3,7,11,15-tetramethylhexadecan-1-yl-palmitate), from L. leonurus flowering 
tops (Figure 1.8). The structure was determined by spectroscopic methods including 1D- and 
2D-NMR spectroscopy. ESI-MS and 
13
C NMR data established the molecular formula as 
C36H72O4. Also, five known metabolites were isolated and they were tested for antimalarial, 
cytotoxicity and antimicrobial activities. None of the compounds tested was cytotoxic to 
mammalian kidney fibroblast (Vero) cells up to a concentration of 4.76 µg/ml. 
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Figure 1.8. Chemical structure of compound 1 (2,3-trihydroxy-3,7,11,15-tetramethylhexadecan-1-yl-
palmitate) isolated from the flowering tops of L. leonurus. The chemical structure was drawn using 
ChemSketch software.   
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1.4.3 Drug delivery systems 
For the effective delivery of a drug to its target tissue, it has to overcome transport barriers. 
One of these critical barriers includes the rapid filtration by the kidney. At the tissue or 
cellular target, drugs must also cross the plasma membrane as well as escaping endolysomes 
within the cell. Other barriers are the nuclear membrane and the multiple drug resistance me-
chanisms that pathological cells can develop (Hubbell and Chilkoti, 2012). With these factors 
to consider, drug delivery is aimed at overcoming such barriers. 
 
The most common drug delivery systems for T2D are oral and injectable drugs. As 
previously discussed in Section 1.4, Table 1.1 lists a selection of such drugs indicating their 
mode of action as well as their possible side effects. Oral drug administration is the suitable 
and safest route of drug administration, and most drugs for T2D administration are made to 
be taken orally. Other modes of drug delivery systems which are not typical of T2D drugs 
include pulmonary delivery, dermal delivery, as well as ocular delivery. 
 
For injectable drugs, the vasculature provides a route to the site of the disease, as well as 
many detours in case the drug is lost on its way to the target tissue. The intravenous adminis-
tration route provides numerous benefits such as immediate action, reduced dosing and 100% 
bioavailability. However, this route of administration has certain limitations as it employs the 
use of excipients which are co-administered with the drug and may cause some side-effects 
(Pawar et al., 2014). 
 
Most of the drugs for ocular therapy are delivered through a topical formulation in the form 
of a solution or suspension. Drug delivery mechanisms are very challenging to the pharma-
ceutical scientist due to the critical and pharmacokinetically specific environment that exists 
in the eye (Behar-Cohen, 2003). In ocular diseases, where angiogenesis is a feature, such as 
choroidal neovascularisation, diabetic retinopathy, central retinal vein occlusion and 
intraocular solid tumours, drug targeting can be an efficient mode of treatment (Kassem et 
al., 2007). 
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Recently, nanocrystal technology has been employed for drugs with poor solubility, drugs 
that are water-insoluble and those with low bioavailability. This approach has seen the pro-
duction of many drug candidates available in the pharmaceutical market. The technology has 
employed the use of most delivery systems discussed above. The increase in the surface area 
of the drug, increase in dissolution velocity, increased physical and chemical stability, and the 
small particle size of the active drug makes it the preferred choice of late for pharmaceutical 
drugs. Also, nanocrystal drugs do not make use of harmful excipients in their development 
process. The different drug nanocrystal delivery systems have been reviewed extensively by 
Pawar et al., (2014).  
 
Another means of combating T2D is through bariatric surgery. This is the most successful 
treatment for significant weight loss, resolution of T2D and the prevention of future weight 
gain. In this surgery, a small stomach pouch is created and connected to the mid-jejunum. 
The remainder of the stomach and the proximal intestine remains in the body and is bypassed 
by nutrient flow. Thus, this procedure results in a decrease in stomach volume as well as a 
change in nutrient flow. This method of surgery is known as the Roux-en-Y gastric bypass 
(Arble et al., 2014). Another surgical method is the vertical sleeve gastrectomy, during which 
roughly 80% of the stomach is excised along the major curvature. The major modification is 
to the size of the stomach, resulting in the route of nutrient flow remaining the same and the 
risk of macro- and micronutrient malabsorption minimised. These surgeries have proved 
particularly effective at weight reduction, with patients maintaining roughly 30% weight loss 
for periods of 10 years or more (Sandoval, 2011). It is very likely to achieve glycaemic 
benefits (blood glucose and HbA1c reduction), as well as diabetes remission with this type of 
surgery. The IDF recommends this surgery for diabetic patients with a BMI of 35 kg/m
2
 or 
more. Also, it can be recommended for diabetic patients with BMI of between 30 kg/m
2
 to 35 
kg/m
2
 who do not respond to lifestyle modification and treatment (Yu et al., 2014).  
 
In the following section, the author will highlight some known methodologies for the analysis 
of compounds within plant extracts. The main types of methods for the separation and analy-
sis of the compounds such as chromatography and mass spectroscopy are discussed.   
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1.5 Analytical and structural analysis of medicinal molecules 
1.5.1  Reversed phase-high performance liquid chromatography and mass spectro-
scopy 
HPLC utilises a column containing the packing material (stationary phase), the mobile pha-
se(s), and a detector that records the retention times of molecules being eluted through the 
stationary phase. Retention times vary depending on the interactions between the stationary 
phase, the molecules being analysed and the solvent(s) used (Bansal, 2010). RP-HPLC has a 
non-polar stationary phase and an aqueous, moderately polar mobile phase. The stationary 
phase is composed of particles of a rigid structure. RP-HPLC operates on the principle of hy-
drophobic interactions, which result from repulsive forces between a polar eluent, the rela-
tively non-polar analyte and the non-polar stationary phase. Particles can occur as bonded 
phases, where the stationary phase is chemically bonded to an inert support such as 
commonly used silica i.e. butyl (C4), octyl (C8) and octadecyl (C18) silane groups. Stationary 
phase particles are packed with a high pressure slurry procedure which involves forming a 
slurry of stationary phase in a solvent of equal density and pumping it into the column under 
high pressure, producing a dense, continuous bed of stationary phase that is free of cracks and 
other imperfections (Wilson and Walker, 2005; Sheehan, 2000). The binding of the analyte to 
the stationary phase is proportional to the contact surface area around the non-polar segment 
of the analyte molecule upon association with the ligand in the aqueous eluent (Bansal, 
2010).  
 
The mobile phase used usually involves ultra-pure HPLC grade solvents that are chemically 
inert. They are often degassed before use to avoid interference with the samples to be investi-
gated. Separation is based on the characteristics of the mobile phase and involves adsorption 
and partitioning mechanisms (Wilson and Walker, 2005).   
 
Recently there has been the introduction of columns with improved core-shell technology for 
enhanced separation and better resolution. One such highly technologically advanced column 
is the Kinetex pentafluorophenyl (PFP) phase column. This column incorporates fluorine 
atoms on the periphery of the phenyl ring to provide unique aromatic and polar selectivity 
(Figure 1.9A). This column has a mechanism dealing with hydrogen bonding, dipole-dipole 
interactions, aromatic π-π and hydrophobic interactions (Environmental expert, 2012). It is 
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recommended for separation of positional isomers, aromatic compounds and conjugated com-
pounds. With the PFP technology, better separation is achieved in comparison with C18 col-
umns, when dealing with complex chemicals such as terpenoids and steroids due to the 
improved chemistry of the stationary phase of the column (Figure1.9B & C). 
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Figure 1.9. (A) Kinetex PFP column with a hydrophobic backbone coupled to an ionic penta-
fluorophenyl, (B) elution profile of a compound using the Kinetex PFP column and (C) elution profile 
of a compound using a C18 column. Adapted from Environmental_expert (2012).  
 
In mass spectroscopy analysis, RP-HPLC is the first dimension of the analysis during which 
different compounds in a complex biological extract are chromatographically separated. 
(Winnik and Kitchin, 2008). HPLC-mass spectroscopy (MS) is used for the analysis of puri-
fied and newly synthesised compounds that can be used to construct a compound library. 
This compound library is routinely used in the drug discovery process. The instrumental com-
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ponents making up a liquid chromatography-MS system include the auto-sampler, the HPLC 
system, the ionisation source (which interfaces the HPLC to the MS) and the MS (Figure 
1.10). Typical RP-HPLC systems connected to an MS have a combination of water and either 
methanol or acetonitrile as the mobile phase. However, there are limitations on the mobile 
phase modifiers since the modifiers have to be volatile. Typical mobile phase modifiers 
would include ammonium acetate, acetic acid and formic acid (Korfmacher, 2005).  
 
 
Figure 1.10. A simplified composition of an LC-MS system. (A) Auto sampler (loads the samples 
onto the HPLC column); (B) HPLC; (C) ionisation source (interface for LC to MS); (D) Mass 
spectrometer. The image is an adaptation from Korfmacher (2005). 
 
MS/MS is tandem mass spectrometry combining two MSs. The first MS is used to select a 
single mass characteristic of a given analyte. The selected mass undergoes another MS 
analysis in which it is fragmented into ions by colliding with a neutral gas (usually helium), a 
process referred to as collision-induced dissociation. The second mass spectrometer is used to 
separate the fragment ions based on its mass. Over recent years the performance 
improvement of the LC-MS/MS equipment, coupled with superior specificity, shorter run 
time and less laborious sample preparation, has made it a preferred choice over GC-MS and 
immunoassay techniques (de Jong et al., 2011; Maurer, 2006). 
 
There are various types of ionisation sources used as an interface between the HPLC eluent 
and the mass spectrometer. The two most commonly used sources are electrospray ionisation 
(ESI) and atmospheric pressure chemical ionisation (APCI). In both cases, ionisation occurs 
at atmospheric pressure. High voltage and heat are used in the provision of ionisation which 
is needed to produce the ions to be assayed by the MS system. In ESI, a high voltage field (3 
A B C D 
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to 5 kV) is used to convert the liquid into a fine spray, resulting in charged droplets that are 
focused towards the mass analyser. The droplets get smaller as they approach the mass 
analyser. As the droplets get smaller, individual ions emerge in a process referred to as ion-
evaporation.  These ions are then separated by the MS system.  In the APCI method, heat is 
used to vaporise the column eluent and a corona discharge is used to ionise solvent mole-
cules, which then produce the analyte ions through chemical ionisation mechanisms (Hsieh, 
2004). There is a third type of ionisation source, termed atmospheric pressure photoionisation 
(APPI). In APPI, the column is heated by vapour (similar to APCI), but the ionisation is pro-
duced by way of an ultraviolet lamp that produces 10-electronvolt (eV) photons. Depending 
upon the solvent system used, the 10 eV photons will either ionise the mobile phase solvent 
or a dopant (toluene, which can be ionised by the 10 eV photons) added to the column 
effluent. These ions then produce the analyte ions through various ionisation mechanisms 
including charge or proton transfer (Hsieh et al., 2003). 
 
An MS system that can be coupled to an HPLC is a single quadrupole MS. The MS provides 
a spectrum of each chromatographic peak eluted from the HPLC column. Another type of 
MS system is the time of flight (TOF) MS or matrix-assisted laser desorption/ionisation time 
of flight (MALDI-TOF). This has the added capability of providing a higher mass resolution 
spectrum from each component analysed. A third type is a triple quadrupole MS-MS system, 
which is most often used for bio-analytical assays but can also be used for metabolite identifi-
cation assays. The fourth type is an ion-trap MS. This has the unique function of producing 
data for structural identifications (Korfmacher, 2005).   
 
1.6 Nanotechnology and nanosuspensions 
Nanocrystals for drug delivery has a characteristic size in the nanometer range. Depending on 
the field of discipline, there has been a discussion on the exact definition of a nanoparticle. 
For example in colloidal chemistry, it is below 100nm. However, in the pharmaceutical area, 
the size 1-1000 nm is more appropriate (Junghanns and Müller, 2008). The properties of 
nanoparticles change due to their small particle size and an increased surface area to volume 
ratio when compared with larger objects. An increased surface area means increased 
reactivity (different elastic, tensile and magnetic properties) and increased conductivity 
(tendency to reflect and refract light). Nanotechnology is gaining popularity because it has 
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the possibility of large-scale manufacture (McNeil, 2009). Nanoparticles are engineered to 
have several applications in healthcare, in aerospace, in food additives, and in information 
technology. The types of nanoparticles used in the nanotechnological biomedical applications 
include liposomes, nanoemulsions, nanocrystals, carbon nanotubes, nanoshells and metal 
oxides (Gao et al., 2013; Shegokar and Müller, 2010). Only a few of these types of 
formulations will be discussed in detail.  
 
Nanosuspensions represent an interesting and potentially useful method for improving the 
bioavailability of hydrophobic drugs. Nanosuspensions are defined as unique liquid sub-
micron colloidal dispersions of nanosized pure drug particles that are stabilised by a suitable 
polymer and/or surfactant (Wang et al., 2013b). Generally, the biopharmaceutical advantages 
of water-insoluble drugs formulated as nanosuspensions include: improvements in formula-
tion performance, (such as high drug loading), reproducibility of oral absorption, improved 
dose-bioavailability proportionality, reduced toxicity and side-effects, and increased patient 
compliance via a reduction in the number of oral units that must be administered (Shegokar 
and Müller, 2010). This technology makes use of an excipient (an inert substance used as a 
diluent or vehicle for a drug), thereby reducing the risk of toxicity by these components. 
 
Certain nanotechnological reformulations of existing drugs show a decreased toxicity in 
comparison with the free native form. A good example is a drug in development by CytIm-
mune Sciences, Inc. (under the trade name Aurimune
®
) (Paciotti et al., 2004). This drug is 
comprised of TNF-α bound to a polyethylene glycol- (PEG)-coated nanosized colloidal gold. 
A decade ago PEG was discontinued as a drug during clinical trials due to immune toxicity. 
However, in this “Aurimune” form, the same quantity of TNF-α is given to patients with mi-
nimal side effects (McNeil, 2009). Nanoparticles can serve as an alternative to conventional 
administration vehicles. For example, paclitaxel (sold under the trade name Taxol
®
) is a 
chemotherapeutic drug that is insoluble in water. For its effective administration, it is mixed 
with the toxic polyoxyethylated castor oil. However, Abraxane
®
, an albumin-bound form of 
paclitaxel, is based on production using nanotechnology of albumin as an alternative to Cre-
mophor EL. Abraxane (which gained approval from the FDA in 2005), has been shown to be 
both more effective and less cytotoxic than Taxol (Desai et al., 2006; Green et al., 2006).  
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It is possible to attach a variety of chemical compounds to a nanoparticle scaffold and each of 
these moieties performs a specific medical function. This renders the nanoparticle multifunc-
tional. As an example, ligands for particular cellular receptors can be attached to the nano-
particle to assist active targeting to the tissues expressing those receptors. In addition, PEG 
can also be bound to the nanoparticle to increase solubility as well as biocompatibility (Patri 
et al., 2005).  
 
1.6.1  Types of nanoformulations  
1.6.1.1  Nanostructured lipid carriers and solid lipid nanoparticles 
Lipid nanoparticles are made from highly purified lipid blends. The particle size is mainly 
between 150-300 nm, smaller sizes, e.g. <100 nm or larger sizes to up to 1000 nm can be 
obtained as well for special needs (Muller et.al., 2011). There are two generations of lipid 
nanoparticles. The first is the nanostructured lipid carriers (NLC) and the second, solid lipid 
nanoparticles (SLN). These nanoparticles can be widely applied to deliver drugs/actives 
through oral, parenteral and topical routes (Das et al., 2012; Müller et al., 2011b). NLCs 
consist of a lipid matrix with a special nanostructure (Figure 1.11). This nanostructure im-
proves drug loading and firmly incorporates the drug during storage. The NLCs can be pro-
duced by high-pressure homogenisation (HPH) and the process can be modified to yield lipid 
particle dispersions with solid contents from 30 to 80% (Radtke et al., 2005). SLNs are made 
from solid lipids only, while the NLCs are made from a blend of solid and liquid lipids, with 
the blend being solid at room temperature. SLN lipids are biocompatible and biodegradable 
with GRAS (Generally Recognised as Safe) status. SLNs have some advantages such as: (i) 
avoiding the use of organic solvents in their preparation, (ii) possessing negligible toxicity, 
(iii) bioavailability of highly lipophilic molecules can be increased via lymphatic uptake and 
(iv) sustained drug release from the nanoparticle matrix is possible due to the solid nature of 
the matrix, leading to prolonged drug release and minimisation of the adverse side-effects of 
the encapsulated drug molecule (Das et al., 2012; Muller and Keck, 2012; Müller et al., 
2001).  
 
The addition of oil to the NLC formulation distorts the formation of the perfect lipid crystal. 
The imperfection created allows for the incorporation of the drug (Müller et al., 2011b). Due 
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to the high drug load and the stability of the formulation during storage, NLC is often pre-
ferred over the SLN formulation. 
 
Figure 1.11. An Illustration of the differences between the NLC and SLN matrix structure. The 
crystalline nature of the SLN allows for a low drug load and with time, the drug precipitates out of 
solution. The modification of the NLC to form a Welsh stone-like model allows for a high drug load. 
With time there is not much change in the lipid formation, resulting in long-term stability. Adapted 
from Müller et al. (2011b). 
 
In the initial phase of the preparation, the lipid phase is melted and the drug is dissolved in 
molten lipid. This drug-lipid melt is dispersed in an aqueous surfactant solution that has also 
been heated to the same temperature. The dispersion is performed using a high-speed stirrer. 
The emulsion is homogenised using a piston-gap high-pressure homogeniser (Radtke et al., 
2005). 
 
As dispersions are stored for a longer period, the particles begin to aggregate. In a highly 
concentrated NLC dispersion, particles form a pearl-like network. Particles are in a fixed po-
sition and cannot undergo collision and peri-kinetic flocculation (Radtke et al., 2005). Once a 
formulation has been administered and diluted with fluids (e.g. gastrointestinal fluids), the 
network is destroyed, leaving single non-aggregated particles. It is very important that NLCs 
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remain stable after preparation for long-term storage and a longer shelf life (Das et al., 2012). 
A well-known area of application of NLCs is in oral administration (Tiwari and Pathak, 
2011; Ghosh et al., 2008). Lipids promote the absorption of a variety of drugs, thus 
promoting the use of lipid particles in drug delivery.  
 
Figure 1.12. The mechanism of drug uptake after an oral administration of a drug-loaded lipid 
nanoparticle. 1) After oral administration, lipid nanoparticles adhere to the gut wall. 2) The drug is 
released exactly where the absorption takes place. 3) Particles are surface-degraded by anchorage of 
the lipase-co-lipase complex into the surface. 4) Triglycerides are degraded on the particle surface to 
form micelles which load themselves in the degrading lipid mix. 5) Micelles interact with bile salts to 
form mixed micelles. 6) Lipids and micelles are absorbed simultaneously. Adapted from Müller et al. 
(2011b). 
 
After oral administration, the lipid nanoparticles adhere to the gut wall (see figure1.12 (1)) 
and the drug is released exactly where the absorption takes place (Figure 1.12 (2)). The par-
ticles are surface degraded by the anchoring of the lipase-co-lipase complex onto the surface 
Figure 1.12 (3)). On the particle surface, the triglycerides are degraded to active 
monoglycerides (figure 3.12 (4)), forming micelles. Micelles interact with bile salts to form 
mixed micelles (figure 3.12 (5)). The micelles load themselves with the drug present in the 
degrading lipid matrix. From the micelles the lipids and drugs are absorbed (Figure 1.12 (6)) 
(Müller et al., 2011b).  
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NLCs can be incorporated into traditional dosage forms like tablets or pellets. This is 
achieved by using the NLC dispersion as granulation fluid or wetting liquid for the pellet 
mass. Another well-known area of application is a topical application. There are many advan-
tages of drug delivery as lipid particles, in comparison with the usual creams and ointments. 
Due to the high constituency of the NLC dispersion, they can easily be used as topical dosage 
forms without additional processing (Radtke et al., 2005). Further applications of NLCs 
include their application for dermal and mucosal application, oral delivery, intravenous injec-
tion and drug targeting, inhalation, ocular delivery, peptide and protein delivery, and as adju-
vants (Mitri et al., 2011; Shegokar and Müller, 2010; Almeida and Souto, 2007). In addition, 
NLCs can be used in nutraceuticals (Müller et al., 2011b).  
 
1.6.1.2 Nanoemulsions 
Emulsions are dispersions of one liquid phase in another immiscible liquid phase, using me-
chanical shear (Figure 1.13C).  
 
Figure 1.13. Formation of a nanoemulsion. (A) Two immiscible liquids, such as oil and water, will 
separate into a layer of the less density. (B) The addition of a surfactant, generally soluble in the 
continuous phase, adsorbs on the oil-water interface and exchanges with monomers and micelles in 
solution. (C) A mechanical shear is applied to the system, causing the oil to break up into droplets that 
are coated with the surfactant and are inhibited from coalescing due to the interfacial repulsion. (D) 
After the shear has been stopped, the emulsion can persist for many years and a fraction of the shear 
energy applied is stored in the greater surface area of the droplets. Adapted from Mason et al. (2006).  
 
A 
C 
B 
D 
63 
 
Nanoemulsions are made up of very fine oil-in-water dispersions and their structures depend 
on the system used in their preparation. Nanoemulsions are very fragile systems by nature. 
They are usually transparent after preparation and usually very fluid. Due to these 
characteristics, destabilisation appears easily and they become opaque and creaming or 
emulsification may be visible (Sonneville-Aubrun et al., 2004).  
 
The emulsification methods for nanoemulsions are generally achieved using high-shear stir-
ring, high-pressure homogenisers and ultrasound generators. The apparatus supplying the 
available energy in the shortest time and having the most homogeneous flow produces the 
smallest sizes. HPH has been shown to be the best apparatus (Solans et al., 2005) and is the 
most commonly emulsifying machinery used in the preparation of emulsions. Generally, the 
conventional high-pressure homogenisers work in a range of pressures between 50 MPa and 
100 MPa. However, pressures as high as 350 MPa have been achieved with modern high-
pressure homogenisers (Müller et al., 2011a).  
 
The small droplet size of a nanoemulsion gives it stability against sedimentation because of 
the Brownian motion and consequently, the diffusion rate, is higher than the sedimentation 
rate induced by the force of gravity. Ostwald ripening or molecular diffusion, which arises 
from emulsion polydispersity and the difference in solubility between small and large 
droplets, is the main mechanism for nanoemulsion destabilisation (Tadros et al., 2004). 
 
The small droplet size, high kinetic stability and optical transparency of nanoemulsions 
compared with conventional emulsions, are advantageous for their use in many technological 
applications. Apart from their applications as reaction media, nanoemulsions are of great 
interest in the pharmaceutical and cosmetic industries. They are used as drug delivery sys-
tems for administration through various systemic routes. Nanoemulsions are advantageous 
for intravenous administration. Due to the strict requirements of this route of administration, 
it is of great importance that the formulation droplet size is lower than 1 µm. Parenteral (in-
jectable) administration of nanoemulsions is employed for a variety of purposes, namely: nu-
trition (including the administration of fats, carbohydrates, vitamins, amongst often), 
controlled drug release and targeting of drugs to specific sites in the body and the delivery of 
vaccines or as gene carriers (Tamilvanan et al., 2005).  
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There have been many cases where nanoemulsions have been used as oral administration of 
drugs and studies showing the absorption of the emulsion in the gastrointestinal tract. These 
studies have been correlated to the small droplet size of the emulsion. Nanoemulsions have 
also been used as ocular delivery systems to sustain the pharmacological effect of drugs in 
comparison with their respective solutions. Another example of an application of nano-
emulsion polymerisation is the production of low-viscosity high-solid-content latexes (Asua, 
2002). The production of polymeric particles that contain fluorescent dyes has been achieved 
using nanoemulsions (Tronc et al., 2004). The preparation of liquid-core capsules which have 
applications in efficient encapsulation and controlled delivery of a wide range of drugs, dyes, 
and numerous other applications, have been achieved in nanoemulsions (Scott et al., 2005).  
 
1.6.1.3 Nanocrystals 
The term nanocrystals is commonly used to define drug nanocrystals with a size in the nano-
metre range and having a crystalline character (Junghanns and Müller, 2008). Another cha-
racteristic of nanocrystal drugs is their composition (100% drug) and the absence of a carrier 
material as in polymeric nanoparticles. Dispersion of drug nanocrystals in liquid media leads 
to “nanosuspensions”, a term often used interchangeably with nanocrystals (Wu et al., 2014; 
Shegokar and Müller, 2010; Sahoo et al., 2008). Depending on the method of processing, 
some nanocrystals can exist in the amorphous state or in a crystalline state. The dispersion 
medium can be either aqueous or non-aqueous. The reduction in the size of nanocrystals 
leads to an increase in surface area, aiding to an increase in dissolution velocity (Shegokar 
and Müller, 2010). The saturation solubility is also increased in nanocrystals as the particle 
size gets smaller. This offers some advantages, in that the dissolution velocity and the con-
centration gradient between the gut and the lumen are enhanced (Junghanns and Müller, 
2008).  
 
Production of nanocrystals can be achieved by precipitation, milling or homogenisation meth-
ods. In precipitation methods, the drug is dissolved in a solvent and then added to the surfact-
ant solution. This leads to the precipitation of finely dispersed drug nanocrystals. The nano-
crystals are often stabilised with a surfactant. They have to be soluble in at least one solvent, 
which may create problems for newly developed drugs that are insoluble in both aqueous and 
organic media. Therefore, this method of production is unpopular (Junghanns and Müller, 
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2008). In the milling method, the classical NanoCrystals
®
 technology uses a bead or a pearl 
mill to achieve particle size reduction. A milling medium, dispersion medium (generally 
water), a stabiliser and drug are added to the milling chamber. The impact of shear force that 
is generated by the movement of the milling media leads to particle size reduction. In contrast 
with HPH, it is a low-energy milling technique. Smaller or larger milling pearls are used in 
the milling process. These pearls consist of ceramics (cerium- or yttrium-stabilised zirconium 
dioxide), stainless steel, glass or highly cross-linked polystyrene resin-coated beads 
(Junghanns and Müller, 2008).  
 
Another type of nanocrystal production method is homogenisation, which employs three im-
portant technologies, namely: 1) microfluidiser technology (insoluble drug delivery platform 
[IDD-P™™] technology), 2) piston gap homogenisation in water, and 3) in water mixtures or 
in non-aqueous media (Nanopure® technology). The microfluidiser technology can generate 
small particles by a frontal collision of two fluid streams under pressures of up to 1 700 bar, 
achieved with a jet stream homogeniser such as a microfluidiser. Surfactants are needed for 
stability of the particles; however, this method of particle size reduction requires a high num-
ber of cycles (50 to 100 cycles). Production of nanoparticles is achieved at room temperature. 
Briefly, a drug is dispersed in an aqueous surfactant solution and subsequently forced by a 
piston through the small homogenisation gap with pressures up to 2 000 bar (Figure 1.14). 
The width of the homogenisation gap, depending on the viscosity of the suspension and the 
applied pressure, ranges from about 5 µm to 20 µm (Möschwitzer, 2005). The resulting high 
streaming velocity of the suspension causes an increase in the dynamic pressure. This is 
compensated for by a reduction in the static pressure which is below the vapour pressure of 
the aqueous phase.   
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Figure 1.14. A schematic showing a cross-section of a high-pressure homogenisation using a piston-
gap homogeniser. The image is taken from Junghanns and Müller (2008). 
 
Formation of gas bubbles occurs because the water starts to boil at room temperature. These 
gas bubbles collapse immediately when the liquid leaves the homogenisation gap, being 
again under normal air pressure (1 bar). This phenomenon of formation and implosion of the 
gas bubbles is called cavitation and it results in shockwaves. The drug particles are reduced in 
size due to high shear forces, turbulent flow and the enormous power of these shockwaves 
(Müller et al., 2001). 
 
Currently, more than half of all new drug candidates that enter the development pipeline fail 
because they are insoluble in water, rendering them with non-optimal physicochemical and 
biopharmaceutical properties (Wang et al., 2013b). Nano-sized pure drug particles are stabil-
ised by a suitable polymer and/or surfactant (Müller et al., 2011a). To improve the stability of 
nanosuspensions, a good stabiliser needs to be chosen for the drug of choice. Some 
applications of nanocrystals include an oral drug delivery system. Table 1.2 shows some 
nanocrystal products on the market. It is vital for a compound to be able to dissolve and 
diffuse through the gastrointestinal membranes for it to achieve its biological activity.  
 
Piston  
Drug suspension 
Valve seat 
Homogenization gap 
Product outlet 
Valve  Nanocrystals 
Piston  
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Table 1.2. Examples of nanocrystal products on the market. Adapted from Shegokar and Müller 
(2010).  
Trade name Therapeutic use 
Applied 
technology 
Pharmaceutical 
company 
Administra
tion route 
Rapamune
®
 
(Rapamycin,  
Sirolimus) 
Immunosuppressive élan nano-
systems 
Wyeth Pharmaceuticals Oral 
Emend
®
 
(Aprepitant) 
Antiemetic élan nano-
systems 
Merck & Co Oral 
Tricor
®
 
(Fenofibrate) 
Hypercholesterolemia élan nano-
systems 
Abbott Laboratories Oral 
Triglide
®
 
(Fenofibrate) 
Hypercholesterolemia IDD-PÂ® 
technology 
Produced by SkyePharma 
marketed by Sciele 
Pharma Inc (Atlanta, GA, 
US). 
Oral 
Megace ES
®
 
(Megestrol 
acetate) 
Antianorexic élan nano-
systems 
Par Pharmaceutical 
Companies Inc (Spring 
Valley, NY,  US) 
Oral 
Avinza
®
 
(Morphine 
sulphate) 
Psychostimulant drug élan nano-
systems 
King Pharmaceuticals Oral 
Focalin
®
 XR 
(Dexmethylpheni
date HCl) 
CNS stimulant (mild 
stimulant) 
élan nano-
systems 
Novartis Oral 
Ritalin
®
 LA 
(Methylphenidate 
HCl) 
CNS stimulant élan nano-
systems 
Novartis Oral 
Zanaflex capsules 
(Tizanidine HCl) 
Muscle relaxant élan nano-
systems 
Acorda Oral 
 
Parenteral or intravenous application methods often require the use of solubilisation by a sur-
factant. The characteristics of nanocrystals have promoted the exploitation of adhesion, fast 
dissolution and increased penetration for dermal and mucosal application. This discovery 
took place when the poorly soluble antioxidants rutin, apigenin, and hesperidin were 
formulated as nanosuspensions for application in skin-protective and anti-ageing cosmetic 
products (Mauludin and Müller, 2013). Nanocrystals have been reported to possess some 
application in nutrition. The nutraceutical market is growing and there are many nutriceutical 
compounds, e g antioxidants, coenzyme Q10, rutin, hesperidin, and apigenin, which are 
poorly soluble (Shegokar and Müller, 2010). 
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1.6.2 Characterisation of nanoformulations 
1.6.2.1 Photon correlation spectroscopy and polydispersity index 
Photon correlation spectroscopy (PCS) is a widely used technique for measuring the size of 
particles in the submicron range (Thode et al., 2000). Dynamic light scattering and quasi-
electric light scattering are alternative expressions for PCS. In PCS, particle dispersions are 
illuminated with a laser light. The dispersed particles have to exhibit random movements due 
to Brownian motion. This limits the particle size to a maximum because no sedimentation or 
flotation of particles should occur. The particle movement is related to the particle size by 
calculating an auto-correlation function from the time-dependent intensity fluctuation of the 
scattered light. Small particles have a higher diffusion velocity, and therefore, a higher time-
dependent intensity fluctuation of the scattered light, which results in a faster decay of the 
calculated auto-correlation function than observed for larger particles. The obtained diameter 
is the diameter of a sphere that has the same diffusion coefficient as the particle (Pecora, 
2013).  
 
The ratio of weight average molecular mass to the number average molecular mass is called 
the polydispersity index (PI). The PI is a dimensionless value ranging from 0 to 1. A PI of 
0.03 to 0.06 indicates a monodisperse particle size distribution. A narrow distribution is de-
scribed with a PI between 0.10 and 0.20. A broad distribution typically has a PI between 0.25 
and 0.50. A PI > 0.5 indicates a broad particle size distribution with an unknown shape 
(Müller and Schuhmann, 1996). 
 
1.6.2.2 Laser diffractometry 
Laser diffractometry (LD) is a technique for measuring the particle size of nanoparticles and 
microparticles. Static light scattering is synonymous with LD. The principle of LD is based 
on the fact that light is not only diffracted but also reflected, refracted and absorbed. 
However, this depends on the particle size of the sample under investigation (Jones, 1977). In 
LD measurement, the laser light is widened by an optical system for the illumination of a 
sample cell. In the sample cell, light is scattered on the particles under investigation. With a 
Fourier lens, the diffraction patterns are focused on the same area of the multi-element 
detector, independent of where the particles are located in the sample cell. The collected 
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information is used to calculate the particle size with the aid of a computer software (Keck 
and Müller, 2008; Ulanowski et al., 2002).  
 
1.6.2.3 Zeta potential 
The zeta potential gives a prediction of the long-term stability that a dispersed system will 
have. Due to the presence of ionised groups on the particle surface, particles exhibit a surface 
charge, which results in the creation of a stern potential (Ψδ), also known as the Nernst poten-
tial, and is related to a distance in the dispersant medium (Schroeder et al., 1987). The bound-
ary between the resident part and the removed part of the diffuse layer is called the hydrody-
namic shear plane. The potential exhibited at the hydrodynamic shear plane is called zeta po-
tential. The zeta potential is measured by Laser Doppler Anemometry by applying an electri-
cal field in which the equilibrium between friction forces and particle acceleration is reached 
and the particles move with a constant velocity. This is also known as electrophoretic mo-
bility.  
 
Figure 1.15. A simplified diagram depicting the model of the electric double layer at a charged inter-
face in an aqueous solution. The image was adapted from Lyklema (2005).  
 
Most particles exhibit a negative surface charge (Figure 1.15). On the negatively charged sur-
face, negative dehydrated ions are adsorbed in most of the cases. At short distances, Van der 
Waals forces are stronger than electrostatic forces, which explains the adsorption of negative-
ly charged particles on the negatively charged particle surface. These forces are strong 
enough to cause the loss of the hydrate layer of the ions. The outer layer, which consists of 
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hydrated, positively charged ions, is fixed due to electrostatic interactions. The inner layer 
and the outer layer also called the stern layer, are fixed to the particle surface, and cannot be 
removed during the movement of the particle in an electrical field. The stern layer is followed 
by the diffuse layer. In the diffuse layer, freely movable, hydrated positively charged ions 
(counter-ions) and negatively charged ions are present. Close to the stern layer the concentra-
tion of positively charged particles is high due to electrostatic attraction and decreases with 
increasing distance from the particle surface. Due to this, an exponential decay of the po-
tential can be observed in the diffuse layer. If the particle is accelerated in an electrical field, 
parts of the diffuse layer can be removed (Lyklema, 2005). 
 
1.6.3 Physical stability of formulations  
Stability tests of formulations provide evidence on how the quality of a formulation varies 
with time under the influence of a variety of environmental factors. Nanosuspensions are con-
sidered to be physically stable if the particle size distribution is not changing or changes only 
within defined limits during the observation period under the storage conditions (Wang et al., 
2013b). Physical instabilities which may occur in suspensions and nanosuspensions are ag-
glomeration, aggregation, sedimentation, flotation, caking and crystal growth (Mauludin and 
Müller, 2013). 
 
The physical stability of dispersions is a function of stabilising electrostatic repulsion and de-
stabilising Van der Waals attraction. Crystal growth in suspensions can occur because of Ost-
wald ripening, which is caused by differences in the solubility and the concentration gradient 
between small and big particles (Wu et al., 2014; Wang et al., 2013b; Muller and Keck, 
2012). Small particles exhibit a higher degree of curvature and, therefore, a higher solubility 
than larger particles. Molecules from the higher concentrated solution around small particles 
diffuse to the vicinity of larger particles, where a lower concentration is present. This causes 
the growth of the large particles due to super-saturation and drug crystallisation. At the same 
time, the concentration in the vicinity of the small particles drops below their saturation 
solubility, leading to a further dissolution of a drug from small particles. This process finally 
leads to the disappearance of the small particles and a further growth of the larger ones 
(Müller et al., 2001).  
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1.6.4 Scanning electron microscopy 
Scanning electron microscopy (SEM) is a type of electron microscopy that visualises a sam-
ple surface by scanning it with a high-energy beam of electrons in a raster scan pattern. This 
method can be used to study surfaces of solid objects directly, e.g. surface topography, com-
position and conductivity. In the current study, SEM was used to obtain information about the 
size and shape of nanoparticles produced by high-pressure homogenisation. 
 
In summary, the literature review covered T2D and its role in peripheral tissues as well as 
how selected proteins and adipokines are affected in the disease. A review was provided by 
the anti-diabetic treatments, including the medicinal plant L. leonurus and marrubiin and the 
use of nanoformulation as a possible drug formulation target. The literature review provided 
the basis for the next chapter which introduces the aims and objectives of the present study.   
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2 CHAPTER 2: INTRODUCTION TO THE PRESENT STUDY 
Marrubiin is a constituent found in the plant L. leonurus. The extraction and quantification of 
marrubiin from a plant extract are usually desired when one needs to investigate its physio-
logical function. Purchasing commercial marrubiin is expensive and therefore effective 
isolation and accurate quantification methods need to be developed for marrubiin from the L. 
leonurus extract as there is no effective reported method in literature. Thus, the initial part of 
this work is aimed at achieving an optimal RP-HPLC method for the effective isolation and 
quantification of marrubiin in the organic leaf extract of L. leonurus.  
 
The medicinal properties of L. leonurus plant extract, as well as marrubiin, have been 
reported extensively in literature (Mazimba, 2015; El-Mohsen et al., 2014; Popoola et al., 
2013; Maphosa, 2012; Mnonopi et al., 2012; Paula de Oliveira et al., 2011). Furthermore, 
recent findings have reported the anti-diabetic potential of the plant extract as well as 
marrubiin (Mnonopi et al., 2012). The mechanism of their anti-diabetic action, however, still 
remains unknown. Thus, the biomarkers affected by T2D will be investigated to gain an 
understanding of the mechanism of anti-diabetic action of the plant extract as well as 
marrubiin. 
 
It is known that insulin resistance and T2D are associated with the dysfunction of various 
adipokines, as well as other proteins and peptides involved in glucose and insulin 
homeostasis. Some of the adipokines that are affected by insulin resistance and diabetes will 
be investigated in the study. Insulin resistance studies are normally performed in muscle, 
liver and adipose tissue, where insulin exerts its main metabolic action. The plasma 
adipokines and expression of proteins associated with peripheral tissues harvested from the in 
vivo rat model will be investigated in these tissues at the genetic level to understand their 
mechanism of action. The following genes will be investigated as they are markers of 
dysfunction in T2D: leptin, adiponectin, resistin, glucose transporters 2 and 4, IRS-1, GK, 
PPAR-γ, PEPCK, FAS and UCP-2. These proteins and adipokines have been discussed in 
Chapter 1. The role that the adipokines and proteins play in T2D can be summarised as 
follows: leptin is involved in appetite suppression and weight gain and is also known to be 
involved in the regulation of insulin synthesis (Newman and Gonzalez-Perez, 2013). 
Adiponectin is known to be a regulator of insulin sensitivity and has a protective effect 
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against many major obesity-related pathologies (Yamauchi et al., 2014). Resistin is involved 
in the induction of insulin resistance. PPAR-γ is involved in adipogenesis, lipid metabolism 
and glucose homœostasis (Al-Suhaimi and Shehzad, 2013). GK plays a key role in glucose 
sensing in β-cells and also regulates glucose metabolism in the liver. The glucose transporters 
are responsible for facilitating glucose uptake in various tissues. PEPCK is an enzyme that 
plays a key role in gluconeogenesis. FAS is regulated by insulin and is involved in weight 
gain as well as obesity (Berndt et al., 2007). The IR substrates are involved in downstream 
signalling of the insulin signalling pathway and defects in its functioning and expression are 
associated with insulin resistance and T2D. The mitochondrial uncoupling proteins are 
responsible for uncoupling oxygen consumption by the respiratory chain from ATP synthesis, 
with UCP-2 acting in the negative regulation of insulin secretion by β-cells and in fatty acid 
metabolism (Diano and Horvath, 2012). Thus, any abnormal functioning of these proteins is 
linked to T2D.  
 
The link between muscle, fat and liver tissue will be further investigated in an in vitro system 
to determine the crosstalk between these tissues. Thus, the effect of conditioned medium 
from muscle (C2C12), Chang liver and 3T3-L1 fat cell lines on insulin secretion in INS-1E 
cells will be investigated.  
 
It is known that the organic leaf extract of L. leonurus, as well as marrubiin, is insoluble in an 
aqueous medium (Agnihotri et al., 2009). For it to be administered effectively it must initially 
be dissolved in an organic solvent. The organic solvent used needs to be safe for in vivo ad-
ministration to minimise toxicity. Currently, no literature is available on the nanoformulation 
of L. leonurus plant extract. The approach of incorporating the plant extract into 
nanoformulation is due to the enhancement of the solubility of poorly soluble drugs (Müller 
et al., 2011b). Thus, the focus of the final section of this study was to effectively incorporate 
the L. leonurus extract into different nanoformulations and determine their stability and 
whether the formulations retain their anti-diabetic properties. Thus, aims to harness the 
advantages that nanoformulations possess, such as enhanced solubility, low toxicity as well 
as its efficacy to maintain its medicinal properties, as an anti-diabetic agent.  After the 
nanoformulations have been prepared, the known anti-diabetic action will be investigated to 
ensure that the extract has retained its anti-diabetic properties.  
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2.1 Aims and objectives 
The aims and objectives of this study include: 
1. The quantification of marrubiin in an aqueous leaf extract of L. leonurus using RP-HPLC 
and MS analysis: 
a) Organic extraction of the leaves of L. leonurus using acetone. 
b) RP-HPLC analysis of the components in the plant extract and quantification of mar-
rubiin. 
c) Detection and confirmation of the chemical structure of the marrubiin using liquid 
chromatography/tandem mass spectroscopy. 
2. To determine the mechanism of action of the organic extract of L. leonurus and marrubiin 
in vivo and in vitro: 
a) Determine the effect of L. leonurus and marrubiin on the expression of genes com-
monly affected by T2D, in the adipose, muscle and liver tissue, associated with the in 
vivo rat model: 
i. Liver tissue: GK, PEPCK, GLUT-2, GLUT-4, FAS, PPAR-γ and IRS-1. 
ii. Muscle tissue: GK, PEPCK, GLUT-4, FAS, PPAR-γ and IRS-1. 
iii. Fat or adipose tissue: GK, PEPCK, GLUT-4, FAS, PPAR-γ, IRS-1, UCP-2, 
leptin, adiponectin and resistin.  
b) Investigating the effect of conditioned medium from adipose tissue, muscle and liver 
cell lines on insulin release in INS-1E cell lines (cross-talk between the peripheral tis-
sues and β-cells) using conditioned media (CM). Conditioned medium  can be defined 
as culture medium containing biologically active components obtained from 
previously cultured cells or tissues that have released metabolites, growth factors and 
extracellular matrix proteins into the medium to affect certain cell functions (e.g., 
growth or lysis) (Dowling and Clynes, 2011).  
 
3. To prepare nanoparticle formulations of  the organic extract of L. leonurus and investigate 
its physical properties as well as its anti-diabetic potential: 
a) Preparation of nanocrystals, nanoemulsions and NLC using the organic leaf extract of 
L. leonurus. 
b) Investigating the physical properties of the formulations. 
c) Investigating the in vitro cytotoxicity (in Chang and INS-1cells) of the prepared form-
ulations. 
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d) Investigating the anti-diabetic properties (i.e. insulin-stimulated glucose uptake in 
Chang cells and insulin secretion in INS-1 cells) of the prepared formulations. 
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3 CHAPTER 3: EXTRACTION AND ANALYTICAL QUANTIFICATION OF 
MARRUBIIN FROM LEONOTIS LEONURUS 
3.1 Introduction  
To best understand the biological properties that a medicinal plant extract elicits, its individ-
ual chemical compounds need to the determined. There are often difficulties in the isolation 
and quantification of the active compound(s) within an extract, due to the low concentration 
of the active compounds and the difficulty of optimising biochemical procedures that are able 
to identify and isolate the individual components within the extract. The aim of this section 
was to isolate and accurately quantify the active compound, marrubiin, from an organic leaf 
extract of L. leonurus.  
 
3.2 Materials and methods  
All reagents used, unless otherwise stated, were of an analytical grade. 
 
3.2.1 Marrubiin extraction from Leonotis leonurus 
L. leonurus was collected at Nelson Mandela Metropolitan University (NMMU) Port Eliza-
beth (South campus) and identified by Mr C W Thomas (curator of the herbarium, Depart-
ment of Botany, NMMU). The extraction procedure was a modification of the method used 
by Light et al. (2002). Briefly, the leaves were rinsed with distilled water and dried at 50˚C in 
an oven. The dried leaves were crushed and immersed in 10 ml of acetone per gram of plant 
material. The plant suspension was sonicated for an hour at room temperature and filtered 
through Whatman No 1 filter paper. The solvent was removed from the filtrate using a rotary 
evaporator at 60˚C. Thereafter the residue was freeze-dried and stored in the dark at 4˚C in a 
desiccator, until further use (Light et al., 2002). 
 
3.2.2 Reversed phase high-performance liquid chromatography 
3.2.2.1 Experimental optimisation for the quantification of marrubiin 
Firstly, marrubiin was quantified in the L. leonurus extract by using a C18 RP-HPLC column 
(Luna 5 µm, C18, 250 µm × 4.60 µm) via Systems Gold software.  The mobile phase and 
flow rate were optimised until a complete separation of all the peaks was achieved. 
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Commercial marrubiin was used as a standard to aid in the identification of the marrubiin in 
the L. leonurus extract. Due to the poor resolution of the peaks in the plant extract, an 
alternative method was employed. A Kinetex 2.6 µm PFP (100 mm × 4.6 mm) column fitted 
with a guard column was used with water and acetonitrile as the mobile phase. Flow rates and 
mobile phase compositions were optimised to achieve an optimal separation.  
 
3.2.2.2 RP-HPLC quantification 
Due to marrubiin having a complex ring structure, RP-HPLC was performed with the Kinetex 
2.6 µm PFP column fitted with a guard column. RP-HPLC was performed on an Agilent 
1290 Infinity HPLC system (Agilent Technologies, US). The mobile phase was acetonitrile 
and water (50:50, v/v). Chromatography was performed at 40°C at a flow rate of 1 ml/min, 
and the run time was 6 min. The column was rinsed with 100% acetonitrile after each run and 
was stored in 95% acetonitrile.  A standard curve was generated using commercial marrubiin 
(LGC Promochem, Germany) at a concentration range of 0.025 to 0.25 mg/ml (Appendix 
Figure A1). 
 
3.2.3 Mass spectrometry analysis 
MS analysis was performed in the Department of Biochemistry at the University of Fort Hare 
(Alice, South Africa), with the assistance and supervision of Prof G Bradley. MS analysis 
was performed on the L. leonurus plant extract to isolate and identify the marrubiin. This was 
performed on an RP-HPLC instrument coupled to an MS instrument. The L. leonurus extract 
was loaded on an Agilent 1200 series HPLC instrument (Agilent Technologies, US), 
equipped with a quaternary pump (G13311A, US), a degasser (G1322A, US), a diode-array 
detector (G1315D, US), an autosampler (G1329A, US) and a column compartment (G1316A, 
US). Chromatography was performed at 40
°
C using a Kinetex 2.6 µm PFP column (100 mm 
× 4.6 mm) fitted with a guard column. The mobile phase for the chromatography was aceto-
nitrile and deionised water (50:50, v/v) at a flow rate of 1.0 ml/min. The injection volume 
was 5.0 µl. A gradient elution system was incorporated into the MS analysis which provided 
for an equilibration step (Table 3.1). Mass spectrometric analysis was operated in the positive 
ESI mode at a spray voltage of 4 500 V and a capillary temperature of 450°C. Nitrogen was 
used as a sheath gas. Ultra-high pure nitrogen was used as a collision gas and the pressure 
was maintained at 45 Torr.  
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Table 3.1. RP-HPLC mobile phase composition for the MS analysis of L. leonurus extract. 
LC run time (min) Acetonitrile (%) Water (%) 
0.00 50 50 
7.50 50 50 
8.00 100 0 
9.00 100 0 
9.50 50 50 
20.00 50 50 
 
3.3 Results and discussion 
In the past, analysis of plant extracts for their biological activities has always relied on HPLC 
fingerprints (Merfort, 2002; Katalinić, 1997; Perez-Souto et al., 1992). Various methods have 
been used in the quantification of active compounds in plant extracts, including, ion-pairing 
HPLC using ion-pairing reagents, thin layer chromatography (TLC) and RP-HPLC (Mnonopi 
et al., 2011).  
 
Marrubiin is obtained from L. leonurus as well as other plant species such as Marrubium vul-
gare and Marrubium alysson. Literature shows that marrubiin has been isolated from these 
plant species and most authors have analyzed low yields of marrubiin (El-Mohsen et al., 
2014). Marrubiin has been successfully extracted with organic solvents, as the aqueous 
extract often reported no marrubiin present upon analysis. This is due to the non-polar nature 
of marrubiin (Mangoni et al., 1972). As discussed in the introductory section, there has been 
numerous published data on the biological importance of marrubiin, making this compound 
an important biomarker for further study.  
 
Quantification of marrubiin in the plant extract was optimised experimentally until a com-
plete separation was attained in the plant extract, allowing marrubiin to be quantified accu-
rately. The result from a chromatographic run of commercial marrubiin showed a single re-
solved peak at 4.96 min (Figure 3.1A). In the plant extract, however, the resulting peaks from 
the extract were not resolved, making accurate analysis and quantification of marrubiin diffi-
cult (Figure 3.1B). The presence of several compounds present in the plant extract may have 
affected the binding properties of marrubiin. To obtain an accurate quantification of 
marrubiin in the plant extract, a more efficient method is required. A chromatographic 
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method able to separate clearly the various compounds in the plant extract into sharp 
symmetrical peaks is needed. Phytochemical analysis of the extract of L. leonurus revealed 
the presence of sterols, diterpenes, triterpenoids, tannins, flavonoids, alkaloids, quinones and 
saponins (Laonigro et al., 1979; Bienvenu et al., 2002). Thus, there are various compounds 
that are present within the plant extract (Mazimba, 2015). And of all the phytochemicals 
reported, marrubiin has shown the most potential biomarker for therapeutic and medicinal 
properties (as discussed previously in this document), including for this study, diabetic 
properties. In figure 3.1B, all the other peaks represent the various phytochemicals within the 
plant extract. However, none has shown medicinal potential, specifically, antidiabetic 
potential.  
 
 
Time (min)  
Figure 3.1. RP-HPLC chromatogram of (A) 0.5 mg/ml commercial marrubiin and (B) 0.5 mg/ml L. 
leonurus plant extract. Chromatography was performed via System Gold software using a Luna 5 µm, 
C18 column (250 µm × 4.60 µm) and water:acetonitrile (70:30) as the mobile phase. Flow rate was 
1.2 ml/min. 
A 
B 
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To achieve effective separation of the compounds in the plant extract, other chromatographic 
methods were investigated. Figure 3.2 shows the optimisation methods for the quantification 
of marrubiin in the extract using the PFP column. Mobile phase composition, as well as flow 
rate, were optimised until the best separation was achieved in the extract. Figure 3.2A shows 
the flow rate at 0.8 ml/min while figure 3.2B shows the flow rate at 1 ml/min. The same 
amount of the extract (1 mg/ml) was loaded in each case, however, binding and separation of 
the components in the plant extract was effective at the higher flow-rate. The commercial 
marrubiin (Figure 3,2C) showed a single symmetrical peak at 4.315 min. The flow rate was 1 
ml/min.  
 
 
 
 
Time (min) 
Figure 3.2. RP-HPLC optimisation experiments of the L. leonurus extract using the PFP column. (A) 
Flow rate 0.8 ml/min, acetonitrile: water (60:40), (B) flow rate 1 ml/min, acetonitrile-water (60:40), 
(C) commercial marrubiin. The flow rate was 1 ml/min, acetonitrile: water (60:40). 
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The Kinetex PFP column has a hydrophobic backbone coupled with ionic interactions of the 
pentafluoride molecules. This improved the separation of the components in the L. leonurus 
extract, when compared with TLC methods as well as various C18 columns protocol (as seen 
in figure 3.1). The chemistry of the column allows for the use of simple solvents such as 
acetonitrile and water. 
 
Wavelength (nm) 
Figure 3.3. Spectral analysis showing the similarity between the different spectra of commercial mar-
rubiin (blue) and the peak of marrubiin in the L. leonurus extract. The analysis was achieved using the 
Kinetex PFP column. mAU = milli absorbance units.  
 
For the quantification of the marrubiin present in the extract, commercial marrubiin was used 
to obtain a calibration curve (Appendix, Figure A1). The areas underneath the peaks of each 
concentration were used to construct the calibration curve and this was used in the analysis of 
the marrubiin content in the L. leonurus extract. A known concentration of the plant extract 
was chromatographed and the area underneath the peak that correlated to the retention time of 
the commercial marrubiin was used in the quantification. In addition, the spectral analysis of 
the commercial marrubiin was compared with the peak of marrubiin in the plant extract. The 
m
A
U
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analysis revealed the peak identity, purity and accurate overlap (Figure 3.3). This analysis 
gave additional evidence that the peak in the plant extract was marrubiin.  
 
Optimisation was further performed for the mobile phase compositions and the best 
resolution of peaks was achieved with acetonitrile:water (50:50) and at a flow-rate of 1 
ml/min. Results showed an effective elution of the commercial marrubiin at 3 min (Figure 
3.4A). The marrubiin in the organic extract also eluted at 3 min (Figure 3.4B) with an elution 
time of only six minutes, attaining resolved peaks for the various components in the organic 
extract of L. leonurus. An additional advantage was that shorter run time used less mobile 
phase. The use of a guard column protects the column from bigger particles which could 
block the column, increasing the longevity of the column and allowing for the analysis of a 
pure sample. 
The concentration of marrubiin in the extract (Figure 3.4B) was calculated to be 10 ± 2% 
(n=3), as extrapolated from the standard curve. This proved to be higher than the yield (0.3%) 
reported by El-Mohsen et al. (2014). 
 
  
 
Figure 3.4. RP-HPLC of commercial marrubiin and L. leonurus extract using a PFP column (10 cm × 
0.46 cm, Phenomenex) (A) Commercial marrubiin (0.2 5mg/ml, 10 µl injection). The retention time 
of commercial marrubiin was 3.01 min. (B) the organic extract (1 mg/ml, 10µl injection). The 
retention time of the marrubiin in the plant extract was 3.00 min. The mobile phase was 
acetonitrile:water (50:50), flow rate, 1 ml/min. Absorbance was monitored at 214 nm. Arrows indicate 
the marrubiin peak. 
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To further confirm that the peak observed using the PFP column was marrubiin, mass 
spectroscopy (LC-MS/MS) analysis was performed on the extract and compared with the 
structure of the commercial marrubiin. The LC-MS/MS results confirmed that the peak 
contained marrubiin (Figure 3.5 A & B).  
 
The marrubiin peak in the organic plant extract was analysed for its structural composition 
and its chemical structure was identified and elucidated using ChemSpider software. This 
yielded a spectrum with an m/z ion of 333.20 (Figure 3.5C). The 333.20 m/z ion analysis re-
vealed a structure which was identical to the structure of marrubiin (Figure 3.5D), thus con-
firming that the peak observed was indeed marrubiin. 
 
Figure 3.5. LC-MS/MS analysis of L. leonurus organic extract for the identification and quantification 
of marrubiin. (A) MS analysis of the leaf extract of L. leonurus, (B) commercial marrubiin, (C) mo-
lecular mass determination of the extract peak from (A), (D) structural analysis of the marrubiin peak 
from (A) using ChemSpider software. Arrows indicate the peaks of marrubiin that were analysed for 
the chemical structure. 
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Structural elucidation of marrubiin has been previously reported by NMR and MS analysis to 
have an m/z value of 333.20. Wu et al. (2013) reported eight new isolated labdane 
diterpenoids from L. leonurus. Although marrubiin was not present in the list, the m/z of the 
structures identified were between 355.20 and 379.20. Marrubiin in the current study was 
identified to have a molecular formula of C20H29O4
+
, similar to that reported by Popoola et al. 
(2013). 
 
The analytical methods for the determination of marrubiin from L. leonurus proved to be ef-
fective. Another labdane diterpene similar to marrubiin is marrubinol. These two compounds 
are both present in M. vulgare. Marrubinol gave a molecular ion peak of m/z = 335.00 in 
negative ES-MS (El Bardai et al., 2003).  
 
The use of the PFP column made quantification easier and faster as compared with conven-
tional methods. MALDI-TOF MS analysis allowed for the structural verification of marrubiin 
in the plant extract. In pharmaceutical industries and toxicology laboratories, LC-MS/MS is 
the method of choice for the development and the quantification and identification of drugs 
(de Jong et al., 2011). For clinical and chemical analyses, LC-MS/MS is rapidly emerging as 
the method of choice, as demonstrated by the number of articles published in the journal 
Clinical Chemistry between 2006 and 2011 that use this technique. LC-MS/MS enables the 
use of sophisticated sample pre-treatment techniques and automation of the whole process by 
on-line coupling of the separate techniques. To account for any losses that will occur during 
sample pre-treatment, analyte separation and detection, stable isotopes of analytes are used as 
internal standards. Non-mass spectrometric methods do not use these isotopes because 
isotopes can only be detected separately from the analyte based on their mass differences. 
Therefore, conventional techniques measure less accurately as compared with LC-MS/MS 
(de Jong et al., 2011). LC–MS/MS has, just as HPLC and GC-MS, the advantage that several 
compounds can be measured simultaneously (Holst et al., 2007), decreasing the analysis 
time.  
 
After the optimisation of the identification and quantification of marrubiin from L. leonurus, 
its anti-diabetic properties were further investigated using an in vivo and an in vitro models, 
in the subsequent chapters.  
85 
 
 
4 CHAPTER 4: ANTI-DIABETIC EFFECT OF LEONOTIS LEONURUS 
EXTRACT AND MARRUBIIN IN VIVO AND IN VITRO  
4.1 Introduction  
Marrubiin and the L. leonurus organic leaf extract have been shown to possess many medi-
cinal properties as reviewed in Chapter 1. Some current findings of the medicinal properties 
of the plant extract and its active constituents include its anti-diabetic properties, which have 
previously been investigated (Mnonopi, 2010; Mnonopi, 2007; Ojewole, 2005). However, 
mechanism of its anti-diabetic action has not been resolved. The effects of marrubiin and the 
organic L. leonurus extract on muscle, fat and liver tissues obtained from obese, insulin-
resistant male Wistar rats were investigated. The initial study which involved treatments of 
rats was performed by Mnonopi et al. (2012).  
 
As discussed in the literature review section, there are various cytokines, proteins and adipo-
kines that are linked to the pathogenesis of T2D. The aim of this chapter’s aim is to determine 
the in vivo effects of marrubiin and the organic extract of L. leonurus on mRNA expression 
levels (of selected adipokines) and cell signalling receptor proteins that are involved in the 
pathogenesis of T2D. The up- or down-regulation of the mRNA levels of these adipokines 
and cell signalling proteins could play a major role in further understanding the mechanism 
by which the plant extract and marrubiin display their anti-diabetic properties.  
 
4.2 Materials and methods 
4.2.1 Experimental animals and treatments 
For the in vivo experiment, tissues (fat, liver and muscle) from male Wistar rats were used. 
The experimental procedures for the routine maintenance, feeding and treatments of the rats 
have been documented (Mnonopi et al., 2012). However, a few important aspects will be 
highlighted for this research. The rats were obtained from the University of Cape Town 
Animal Unit. They were housed at NMMU in pairs/triplicates in standard animal cages and 
were exposed to a 12-hour day and night cycle and randomly divided into six groups, with 
seven rats per group. The obese rats were fed for 8 weeks on a cafeteria diet (18% protein, 
41.4% carbohydrate and 4.5% fat content; caloric consumption was 15% protein, 68% 
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carbohydrates and 17% fat) and water ad libitum and thereafter treatment commenced and 
lasted for two weeks. The rats were maintained on the cafeteria diet and water ad libitum 
throughout the treatment period. In this study, it should be noted that all the obese rats in the 
study were insulin-resistant prior to treatment. Their insulin-resistant state was confirmed by 
the IPITT and IPGTT tests (Mnonopi et al., 2012). Thus, the changes observed due to treat-
ment were compared with the insulin-resistant obese control. The various treatments per-
formed are shown in Table 4.1. The untreated control group was treated with the vehicle, 1% 
(v/v) Tween-20 in saline. Other treated control groups were with metformin, sulfonylurea and 
aspirin. Metformin, rather than acarbose was the drug of choice for this study as it is the drug 
commonly used for T2D patients in the Eastern Cape region of South Africa. 
 
Table 4.1 Experimental conditions and treatments administered to the rats. 
Group Treatment  
Obese control 1% (v/v) Tween-20 in saline 
Obese metformin Metformin (50mg/kg) – Positive control for glucose uptake  
Obese sulfonylurea Gliclazide (50mg/kg) – Positive control for insulin secretion  
Obese aspirin Aspirin (50mg/kg) – Positive control for inhibiting platelet 
aggregation  
Obese extract Organic extract of L. leonurus (50mg/kg) 
Obese marrubiin Synthetic marrubiin (50mg/kg) 
  
4.2.2 Tissue collection  
Liver, muscle and adipose tissue were excised from the adult male obese Wistar rats after 
they were euthanised using pentobarbital sodium anaesthesia. The tissues were stored in 
RNAlater, flash frozen in liquid nitrogen and thereafter transferred to -80°C until ready for 
RT-qPCR analysis.  
 
4.2.3 Selected genes of interest 
Primers of the genes of interest used as well as the reference genes were synthesised using 
Beacon Designer software (BIO-RAD). They were cross-referenced with other biological se-
quences using BLAST software for sequence homologies. The final primer sequences were 
purchased from Inqaba Biotech (South Africa). A number of reference genes were tested and 
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GeNorm software was used for this analysis, in the selection of the most stable reference 
genes. Based on the pairwise variation values (≤ 1.5), the best two genes were selected. The 
reference genes investigated were: cyclophilin A, hydroxymethylbilane synthase (HMBS), T-
cell receptor, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-2-macroglobulin 
(B2M), alpha albumin, β-glutamate, tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta (YWHAZ), 18S-RNA and TATA-BOX. At least two 
stable reference genes per tissue type were selected from this list of reference genes. A 
summary of the genes of interest and the respective peripheral tissues in which they were 
investigated is given in Table 4.2. Each sample was analysed in duplicate and was normalised 
to the gene expression of the reference genes. Data were analysed using the ΔΔCt analysis 
method. 
Table 4.2. A summary of genes analysed from the different peripheral tissues. 
Gene name 
Tissue type 
Adipose 
tissue 
Liver tissue Muscle tissue 
Leptin YES            –            – 
Adiponectin YES – – 
Resistin YES – – 
GLUT-4 YES – YES 
GLUT-2 – YES – 
IRS-1 YES YES YES 
PPAR-γ YES YES YES 
Glucokinase YES YES YES 
Fatty acid synthase  YES YES YES 
PEPCK YES YES YES 
UCP-2 YES – – 
        (-) Not investigated in that specific tissue 
 
4.2.4 Ribonucleic acid extraction 
Total RNA extraction from adipose tissue was performed using the RNeasy Lipid Mini kit 
(QIAGEN), and from muscle and liver tissues using RNeasy
®
 Mini kit (QIAGEN) according 
to the manufacturer’s instructions. 
 
4.2.5 RNA integrity determination 
The RNA integrity (RIN) was determined using a 50 times dilution of the extracted RNA in 
10mM Tris-HCl buffer (pH 7.5) and measuring the absorbance in a spectrophotometer at 
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260nm and 280nm using a quartz cuvette. The absorbance 260/280 ratio was used to deter-
mine the RIN and an average 260/280 ratio was reported for all samples, indicating a good 
quality RNA that is devoid of protein and phenol contamination (Taylor et al., 2010).  
 
4.2.6 Complementary deoxyribonucleic acid synthesis 
Complementary DNA (cDNA) was synthesised from 2 µg of RNA in a final volume of 40 µl 
using the QuantiTect Reverse Transcriptase Kit (QIAGEN). The procedure for the cDNA 
synthesis was according to manufacturer’s guidelines. 
 
4.2.7 Quantitative polymerase chain reaction analysis 
cDNA of the samples was amplified in duplicate using reverse transcriptase quantitative real-
time PCR on a BIO-RAD I-Cycler (BIO-RAD), and SYBR-green chemistry. Each tube 
contained 2 μl of cDNA template, 0.6 μl forward primer (300 nM), 0.6 μl reverse primers 
(300 nM), 10 μl SYBR Green solution and 4.8 μl dH2O. The following protocol was used for 
the experiments: hold at 50°C for 2 min, hold at 95°C for 2 min, followed by 40 cycles of 
15sec at 95°C and 30sec at 60°C. The annealing temperature was adjusted for each primer set 
where necessary. PCR amplification was completed in 20 µl reactions and the reaction 
mixture was set up as recommended by BIO-RAD guidelines. Quantitative measurements 
were performed by establishing a linear amplification curve (standard curve) to determine the 
gene efficiency. This was achieved by serial dilutions (10-fold) of each primer set. The 
maximum increase of amplicon per cycle is two-fold, representing a reaction that is 100% 
efficient. Standard curves with low gene efficiency (<90%) are usually caused by high or 
suboptimal annealing temperatures, poorly designed primers, or amplicons with secondary 
structures (Bustin et al., 2009). Higher efficiencies (>110%) are generally the result of 
primer-dimer formation or non-specific amplicons. Thus, for optimal gene efficiency, a linear 
standard curve with 90% to 110% reaction efficiency is desired.  
 
4.2.8 Annealing temperature and PCR gene efficiency 
In PCR it is very important for the annealing of primers to be performed at the right tempera-
ture. Non-specific annealing and primer-dimer formation is the result of primers annealing at 
the wrong annealing temperature. All the primers used in the experiments were tested using a 
thermal gradient to determine their optimal annealing temperatures. A range of temperatures 
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around the calculated melting temperature (Tm) for each primer set was tested (Table 4.3). 
The gene sequence for the genes of interest performed in this study is also shown in the table. 
A melt curve analysis, performed at the end of PCR cycles, confirmed the specificity of 
primer annealing as well as a check for primer-dimer formation. The melt curve displayed a 
single sharp peak, indicating the formation of a single product.  
 
The purpose of a standard curve is to determine PCR efficiency (Taylor et al., 2010; Bustin, 
2002). The equation of the linear regression line, along with Pearson’s correlation coefficient 
(r) or the coefficient of determination (r
2
), can then be used to evaluate whether the RT-qPCR 
assay is optimised. An r
2
 value > 0.980 is desirable for RT-qPCRs. The efficiency is a mea-
sure of the rate by which the polymerase converts the reagents (deoxyribonucleotide triphos-
phates (dNTPs), oligonucleotides, and template cDNA) to amplicon. Low-efficiency PCR re-
actions (<90%) may sometimes be caused by poorly calibrated pipettes or poor pipetting 
techniques (Taylor et al., 2010). 
 
Table 4.3. Primer sequences and annealing temperatures of the genes of interest and the reference 
genes used for RT-qPCR analysis. 
Gene name 
Annealing 
Temp. 
Sense Strand Antisense strand 
*B2M 58 °C 5’-CGTGATCTTTCTGGTGCTTGTC-3’ 5’-TCTATCTGAGGTGGGTGGAAC-3’ 
*YWHAZ 
58 °C 5’-
CCGCTCGAGCCGGCCTTCCAACCTTTGTC
-3’ 
5’-
GAATGCGGCCGCTCCCATCATCAATATT
TATTGAGCATTTAC-3’ 
*HMBS 58 °C 5’-ACCTCAACACCCGCCTAC-3’ 5’-TCCCTGACCCACAGCATC-3 
PPAR-γ 
60 °C 
5’ - GGAATTAGATGACAGTGACTTGG - 3’ 5’ – GAGCACCTTGGCGAACAG - 3’ 
RESISTIN 
60 °C 
5’ – GGCACAACCGTCACTAGC -3’ 5’ - AGTTCTCAATCAACCGTCCTC - 3’ 
GLUCOKINASE 
60 °C 
5’ - CCGAGTGGCTTACAGTTCTG- 3’ 5’ – ACCTGAGTGTTGGAGATGATTC - 3’ 
LEPTIN 
60 °C 
5’- GCCAG GCTGCCAGAATTG-3’ 5’- CTGCCCCCCAGTTTGATG – 3’ 
ADIPONECTIN 
58 °C 
5’ -  CGCTCCTGTTCCTCTTAATCC- 3’ 5’ -GAGTGCCATCTCTGCCATC  - 3’ 
GLUT-2 
60 °C 
5’-ATGACATCAATGGCACAGACAC-3’ 5’-GGACACAGACAGAGACCAGAG-3’ 
GLUT-4 
60 °C 
5’-TCCATCCCACAAGGCACC-3’ 5’-AATCATGCCACCCACAGAGAA-3’ 
IRS-1 
58 °C 
5’-GCTACTCACCTCTTCCTTG-3’ 5’-CACTCCTGGTTATGGTTGG-3’ 
PEPCK 
58 °C 
5′-GAGATAGCGGCACAAT-3′ 5′-TTCAGAGACTATGCGGTG-3′ 
FAS 
58 °C 
5′-GAGGACTGCAAAATGAATGGGG-3′ 5′-ACAACCATAGGCGATTTCTGGG-3′; 
UCP-2 
60 °C 
5’-TGGCGGTGGTCGGAGATAC-3’ 5’-GGGCAACATTGGGAGAGG-3’ 
*Reference genes  
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4.2.9 Statistical analysis 
All the data for this section were expressed as means ± SEM, n=3. There were seven animals 
per group and the tissue samples were pooled to obtain n=3 for the qPCR study. Tissues from 
rats 1 and 2 were pooled, 3 and 4 pooled and finally, 5, 6 and 7 were pooled. Significance 
between the various groups was evaluated using the Student’s t-test. Significant differences 
were reported as p<0.05 or p<0.01, where applicable. The experimental groups were 
compared with the control group and the corresponding significant levels are indicated in the 
figures. For the RT-qPCR analysis, the obese control gene expression was set to a reference 
of 1, and all treatments were compared, relative to the obese control.  
 
4.3 Results and discussion 
4.3.1 Annealing temperature, melt curve and PCR gene efficiency 
Based on the results obtained for the selection of the reference genes, the two best reference 
genes that were stable for adipose tissue were YWHAZ and B2M. For liver and muscle tissue 
the two most stable were YWHAZ and HMBS.  
 
Figure 4.1 illustrates an example of the gene expression of the different samples (treatments) 
that were evaluated, with the sample having the highest gene expression showing a low Cq 
value. A melt curve of product formation was observed for all the genes analysed. An 
example is given in Figure 4.2. This gives an indication of the specificity of the annealing 
primers with no primer-dimers. This was the case with all the genes analysed. The single 
peak indicates a single product formation. The gene used in this example was resistin. A 
standard curve to determine PCR gene efficiency (Appendix, Figure A2) was performed for 
each gene of interest as well as the reference genes (Table 4.4). The PCR gene efficiency for 
resistin, adiponectin as well as FAS were outside the range of accepted values. This can 
possibly be explained by technical errors which may have been introduced during ex-
perimentation. Since an optimal annealing temperature was obtained for the primers, the 
possibility of an incorrect annealing temperature can be ruled out.  
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Figure 4.1. An example of a cycle threshold plot showing the Cq of the gene of interest. The resistin 
gene was used in this example. 
 
 
Figure 4.2. A single peak on the melt curve analysis showing a single product formation for the pri-
mer used. The figure shows the primer set for the gene resistin. 
 
Based on the Cq values obtained, the expression of the genes was analysed and normalised to 
the reference genes. In the following section genes of interest from adipose tissue, muscle and 
liver tissues of the insulin-resistant rats were investigated. The relative mRNA expression 
values obtained from the quantification cycles are represented as bar graphs for the various 
treatments. As indicated, all genes were normalised using two reference genes and the ana-
lysis of the results was performed using the ΔΔCq method (Taylor et al., 2010; Bustin et al., 
2009). A summary of the changes in the gene expression in the various tissues is provided in 
Table 4.5 at the end of this section. 
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Table 4.4. Correlation coefficient and the PCR gene efficiency of genes of interest used for RT-qPCR. 
Gene name Correlation coefficient (r
2
) PCR gene efficiency % 
*B2M 0.989 102.7 
*HMBS 0.999 101.8 
*YWHAZ 0.998 102.1 
PPAR-γ 0.989 102.4 
RESISTIN 0.981 88.3 
GLUCOKINASE 0.983 102.9 
LEPTIN 0.995 99.6 
ADIPONECTIN 0.995 112.0 
GLUT-2 0.996 101.5 
GLUT-4 0.900 100.9 
IRS-1 0.953 99.8 
PEPCK 0.983 99.9 
FAS 0.900 119.0 
UCP-2 0.990 110.0 
*Reference genes   
 
4.3.2 Leptin gene expression in adipose tissue 
Gene expression of leptin, the white adipose tissue-derived hormone, was completed in adi-
pose tissue to determine the effect of treatment. It is known from literature findings that leptin 
expression is increased in obesity and insulin resistance, and reduced in normal individuals 
(Joffin et al., 2012; Roubos et al., 2012). From Figure 4.3, it is observed that the obese con-
trol had a significant up-regulation of the gene in comparison with the rest of the treatments, 
which is in agreement with literature findings.  
 
Comparing the effects of treatments in the insulin-resistant state with the obese control, it was 
observed that L. leonurus extract, marrubiin and sulfonylurea treatment significantly de-
creased (p<0.05) leptin gene expression in the adipose tissue. Metformin treatment showed 
no effect on leptin gene expression levels in comparison with the obese control. A study has 
shown that metformin restores serum leptin sensitivity in obese rats (Kim et al., 2006). 
Although gene expression was investigated in this study (and not serum levels of leptin), the 
serum leptin levels may serve as an indicator of the leptin levels produced by the adipose 
tissue. The current data, however, did not show metformin either to increase or to decrease 
leptin levels. Further investigation into its leptin-lowering effect will need to be explored. 
The positive control drug, sulfonylurea, also had a significant (p<0.05) down-regulatory 
effect in comparison with the obese control. Aspirin showed a non-significant decrease. 
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Figure 4.3. Leptin gene expression in rat adipose tissue. The treatments were compared to the obese 
control, set to a reference of 1. Data represent the mean ± SEM (n = 3). *p<0.05 in comparison with 
the obese control.   
 
Leptin levels are increased in diet-induced obesity as well as in a genetic model of obesity 
and insulin resistance. TZD is a known drug used to suppress leptin gene expression in T2D 
patients and improve target-tissue sensitivity to insulin (Al-Suhaimi and Shehzad, 2013; 
Dardeno et al., 2010). A higher amount of leptin is secreted by subcutaneous adipocytes than 
by the visceral adipocytes (Al-Suhaimi and Shehzad, 2013). The finding from this study 
showed that L. leonurus extract, marrubiin and sulfonylurea could be possible drug 
candidates for the suppression of leptin in obese and/or T2D patients. Of particular interest in 
this study is the L. leonurus extract and marrubiin, both showing a down-regulation of the 
leptin gene expression. Leptin has been known to be a regulator of insulin sensitivity and 
moreover, Sivitz et al. (1997) have shown that an increase in circulating leptin (serum levels) 
increased insulin sensitivity in normal rats. Circulating leptin levels are reduced during fast-
ing and elevated during feeding, causing a drastic change in the energy balance and hormonal 
levels. Thus, it can be summarised from the current findings that the treatments (L. leonurus, 
marrubiin, and sulfonylurea) showed a beneficial effect in lowering leptin levels, in the 
adipose tissue. This could further suggest that these drugs exhibit their mechanistic effect 
through the adipose tissue. 
 
4.3.3 Adiponectin gene expression in adipose tissue 
Adiponectin is known to play an important role in the regulation of insulin sensitivity, there-
by having a glucose homœostatic effect (Garaulet et al., 2004). Adiponectin levels are known 
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to be reduced in obesity, in an insulin-resistant state as well as in T2D subjects. The 
adipokine is, therefore, more abundant in lean and normal mammals (Yamauchi et al., 2014).  
 
Comparing the treatments with the obese control, it was observed that L. leonurus extract as 
well as metformin significantly (p<0.05) up-regulated the gene expression of adiponectin 
(Figure 4.4). Marrubiin, sulfonylurea and aspirin treatments significantly decreased (p<0.05) 
adiponectin gene expression, relative to the obese control. It can be observed once again that 
the plant extract shows promising results based on these findings. The extract caused a de-
crease in leptin gene expression and an increase in adiponectin, conditions that are observed 
in normal mammals. However, marrubiin did not have a similar effect. Although marrubiin is 
a constituent of the L. leonurus plant extract, it did not exhibit a similar effect as compared 
with the plant extract. It is possible that other compounds present within the plant extract play 
a role in its anti-diabetic action. 
  
Figure 4.4. Adiponectin gene expression in rat adipose tissue. The treatments were compared to the 
obese control, set to a reference of 1. Data represent the mean ± SEM (n=3). *p<0.05 in comparison 
with the obese control.  
 
Shehzad et al. (2012) showed that the expression of adiponectin receptors AdipoR1 and Adi-
poR2 declined by 30% in the subcutaneous fat of obese individuals, while they normalised 
following weight loss. Serum adiponectin, as well as its gene expression, are reduced in insu-
lin resistance as well as T2D, and adipose tissue accumulation is one of the factors that lead 
to the progression of T2D (Shehzad et al., 2012). Adipose tissue accumulation is also 
responsible for the secretion of adipokines such as leptin, adiponectin, and resistin, and their 
dysregulation is known to be involved in the onset of insulin resistance and the progression 
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into T2D. Reduced levels of adiponectin are present in patients with non-alcoholic fatty liver 
disease, a condition often associated with obesity and insulin resistance (Fantuzzi, 2013). 
Increased adiponectin expression seen in mouse white adipose tissue has been linked to an 
increase in insulin sensitivity, improved insulin resistance and hypertriglyceridaemia 
(Yamauchi et al., 2014). A drug target for adiponectin therapy will have to increase gene 
expression of this adipokine as well as its circulating plasma levels. Thus, the changes 
brought about by the plant extract and metformin could have beneficial effects.  
 
Several commonly used drugs regulate adiponectin production. These include not only TZDs 
and fibrates but also sulfonylureas, valproic acid, modulators of the renin-angiotensin system, 
calcium channel blockers and possibly different immunosuppressive/anti-inflammatory 
therapies, including methotrexate, cyclosporine and anti-TNF-α treatment (Shehzad et al., 
2012). Some of these drugs directly alter adiponectin production and release, while others 
modulate circulating levels indirectly (Shehzad et al., 2012). It is thus surprising that sulfony-
lurea did not play any role in enhancing adiponectin gene expression in the current study. L. 
leonurus and metformin treatments were the possible treatment candidates to up-regulate adi-
ponectin gene expression. Grisouard et al., (2011) demonstrated that metformin treatment 
increased adiponectin plasma levels in women with polycystic ovary syndrome and T2D 
patients while metformin treatment decreased IL-6 plasma levels, as well as circulating levels 
of leptin in polycystic ovary syndrome patients, and significantly reduced resistin and TNF-α 
plasma levels in T2D patients. This supports the current findings observed with metformin 
treatment. L. leonurus could potentially serve as an effective treatment for the up-regulation 
of the adiponectin gene in the adipose tissue. Although metformin has been shown to have a 
regulatory effect on circulating adiponectin levels, it could additionally be playing a role at 
the mRNA level.  
 
4.3.4 Resistin gene expression in adipose tissue 
The term resistin was named due to its resistance to insulin action. Some recent genetic stud-
ies have demonstrated an association between resistin and insulin resistance and obesity (Al-
Suhaimi and Shehzad, 2013).  
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Comparing the treatments in the insulin-resistant state with the obese control, it was noted 
that the L. leonurus plant extract had no effect on resistin expression and normalised its gene 
expression to that of the obese control (Figure 4.5). So far, the extract has shown promising 
results in the regulation of the adipokines (leptin and adiponectin) in improving obesity and 
insulin resistance. Marrubiin and aspirin significantly (p<0.05) reduced gene expression in 
comparison with the control. Metformin and sulfonylurea treatment significantly (p<0.05) 
up-regulated resistin gene expression two-fold in comparison with the obese control.  
  
Figure 4.5. Resistin mRNA expression levels in rat adipose tissue. The treatments were compared to 
the obese control, set to a reference of 1. Data represent the mean ± SEM (n=3). *p < 0.05 in 
comparison with the obese control. 
 
Metformin treatment is known to reduce resistin expression in T2D patients (Grisouard et al., 
2011). However, the opposite effect was observed in the current findings in the rats. Fujita et 
al. (2002) showed a 66% increase in resistin protein expression levels in obese rats treated 
with metformin in comparison with the obese control subjects, supporting the author’s 
findings of the increase in resistin gene expression with metformin treatment. Interestingly, 
experiments in humans have shown no differences in resistin expression among normal, 
insulin-resistant and T2D patients (Lee et al., 2003). This could explain why the L. leonurus 
extract brought about no change in resistin gene expression. Since resistin gene expression is 
down-regulated by anti-diabetic drugs such as TZDs, it is also likely that aspirin could act as 
a potential drug target.  
 
Resistin expression levels, as well as its circulating plasma levels, are increased in obesity 
and T2D, and loss of resistin in obesity decreases the blood glucose levels and improves 
insulin sensitivity (Al-Suhaimi and Shehzad, 2013; Stofkova, 2010). High expression levels 
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of resistin are associated with low insulin signalling in muscle and liver, stimulating SOCS-3 
to inhibit the insulin signalling pathway. Therefore, low levels of resistin will improve T2D 
(Stofkova, 2010). 
 
Resistin is produced primarily by adipose tissue and acts at sites distant from where it is pro-
duced. It is known that elevated expression of resistin leads to glucose intolerance and 
hyperinsulinaemia, together with impaired insulin signalling in skeletal muscle, liver, and 
adipose tissue (Al-Suhaimi and Shehzad, 2013). It is, therefore, vital to regulate resistin ex-
pression as produced by its endocrine organ. Resistin stimulates SOCS-3 in mouse adipose 
tissue and the stimulated SOCS-3 inhibits the insulin signalling pathway in tissues. 
Furthermore, resistin affects glycogen metabolism, leading to T2D diabetes (Al-Suhaimi and 
Shehzad, 2013).  
 
Glucose homœostasis and insulin sensitivity are major biological effects of resistin. In T2D 
patients, the significantly high resistin levels have been correlated with an increase in body 
mass (Habib, 2012). Circulating resistin levels are decreased by the anti-diabetic drug 
rosiglitazone and increased in diet-induced and genetic forms of obesity (Catta-Preta et al., 
2012). Administration of an anti-resistin antibody improves blood sugar levels and insulin 
action in mice with diet-induced obesity (Steppan et al., 2001). Moreover, treatment of 
normal mice with recombinant resistin impairs glucose tolerance and insulin action. Insulin-
stimulated glucose uptake by adipocytes is enhanced by neutralisation of resistin and is 
reduced by resistin treatment. Therefore, resistin is a hormone that potentially links obesity to 
diabetes (Steppan et al., 2001).   
 
In summary, the current findings indicate that marrubiin and aspirin were effective in lower-
ing resistin expression, relative to the obese control. Metformin and sulfonylurea showed a 
significant up-regulation of its gene expression. L. leonurus treatment had no effect on the in-
sulin-resistant state in comparison with the obese control. Diabetic treatments targeting the 
control of resistin gene expression have been of interest due to the link to obesity and insulin 
resistance. The anti-diabetic drugs, TZDs, which lower blood glucose by activating the 
nuclear receptor PPAR-γ, have been shown to also control resistin expression (Stofkova, 
2010). Although both marrubiin and the L. leonurus extract have shown anti-diabetic 
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potential, only marrubiin has been shown to be effective in significantly lowering resistin 
levels.  
 
4.3.5 GLUT-2 gene expression in rat liver tissue  
Glucose transporters are the main facilitators of glucose uptake within cells (Akarte et al., 
2012) with GLUT-2 being the principal transporter in liver cells. Comparing the treatments in 
the insulin-resistant state with the obese control, all the treatments (except metformin) 
showed a significant (p<0.05) decrease in GLUT-2 gene expression (Figure 4.6). The current 
finding of metformin is in agreement with metformin increasing GLUT-2 gene expression in 
the liver of STZ-induced obese diabetic rats (Ismail et al., 2013).  
 
The high expression level of GLUT-2 in the obese control could be due to high fasting blood 
sugar levels in the obese control rats (8.9 mmol/l ± 0.11 mmol/l) (Mnonopi et al., 2012). 
High levels of glucose in the blood trigger the translocation of GLUT vesicles to the cell 
surface for glucose uptake into cells. The insulin-sensitive metformin is promoting this effect 
by gene up-regulation of the GLUT-2 receptor gene in the liver. The L. leonurus extract, 
marrubiin, sulfonylurea and aspirin significantly (p<0.05) reduced the gene expression levels 
in the liver. These compounds seem not to have a beneficial effect on its mechanism of action 
in the liver tissue, as compared to their effects in the adipose tissue. The decreased effect 
could have a suppressive effect on glucose uptake in the liver tissue (Thorens, 2011). It is 
observed that low insulin and high glucose levels in STZ-induced diabetic rodents increase 
GLUT-2 expression in the intestine and liver (Leturque et al., 2009). It is possible that the 
low gene expression observed by the treatments could be due to the low glucose levels in the 
blood as the rats were fasted prior to experimentation.  
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Figure 4.6. GLUT-2 gene expression in rat liver. The treatments were compared to the obese control, 
set to a reference of 1. Data represent the mean ± SEM (n=3). *p < 0.05 in comparison to the obese 
control. 
 
Regulation of GLUT-2 gene expression is complex and has been the subject of several stud-
ies focused on tissue specificity. Drug candidates such as GLP-1 are known to increase the 
expression of GLUT-2. GLP-1 treatment seems to act on liver GLUT-2 at the transcriptional 
as well as translational level. It also increases glycogen synthase activity, glycogen synthesis 
and glucose oxidation and utilisation (Akarte et al., 2012). In diabetic rats, vildagliptin treat-
ment seems to act on liver GLUT-2 and muscle GLUT-4 expression at the post-transcrip-
tional level, by stimulating the translational process toward normalisation of glucose trans-
porter proteins (Akarte et al., 2012). In rats fed a high-fat diet, a modest 30% alteration of 
GLUT-2 cell surface levels was sufficient to alter liver function significantly, indicating that 
GLUT-2 location might be a regulatory step in liver physiology (Leturque et al., 2009). In the 
current study, metformin treatment could possibly act as a drug candidate for the regulation 
of GLUT-2 gene expression, similar to that of GLP-1, although, the increase was not 
significantly observed, in relation to the obese control. 
 
Re-feeding after a fast or low vs high carbohydrate diet modulates GLUT-2 expression in the 
intestine, kidney, liver and pancreas (Thorens, 1996). Low insulin and high glucose levels in 
STZ-induced diabetic rodents increase GLUT-2 expression in the intestine and liver, 
suggesting that glycaemia and insulinaemia control GLUT-2 expression (Miyamoto et al., 
1991). Apart from metformin, neither marrubiin nor the L. leonurus extract was able to cause 
an increase in GLUT-2 gene expression in the liver of the obese rats.  
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4.3.6 GLUT-4 gene expression in rat adipose and muscle tissues  
GLUT-4 performs a similar function to GLUT-2, the only difference being their tissue distri-
bution. Under normal resting conditions, GLUT-4 molecules reside in membrane vesicles in 
the cell. In response to insulin or muscle contraction, GLUT-4 translocates to the cell mem-
brane and glucose enters the cell by facilitative diffusion for it to be metabolised (Dohm, 
2002). 
 
In the adipose tissue, it was observed that metformin treatment significantly (p<0.01) up-reg-
ulated the gene expression (Figure 4.7A). The plant extract, as well as marrubiin, enhanced 
GLUT-4 expression in adipose tissue. However, this was not significant.  
 
Figure 4.7. GLUT-4 gene expression in rat (A) adipose and (B) muscle tissue. In graphs A and B the 
treatments were compared to the obese control, set to a reference of 1. Data represent the mean ± 
SEM (n=3). *p<0.05 in comparison to the obese control. 
#
p<0.01 in comparison with the obese 
control. 
 
In adipose tissue, metformin plays a major role in enhancing glucose uptake, as is known in 
the literature (Nar and Gedik, 2009). An increase in GLUT-4 expression in the cells plasma 
membranes following insulin stimulation is closely associated with enhanced glucose uptake 
of adipocytes and skeletal muscle cells (Koren-Gluzer et al., 2013). In the muscle, GLUT-4 
gene expression was also up-regulated by metformin in comparison with the obese control. 
However, the effect was not significant (Figure 4.7B). The findings are supported by the 
study of (Franciosi et al., 2013), which shows metformin to promote insulin-stimulated 
glucose uptake in skeletal muscle. L. leonurus, marrubiin and sulfonylurea caused a 
significant decrease in GLUT-4 gene expression in the muscle. Sulfonylurea treatment 
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showed the least gene expression of GLUT-4. It is known that glucose uptake is 
predominantly observed in the skeletal muscle rather than in adipose tissue (Samuel and 
Shulman, 2012). The author compared the gene expression of GLUT-4 in the adipose and 
muscle tissue (Figure 4.7 A and B, respectively) and observed a relative increase in gene ex-
pression in the muscle tissue, in comparison with adipose.  
 
Metformin enhanced GLUT-4 gene expression in the adipose and muscle tissue, in 
comparison with the obese control. In adipose tissue, the obese control revealed a low gene 
expression. It is known that the suppression of GLUT-4 appears to be the key mechanism in 
the development of insulin resistance (Garvey, 1992). The increase in gene expression with 
metformin treatment in the muscle correlates to findings also observed in adiponectin gene 
expression in the adipose tissue with metformin treatment (Figure 4.4 and Table 4.5). It is 
known that in skeletal muscle, full-length or the globular domain of adiponectin, causes an 
increase in glucose uptake by promoting the translocation of GLUT-4 to the plasma 
membrane (Cheng et al., 2013). Leptin and insulin have also been shown to regulate GLUT-4 
expression through the JAK-2/IRS/PI3K/AKT pathway (Al-Suhaimi and Shehzad, 2013) and 
this could possibly be the mechanism through which the treatments in this study are acting.  
 
GLUT-4 gene expression is known to be regulated by leptin and adiponectin (Turer and 
Scherer, 2012). In a summary table at the end of this section (Table 4.5), it was observed that 
metformin significantly up-regulated gene expression of GLUT-4 in adipose tissue. 
Therefore, the increase in adiponectin gene expression in adipose tissue resulted in a 
significant increase in GLUT-4 in the adipose tissue. Although treatment with the extract 
resulted in a significant increase in adiponectin gene expression in adipose tissue, it did not 
cause a significant increase in GLUT-4 expression in the adipose tissue, as was noted for 
metformin. This is because adiponectin stimulates glucose uptake in muscle via causing 
translocation of the glucose transporter GLUT-4 to the cell surface (Liu and Sweeney, 2013). 
Thus, the increase in adiponectin gene expression had a significant effect on GLUT-4 
expression in adipose tissue (metformin treatment), but not in the muscle. The L. leonurus 
extract was able to significantly increase adiponectin gene expression in adipose tissue but 
did not have an effect in GLUT-4. There was a significant decrease in adiponectin expression 
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in the adipose tissue with marrubiin treatment and this resulted in a reduced expression of 
GLUT-4 in the muscle tissue.  
 
In the muscle, the obese control and metformin-treated rats showed a high expression of 
GLUT-4 (Figure. 4.7B). Studies showed that muscle GLUT-4 was increased during exercise 
(Dohm, 2002). In patients with T2D, protein expression of GLUT-4 was reduced in adipose 
tissue, but preserved in skeletal muscle, thus supporting the findings observed in this study. 
Since skeletal muscle is an important tissue in maintaining postprandial glucose homœostasis, 
increasing GLUT-4 protein or gene expression is important in the treatment of 
hyperglycaemia associated with T2D (Jones and Dohm, 1997). In muscle and adipose tissue, 
metformin treatment up-regulated GLUT-4 gene expression.  
 
4.3.7 PPAR-γ gene expression in rat adipose, muscle and liver tissues 
In the analysis of PPAR-γ gene expression in the adipose tissue (Figure 4.8A), it was ob-
served that the L. leonurus extract significantly (p<0.05) up-regulated the gene, in 
comparison with the obese control. Marrubiin and metformin also increased PPAR-γ gene ex-
pression in the adipose tissue but the effect was not significant. Sulfonylurea and aspirin 
reduced gene expression, compared with the obese control, but this was not significant. None 
of the treatments increased the expression of PPAR-γ in muscle and liver tissue (Figure 4.8B 
and 4.8C). In comparison with the obese control, L. leonurus, marrubiin and sulfonylurea 
caused a significant (p<0.05) decrease in PPAR-γ gene expression in the muscle and liver 
tissue (Figure 4.8B and C). Metformin treatment showed a non-significant increase of the 
gene expression in comparison with the obese control in muscle tissue. Aspirin treatment 
showed gene expression levels similar to those of obese control rats (Figure 4.8A and 4.8B), 
in adipose tissue and muscle, and significantly (p<0.05) reduced expression levels in liver 
tissue (Figure 4.8C).   
 
Adipose tissue is the major tissue expressing PPAR-γ where it plays a central role in adipo-
genesis and appears to be primarily involved in the regulation of lipid metabolism (Grygiel-
Górniak, 2014).  In the muscle, it is observed that trace amounts of PPAR-γ are found 
(Grygiel-Górniak, 2014). Adipose tissue has the most notable gene expression changes in re-
sponse to treatment with PPAR-γ agonists (Tyagi et al., 2011). Adipose tissue showed an ele-
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vated gene expression of PPAR- γ (across the treatment types) in comparison with muscle 
and liver tissue in this study (data not shown). In adipose tissue, PPAR-γ up-regulates genes 
involved in glucose uptake and also controls the expression of adipocyte-secreted factors, 
such as adiponectin, that communicate with other organs to affect whole-body insulin 
sensitivity (Tyagi et al., 2011). 
 
 
Figure 4.8. PPAR-γ gene expression in rat (A) adipose tissue, (B) muscle and (C) liver tissue. The 
treatments were compared with the obese control, set to a reference of 1. Data represent the mean ± 
SEM (n=3). *p<0.05 in comparison with the obese control. 
 
L. leonurus and marrubiin caused a significant decrease in PPAR- γ in muscle and liver 
tissue. PPAR-γ increases adiponectin levels and secretion by stimulating the expression of 
proteins involved in adiponectin assembly and secretion (Shehzad et al., 2012). The effect of 
an increase in adiponectin gene expression with the extract treatment could also have caused 
an increase in the PPAR-γ gene expression in adipose tissue. Also, metformin treatment in 
adipose tissue elevated adiponectin expression as well as PPAR-γ expression (non-
significantly) in the adipose tissue. 
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Mice with adipose-specific ablation of PPAR-γ show insulin resistance in adipose tissue and 
liver but not in skeletal muscle. In these mice, TZDs improved insulin sensitivity in the skele-
tal muscle and liver tissue but not in adipose tissue, indicating a direct action of TZDs in ske-
letal muscle and liver (He et al., 2003). This also indicates that although PPAR-γ is mostly 
expressed in adipose tissue, its regulatory effects are also seen in muscle and liver tissues. 
However, none of the treatments enhanced gene expression in these tissues. Park et al. (1997) 
have shown that PPAR-γ gene expression was elevated in human skeletal muscle of T2D and 
in obese subjects, supporting the current findings in muscle tissue with the extract, marrubiin 
and sulfonylurea contributing to lowering PPAR-γ gene expression. 
 
PPARs control the expression of networks of genes involved in adipogenesis, lipid metabo-
lism, inflammation and maintenance of metabolic homœostasis (Ahmadian et al., 2013). It is 
known that inflammation is one of the major causes of insulin resistance and anti-inflamma-
tory therapy can be an effective measure for treating this metabolic disorder. PPAR-γ recept-
ors are highly expressed in adipocytes and in macrophages where they negatively regulate a 
large set of inflammatory pathway genes (Olefsky and Glass, 2010). PPAR-γ belongs to the 
nuclear receptor superfamily and is regulated by FFAs and their metabolites (Olefsky and 
Glass, 2010). FFAs and their metabolites are required for the cell development of adipose tis-
sues and are the target for the insulin-sensitising drug TZD, which is used clinically for treat-
ment of T2D (Lumeng et al., 2007). Jones et al. (2005) found that deletion of PPAR-γ in adi-
pose tissue of mice helps protect against high fat diet-induced obesity and insulin resistance.  
  
PPAR-γ is known to inhibit leptin secretion and a drug such as TZD is known to control insu-
lin resistance and T2D. PPAR-γ expression levels are known to be high in obesity and insulin 
resistance, and rare inactivating mutations of the gene encoding PPAR-γ are associated with 
insulin resistance, T2D and hypertension, whereas a rare gain of function mutation causes ex-
treme obesity (Celi and Shuldiner, 2002). PPAR-γ is important for controlling genes involved 
in glucose homœostasis, which include increasing the expression of GLUT-4 (Ahmadian et 
al., 2013). PPAR-γ was significantly increased in the adipose tissue with L. leonurus 
treatment. However, its effect on GLUT-4 in adipose tissue (L. leonurus-treated) was not 
significantly observed. The significant decrease of PPAR-γ was observed in the muscle and 
liver tissues with the extract and marrubiin treatment. Their effect on muscle GLUT-4 and 
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liver GLUT-2 was also significantly reduced. Thus, the current findings are in agreement 
with literature. The up-regulation of PPAR-γ has been reported to improve metabolic indices 
in T2D and other chronic conditions (Janani and Ranjitha Kumari, 2015). Marrubiin and the 
plant extract lowered the expression of PPAR-γ in muscle and liver tissue but increased in 
adipose tissue, indicating that the most pronounced effects are noted within adipose tissue, 
rather than in liver and muscle tissue.  
 
4.3.8 Fatty acid synthase gene expression in adipose, muscle and liver tissues 
FAS is known to play a role in regulating body weight and obesity, and an increase in FAS 
gene expression is observed in obesity, linked to visceral fat accumulation (Nakamura et al., 
2012) and to the metabolic syndrome (Currie et al., 2013). In the adipose tissue, only L. 
leonurus treatments significantly (p<0.05) increased gene expression of FAS in comparison 
with the obese control rats (Figure 4.9A). All other treatments did not significantly change 
gene expression, relative to the obese control.  
  
 
Figure 4.9. Fatty acid synthase gene expression in (A) rat adipose tissue, (B) rat muscle tissue and (C) 
rat liver tissue. The treatments were compared with the obese control, set to a reference of 1. Data 
represents the mean ± SEM (n=3). *p<0.05 in comparison with the obese control.  
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In the muscle, L. leonurus significantly (p<0.05) up-regulated the gene expression of FAS 
and in the liver, a significant decrease (p<0.05) was observed (Figure 4.9 B & C).  Metformin 
as well as aspirin significantly (p<0.05) increased gene expression of FAS in the muscle. The 
extract caused a 10-fold increase in the gene expression of FAS, while metformin caused a 
14-fold increase and aspirin had a 5.5-fold increase in the expression, in comparison with the 
obese control in the muscle. Marrubiin, however, seems to show expression levels similar to 
the obese control in the muscle. In the liver, metformin showed no change in gene expression 
relative to the obese control. Metformin is known to inhibit fatty acid synthesis in 
hepatocytes (Lin et al., 2000). Marrubiin and sulfonylurea significantly (p<0.05) increased 
FAS gene expression in liver (Figure 4.9C). Aspirin did not cause any change in the expres-
sion of FAS in the liver. 
 
The role of FAS in the liver is to produce lipids for export to tissues, such as fat. It is known 
that obese mice have increased FAS activity in hepatocytes (Donnelly et al., 2005). In muscle 
tissue, the inhibition of FAS activity prevents obesity as well as T2D (Funai et al., 2013). 
Adipose tissue remains an important site of endogenous fatty acid synthesis (Swierczynski et 
al., 2000). Studies in which humans are fed a high carbohydrate diet demonstrated that total 
body fat synthesis significantly exceeded hepatic de novo lipogenesis. This suggested that 
adipose tissue may be the major site for fat synthesis, with the adipose tissue accounting for 
up to 40% of whole-body lipogenesis under these conditions (Menendez et al., 2009). FAS 
activity is usually predominant in adipose tissue and to a lesser extent in the muscle and liver 
tissues (Berndt et al., 2007). In the current study adipose tissue showed the highest gene 
expression of FAS in comparison with muscle and liver tissue. The FAS gene is over-
transcripted in the adipose tissue of genetically obese rats. It has been demonstrated that the 
human FAS gene and de novo lipogenesis are regulated in human adipose tissue (Wang et al., 
2004). FAS gene expression in adipose tissue appears to be linked to visceral fat 
accumulation (Berndt et al., 2007). Inhibition of FAS activity blocks adipocyte differentiation 
and leads to the reduction of adipocyte numbers. In adipose tissue in the present study, none 
of the treatments reduced FAS gene expression in comparison with the obese control.  
 
FAS inhibitors were tested in mouse models for the treatment of obesity and T2D, causing 
dramatic weight loss as well as an improvement in hepatic steatosis in obese mice (Loftus et 
al., 2000). Another treatment in diabetic mice with platensimycin (an antibiotic isolated from 
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extracts of Streptomyces platensis) reduced hepatic FAS activity, hepatic lipid accumulation 
and hepatic fatty acid oxidation (Wu et al., 2011). In a typical obese liver, it is observed that 
there is an increase in FAS gene expression as compared with lean individuals. L. leonurus 
treatment in the liver was able to decrease the expression of the gene compared with the 
obese control. FAS may be a therapeutic target for treating fatty liver and dyslipidaemia, both 
being common features of the metabolic syndrome, and both also being independent risk 
factors for coronary artery disease (Jensen-Urstad and Semenkovich, 2012).  
 
4.3.9 IRS-1 gene expression in adipose, muscle and liver tissues  
Insulin resistance impairs IRS-1 function and reduced expression of IRS-1 is observed in an 
obese insulin-resistant state in comparison with normal mammals. In adipose tissue, 
marrubiin treatment showed a significant (p<0.05) up-regulation of IRS-1 in comparison 
with the obese control (Figure 4.10A).  In the muscle, all treatments, except marrubiin, 
significantly (p<0.05) reduced IRS-1 gene expression in comparison with the obese control 
(Figure 4.10B), while in marrubiin treatment caused no significant change in gene 
expression. In the liver, all the treatments, with the exception of metformin, significantly 
(p<0.05) decreased gene expression of IRS-1 in comparison with the obese control (Figure 
4.10C).  
   
The liver is a key organ for maintaining nutritional homœostasis. Glycogen storage and the 
oxidisation of FAs are some of the important functions of the liver. It has been shown that 
signals delivered by IRS-1 or IRS-2 regulate hepatic gene expression that coordinates glucose 
homœostasis and systemic growth (Dong et al., 2006), highlighting the importance of these 
receptors in maintaining glucose homœostasis. The current findings suggest that in adipose 
tissue, marrubiin could be playing a role in IRS-1 functioning in attenuating insulin 
resistance. Although not investigated in the current study, it has been shown that the increase 
in gene expression of IRS-1 could possibly be linked to an up-regulation of serine phosphory-
lation of IRS-1 (Turdi et al., 2013) – thus playing a vital role in insulin signalling. Once the 
IR is activated, it promotes the phosphorylation of multiple Tyr residues of the IRSs and 
subsequently promotes its binding to the Src H2 domain on various downstream signalling 
proteins including the PI3-K, Grb2, SHP2 (Lu et al., 2013). One of the membrane-associated 
kinases, Akt/PKB, is known to phosphorylate multiple downstream effectors to bring about a 
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biological response such as the regulation of gene expression and the stimulation of glucose 
transport (Lu et al., 2013). 
 
 
Figure 4.10. Insulin receptor substrate subtype-1 (IRS-1) gene expression in rat (A) adipose tissue, (B) 
liver tissue and (C) muscle tissue. The treatments were compared with the obese control, set to a 
reference of 1. Data represent the mean ± SEM (n=3). *p<0.05 in comparison with the obese control.  
 
A study has shown genipin, a compound derived from the fruit of Gardenia jasminoides, to 
stimulate glucose uptake in myotubes by promoting GLUT-4 to the cell surface and also in-
creasing the phosphorylation of IRS-1 (Ma et al., 2013). The study concluded that genipin ac-
tivates IRS-1, PI3-K, and downstream signalling pathway and increases concentrations of 
calcium, resulting in GLUT-4 translocation and glucose uptake increase in C2C12 myotubes. 
All the treatments in the current study reduced gene expression of IRS-1 in muscle tissue and 
also reduced gene expression of GLUT-4. Skeletal muscle is the main tissue accounting for 
insulin-stimulated glucose disposal and many other studies have reported the effect of treat-
ment on insulin sensitivity and insulin signalling, the aim of which is to improve the insulin-
resistant state as well as T2D. Muscle atrophy has been linked to reduced levels of IRS-1 lea-
ding to reduced PI3-K activity and the activation of FoxO transcription factors and it has 
been shown that C1-Ten, a novel protein tyrosine phosphatase (PTPase) of IRS-1, acts as me-
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diator to reduce IRS-1 under catabolic conditions, resulting in muscle atrophy (Koh et al., 
2013). In liver tissue, it has been shown that treatment of STZ-induced diabetic rats with sele-
nium or exendin-4 resulted in increased levels of GLP-1R and decreased levels of IRS-1, 
compared with the levels in diabetic rats (Barakat et al., 2012). However, in the present 
study, none of the treatments increased gene expression of IRS-1 in the liver.  
 
Leptin is known to play a regulatory role, together with insulin, in IRS-1 functioning. The 
mechanism of action is through the JAK/STAT signal transduction pathway. Leptin 
phosphorylates IRS-1, thereby inducing insulin resistance. The increase in leptin gene 
expression observed in the adipose tissue of the obese control had an effect on IRS-1 gene 
expression in the liver of the obese control, and to a lesser extent in the adipose tissue, but not 
in the muscle tissue (Joffin et al., 2012). In summary, marrubiin significantly up-regulated 
IRS-1 gene expression in the adipose tissue, significantly reduced it in the liver and had no 
effect in the muscle, in relation to the obese control in each tissue type.   
 
4.3.10 Glucokinase gene expression in rat adipose, muscle and liver tissues  
With the exception of sulfonylurea, all the treatments (including marrubiin and the plant ex-
tract) significantly (p<0.05) increased GK expression in comparison with the obese control in 
adipose tissue (Figure 4.11A). In adipose tissue, sulfonylurea treatment maintained GK 
expression levels similar to that of the obese control. In muscle tissue, the plant extract and 
sulfonylurea significantly (p<0.05) reduced GK gene expression relative to the obese control. 
In liver tissue, only marrubiin significantly (p<0.05) enhanced GK gene expression in 
comparison with the obese control (Figure 4.11C), while L. leonurus and aspirin significantly 
(p<0.05) reduced the expression of GK in comparison with the obese control.  
 
The glucose phosphorylating enzyme, GK, was identified as a drug target for developing 
anti-diabetic medicines because it has an exceptionally high impact on glucose homœostasis 
due to its glucose sensor role in pancreatic β-cells and as a rate-controlling enzyme for hepat-
ic glucose clearance and glycogen synthesis; both processes being impaired in T2D 
(Matschinsky, 2009). The normal functioning of GK is essential for cellular processes and in 
alleviating diabetic symptoms. Animals that do not express GK die a few days after birth with 
severe diabetes. Animals overexpressing GK have improved glucose tolerance while mice 
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lacking hepatic GK suffer from impaired insulin secretion. By contrast, overexpression of GK 
in the livers of diabetic or non-diabetic mice resulted in improved glucose tolerance (Pal, 
2009).  
  
 
Figure 4.11. GK mRNA expression in rat (A) adipose tissue (B) muscle and (C) liver tissue. 
The treatments were compared with the obese control, set to a reference of 1. Data are shown 
as the mean ± SEM (n=3). *p<0.05 in comparison with the obese control.  
 
Hepatic GK activity and the intracellular location of GK are controlled by a protein produced 
in hepatocytes called glucokinase regulatory protein (Filipski et al., 2012). Small molecules 
may activate GK either directly or by destabilising the GK regulatory protein complex. These 
molecules could be predicted to stimulate glucose utilisation in the liver. T2D is characterised 
by defects in glucose utilisation, therefore such molecules regulating the activity of GK could 
be effective for the treatment of T2D (Pal, 2009). Thus, the current findings in liver and adi-
pose tissue relating to marrubiin treatment support the notion that marrubiin is possibly acting 
as a glucokinase activator or regulator. Also, in adipose tissue, the plant extract could act as a 
potential glucokinase activator in lowering blood glucose. It is known that GK activators are 
involved in the lowering of blood glucose in T2D patients. Since its initial development in 
2003, many other GK activators have been developed (Grimsby et al., 2003). GK activators 
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are also known to stimulate insulin secretion in a Ca
2+
-dependent manner in MIN-6 cells and 
in rodent islets, as well as stimulation of IRS-2 production (Milne et al., 2007).  
 
Marrubiin, L. leonurus as well as metformin and aspirin treatments significantly increased 
GK gene expression in the adipose tissue. The increase in GK in the adipose tissue also 
correlated with the increase of GLUT-4 gene expression in the adipose tissue with metformin 
treatment. This agrees with the findings that the expression of GK selectively in adipose 
tissue of transgenic mice leads to an increase in glucose uptake, but not to G-3-P formation 
and fat accumulation (Muñoz et al., 2010). In the muscle, however, all the treatments reduced 
glucokinase gene expression. Thus, in adipose tissue the marrubiin and L. leonurus extract 
could act as potential GK activators to promote glucose clearance. However, it is known in 
literature that GK activity is predominantly observed in the liver where it maintains glucose 
homœostasis and controls the rate of glucose clearance (Matschinsky et al., 2011). In the 
current study, treatment with marrubiin in the tissue showed a significant (p<0.05) increase. 
GLUT-2 is the main plasma membrane glucose transporter in the liver which resulted in the 
transports glucose across the cell membrane (Thorens, 1996). Under physiological glucose 
concentrations, this process is not rate-limiting to the overall rate of glucose uptake in these 
cells. The rate of glucose uptake is limited by the rate of phosphorylation of glucose to G-6-P, 
catalysed by GK (Pal, 2009). It was observed in the current findings that the decrease in gene 
expression of GLUT-2 in liver tissue with the extract treatment correlated to the decrease in 
gene expression of GK in liver.  
 
In summary, it was observed that the plant extract and marrubiin treatment, in the adipose tis-
sue, caused a significant up-regulation of GK. The plant extract reduced the gene expression 
of GK significantly (p<0.05) in the muscle and liver tissue and marrubiin caused a significant 
(p<0.05) increase in GK expression in the liver.  Thus, the extract and marrubiin are once 
again playing a positive role in their mechanism of action through the adipose tissue.  
 
4.3.11 PEPCK gene expression in adipose tissue, muscle and liver tissues 
In adipose tissue, it was observed that none of the treatments caused a significant change in 
PEPCK gene expression in comparison with the obese control. Marrubiin, metformin and the 
plant extract seemed to have no effect on treatment in the adipose tissue (Figure 4.12A). 
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Figure 4.12. PEPCK expression in rat (A) adipose tissue, (B) muscle and (C) liver tissue. the 
treatments were compared with the obese control, set to a reference of 1. Data represent the mean ± 
SEM (n=3). *p<0.05 in comparison with the obese control. 
 
Skeletal muscle tissue is known to express lower levels of PEPCK as most of the tissue distri-
bution of this enzyme is principally expressed in the liver, kidney and adipose tissue (Stark et 
al., 2014). The effect of treatment by L. leonurus on PEPCK gene expression was 
significantly (p<0.05) down-regulated in comparison with the obese control in the liver and 
muscle. In liver tissue, sulfonylurea caused a significant (p<0.05) increase, while aspirin 
caused a significant decrease. 
 
PEPCK and G6Pase are 2 key hepatic gluconeogenic enzymes whose expression and activity 
are increased in T2D and in animal models of diabetes (Samuel et al., 2009). The increase in 
the rate of gluconeogenesis contributes to increased hepatic glucose output. PEPCK is an en-
zyme in the lyase family, used in the metabolic pathway of gluconeogenesis. It converts ox-
aloacetate into phosphœnolpyruvate and carbon dioxide (Xiong et al., 2011). It is well known 
that fasting hyperglycaemia results in an increase in exogenous glucose production and this is 
due to an increase in gluconeogenesis. Samuel et al. (2009) demonstrated that increased 
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transcriptional expression of PEPCK and G6Pase does not account for increased gluconeo-
genesis and fasting hyperglycaemia in patients with T2D. It was found that in diabetic rats 
with notable increases in fasting plasma glucose concentrations and rates of endogenous 
glucose production, there was surprisingly no detectable increase in PEPCK or G6Pase ex-
pression (Samuel et al., 2009). AMPK is also known to lower liver G6Pase and PEPCK 
mRNA expression. Adiponectin activates AMPK and this blocks PEPCK and G6Pase expres-
sion (Combs and Marliss, 2014). Adiponectin expression also lowers PEPCK and G6Pase 
gene expression in the liver (Combs and Marliss, 2014). The L. leonurus treatment increased 
adiponectin gene expression in adipose tissue, while significantly reducing liver PEPCK gene 
expression, which correlates with the regulatory role of adiponectin in the liver.   
 
The cytosolic form of PEPCK has been shown to be up-regulated in diabetic rodent models. 
Studies conducted by Rajas et al. (2000) have, however, shown that fasting hyperglycaemic 
conditions in diabetics are not associated with an increase in PEPCK as well as G6P gene ex-
pression, and treatment of the diabetic rats with insulin caused a decrease in the expression of 
the gene. This could explain the current results of low mRNA expression especially with L. 
leonurus treatment in the muscle and liver tissues, as the animals were fasted prior to being 
euthanised. A study by Hanson and Hakimi (2008) reported that the mode of action of met-
formin is via the activation of hepatic AMPK, which in turn inhibits expression of G6P and 
PEPCK. It has been shown that overexpression of the PEPCK gene in muscle could have 
non-beneficial effects, in that it might cause mammals to be hyperactive (Hanson and 
Hakimi, 2008). It is observed that hyperglycaemia seen in patients with T2D cannot be 
attributed to increased expression of these key gluconeogenic enzymes (Samuel et al., 2009). 
The catapleorosis of PEPCK links it to glucose synthesis and it has been shown that deleting 
the gene for PEPCK in rat liver stops gluconeogenesis (Hanson and Hakimi, 2008). Thus, in 
muscle and liver tissue, L. leonurus treatment could possibly promote the reduction of 
PEPCK gene expression. An increase in PEPCK gene expression is usually observed in 
fasting hyperglycaemia-associated T2D (Samuel et al., 2009) since the rate of 
gluconeogenesis is increased in these tissues. 
 
In summary, PEPCK gene expression was not affected by treatments with marrubiin and the 
L. leonurus extract in adipose tissue. In muscle and liver tissue, however, a significant de-
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crease was observed with L. leonurus treatment, while marrubiin did not show a significant 
decrease in the liver and muscle tissues.   
 
4.3.12 Uncoupling protein-2 gene expression in adipose tissue 
UCP-2 expression is known to be increased in adipose tissue of genetically-induced obese 
mice (Aubert et al., 1997). In the analysis of this protein in the adipose tissue, it was observed 
that the L. leonurus extract and metformin treatments significantly (p<0.05) increased the ex-
pression of the UCP-2 mRNA (Figure 4.13) in comparison with the obese control. Marrubiin, 
sulfonylurea and aspirin had no effect on UCP-2 gene expression in adipose tissue.  
 
Figure 4.13. Gene expression of uncoupling protein-2 (UCP-2) in rat adipose tissue. The treatments 
were compared with the obese control, set to a reference of 1. Data represent the mean ± SEM (n=3). 
*p<0.05 in comparison with the obese control. 
It is known that UCP-2 has a protective role against oxidative stress which is a major contrib-
utor to the development of T2D. Therefore, L. leonurus extract and metformin may play a 
protective role against oxidative stress through the action of UCP-2 in adipose tissue. As the 
L. leonurus extract showed a significant increase in gene expression, it is possible that other 
elements (besides marrubiin) present in the extract could be responsible for the increased 
gene expression. Therefore, this aspect needs further investigation.   
 
The L. leonurus extract and metformin could potentially aid in the mitochondrial proton leak 
in the inner mitochondrial membrane of adipose tissue via the action of UCP-2. Skulachev 
(1996) observed that an increase in the proton leak in the mitochondrial membrane would 
stimulate oxygen consumption and decrease the formation of ROS. The uncoupling of UCP-2 
is known to cause an increase in glycolysis and the synthesis and translocation of GLUT-4, as 
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well as the breakdown of FAs, leading to a reduction in blood glucose and fat mass, 
improving glucose tolerance (Almanza-Perez et al., 2010). Leptin has been shown to increase 
UCP-2 mRNA expression in brown and white adipose tissue in obese mice and in obese 
subjects (Scarpace et al., 1998). This effect was evident in adipose tissue (Figure 4.13), 
where an increase in gene expression of leptin also resulted in up-regulation of UCP-2 when 
treated with the extract indicating that a possible mechanism of action is through the 
regulation of leptin. The regulatory role of leptin on UCP-2 expression, as shown by Scarpace 
et al., (1998) therefore supports the current findings.  
 
It is observed that circulating levels, as well as gene expression levels of adiponectin, are re-
duced in UCP-2 null mice (Chevillotte et al., 2007). Several studies have reported that the in-
sulin-resistant state, as well as T2D, are associated with low adiponectin levels and a reduced 
UCP-2 expression in adipose tissue. It is known that increasing the UCP-2 mitochondrial lev-
els induced adiponectin gene expression (Chevillotte et al., 2007). This supports the current 
findings that marrubiin, sulfonylurea and aspirin treatment did not change UCP-2 expression 
in the adipose tissue. However, this resulted in a significant decrease in adiponectin, with the 
respective treatments in adipose tissue. The current study also showed that the increase in 
adiponectin gene expression induced by L. leonurus treatment resulted in up-regulation of 
UCP-2 gene expression. The changes in the mitochondrial action of UCP-2 occur via changes 
in ROS levels and involve changes in the levels of CHOP-10 (a member of the 
CCAAT/enhancer-binding proteins (C/EBPs) family of transcriptional factors that regulate 
cell cycle and apoptosis), which acts as a negative regulator of adiponectin gene transcription 
by interfering with the C/EBP-binding site in the promoter (Chevillotte et al., 2007).  
 
TZD drugs mainly target adipose tissue for effective treatment while in the liver TZD-like 
drugs are able to reduce glucose production. Their insulin-sensitising effect is usually brought 
about by inducing gene expression of mitochondrial proteins such as UCP-2 as well as 
inducing adiponectin gene expression (Hondares et al., 2006). These drugs are also known to 
restore circulating adiponectin levels. Thus, the L. leonurus extract could complement the 
actions of TZD thereby promoting insulin sensitivity. 
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Table 4.5 gives a brief summary of the findings observed in the qPCR study. The up- or 
down-regulation of the genes with each treatment is highlighted. In the adipose tissue, leptin 
showed a significant decrease with the L. leonurus extract and marrubiin treatments. 
Adiponectin expression was significantly increased with L. leonurus treatment and resistin 
was significantly (p<0.05) reduced with marrubiin treatment. GLUT-2 expression showed no 
significant increase in the liver, however, GLUT-4 expression was increased in adipose tissue 
with all treatments, being significantly observed with metformin treatment.  
 
Table 4.5. A summary of the key findings observed in the qPCR work. The treatments (red and green 
arrows) were compared with the obese control. The summary is the results of the significant (p<0.05) 
changes observed when compared with the obese control.  
Gene Tissue 
Treatments (relative to OC) 
L. l Marr Sul Met Asp 
LEPTIN adipose  * * * --  
ADIPONECTIN adipose * * * * * 
RESISTIN adipose -- * * * * 
GLUT-2 liver  * * *  * 
GLUT-4 adipose    #  
muscle  * * *  -- 
PPAR-γ 
adipose  *     
muscle  
liver  
* 
* 
* 
* 
* 
* 
 
 
-- 
* 
FAS 
adipose 
muscle  
liver  
* 
* 
* 
 
-- 
* 
-- 
-- 
*  
   
* 
 -- 
-- 
* 
-- 
IRS-1 
adipose -- * --   
muscle  
liver 
* 
* 
 
* 
* 
* 
* 
-- 
* 
* 
GLUCOKINASE 
adipose  * 
* 
* 
* -- * * 
muscle  
liver  
* 
* 
* 
 
 
 
 
* 
PEPCK 
adipose  
muscle  
liver  
-- 
* 
* 
-- 
 
 
 
* 
* 
-- 
 
* 
 
 
* 
UCP-2 adipose * -- -- * -- 
Key: OC; obese control, Ll; Leonotis leonurus, Marr; marrubiin, Sul; sulfonylurea, Met; metformin, 
Asp; aspirin.    Down-regulation relative to OC.    Up-regulation relative to OC, --; no change relative 
to obese control.*p<0.05 and 
#
p<0.01. 
 
In the three tissue types investigated, the genes investigated exhibited their action through the 
adipose tissue with treatment with the plant extract and/or marrubiin. PPAR-gamma, GK and 
UCP-2 were significantly (p<0.05) increased in the adipose tissue. Marrubiin treatment 
117 
 
increased IRS-1 gene expression in the adipose tissue, however, no change was observed for 
PEPCK treatment in the adipose tissue. FAS gene expression was decreased in the adipose 
tissue by marrubiin and the L. leonurus treatment. Thus, a significant effect of the treatments 
was observed in the adipose tissue in relation to the liver and muscle tissue.  
 
In the following section, the in vitro cross-talk between adipose tissue, muscle and liver, and 
their effect on insulin secretion by the β-cells will be explored to gain a deeper understanding 
of the insulin secretagogue effect of the respective treatments.  
 
4.4 Crosstalk between fat, muscle, liver and pancreas: an in vitro study 
4.4.1 Introduction  
Although there are studies that have shown the anti-diabetic properties of the extract of L. 
leonurus and its constituent, marrubiin (Mnonopi et al., 2012), the mechanism of its anti-dia-
betic action is still not known and understood. A better understanding in terms of its tissue 
specificity and an understanding of the mechanism of its anti-diabetic action is required.   
 
The aim of this section is to investigate the link between the peripheral tissues (muscle, liver 
and fat) and the in vitro effect that secreted cytokines from these tissues have on insulin se-
cretion. Thus, the diabetic state under in vitro conditions was investigated to establish the link 
between adipocytes, muscle and liver tissues, and the crosstalk between these tissues and 
insulin secretion in INS-1E β-cells (a model for β-cells). An increase in ROS and free 
radicals in β-cells are known to be a hallmark of T2D. Therefore, the effect of the treatments 
on oxidative stress on adipocytes, muscle and liver cells will be investigated.  
 
Certain cell types require conditioned medium from other cell types as they make use of, or 
are dependent on, their metabolites. Such metabolites and nutrients include glucose, amino 
acids, nucleosides, adipokines (such as leptin, adiponectin and resistin), growth factors (such 
as interleukins, epidermal growth factor [EGF], and platelet-derived growth factor [PDGF]), 
and matrix proteins (such as collagen, fibronectin and various proteoglycans) (Phelan, 2007).  
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4.4.2 Materials and methods 
Fat (3T3-L1), muscle (C2C12) and liver (Chang liver) cells were cultured in normal medium. 
The cells were treated with marrubiin and L. leonurus extract under normoglycaemic (11.1 
mM glucose) and hyperglycaemic (33.3 mM glucose) conditions for 48h. The conditioned 
medium was collected afterwards and applied to INS-1E cells as treatment for a further 48h 
at the same glucose concentrations. The INS-1E cells were also treated with marrubiin, the 
plant extract, sulfonylurea (positive control) and media without any treatment to serve as 
(control). The CM experiment was compared with INS-1E cells exposed to RPMI media only 
to the two conditions. The following key were used to distinguish various experimental 
conditions and will be used in this section: 
INS-1E cells exposed to conditioned media from fat, muscle and liver cells; 
 CC – refers to conditioned medium obtained from cells with no treatment, i.e. 
conditioned medium from control cells 
 MC – refers to conditioned medium obtained from cells treated with marrubiin (10 
ng/ml). 
 EC – refers to conditioned medium obtained from cells treated with L. leonurus 
extract (10 µg/ml). 
INS-1E cells directly exposed to the following conditions 
 Marr – refers to INS-1E cells treated with marrubiin (10 ng/ml).  
 Extr – refers to INS-1E treated with (10 µg/ml) L. leonurus extract  
 Sul – refers to INS-1E treated with sulfonylurea (10 µM), positive control 
 Cont – refers to INS-1E with no treatment (control or reference) 
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Figure 4.14. A schematic representation of the experimental design associated with the crosstalk 
studies. Fat, liver and muscle cells were cultured for 48h under normo- (11.1 mM) and 
hyperglycaemic (33.3 mM) conditions in the presence/absence of Marr and Extr. INS-1E cells were 
then exposed for a further 48h to conditioned medium: RPMI medium (80:20), with/without Marr, 
Extract, Sulfonylurea. Insulin secretion was quantified thereafter (n=3).  
 
A schematic representation showing the experimental plan for these studies is shown in Fig-
ure 4.14. After CM was collected from adipocytes, muscle and liver cells, INS-1E cells were 
exposed for 48h to a mixture of conditioned medium and INS-1E medium at a ratio of 80:20. 
This ratio was optimised using either 80% RPMI or DMEM, where RPMI was found to be a 
better option for the INS-1E cells. After CM exposure, the insulin secretion effect in the INS-
1E cells was investigated.  
 
4.4.2.1 Cell culture and maintenance of cell lines 
All cells were maintained in a 37°C humidified environment with a 5% CO2 atmosphere. 
C2C12 and Chang liver cells were maintained in RPMI-1640 (Gibco) supplemented with 10% 
(v/v) FCS. 3T3-L1 cells were maintained in DMEM (Gibco) supplemented with 10% (v/v) 
FCS and INS-1E cells were maintained in RPMI-1640 containing 25 mM HEPES (Sigma, 
US) and supplemented with 10% (v/v) FCS, 50mM β-mercaptoethanol (Sigma, US), 1 mM 
sodium pyruvate and  100 U/ml penicillin/streptomycin.  
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4.4.2.2 Differentiation of 3T3-L1 pre-adipocytes 
Prior to experimentation, 3T3-L1 pre-adipocytes were differentiated into mature adipocytes. 
Pre-adipocytes were cultured in 10 cm dishes in DMEM medium supplemented with 10% 
FCS. Once attached and confluent, media was replaced with differentiation media for two 
days. The differentiation medium was composed of DMEM containing 0.5 mM 
isobutylmethylxanthine (IBMX), 0.25 µM dexamethasone, 10 µg/ml insulin and 10% FCS. 
On the third day, the differentiation media was replaced with DMEM containing 10 µg/ml 
insulin until the sixth day.  
 
4.4.2.3 Preparation of conditioned medium and exposure to INS-1E cells 
Conditioned medium was prepared using adipose 3T3-L1 cells, muscle C2C12 cells and 
Chang liver cells. The cells were treated with marrubiin and L. leonurus organic extract at a 
concentration of 10 ng/ml and 10 µg/ml respectively, for 48 h. The concentrations chosen 
have previously been used by our research group for an anti-diabetic study and have been 
shown to be non-cytotoxic, and effective in having anti-diabetic properties. After 48 h, the 
media from each cell line was collected as conditioned medium, for further experimentation. 
Conditioned media were prepared from the cell lines under normoglycaemic (11.1 mM 
glucose) and hyperglycaemic conditions (33.3 mM glucose). The effect of the conditioned 
medium on chronic insulin release was investigated.  
 
INS-1E cells were seeded at a density of 5×10
3
 in 96-well plates and allowed to attach over-
night. Cells were treated for a further 48h with conditioned medium prepared from adipose, 
liver and muscle cells. The experimental medium contained 20% (v/v) of original INS-1E 
medium and 80% of the respective conditioned medium. Insulin release was determined us-
ing an insulin ELISA kit (Millipore, US). A standard curve of insulin was completed (Appen-
dix Figure A3) and unknown concentrations were determined from the standard curve. A 50 
times dilution was obtained for the samples prior to insulin determination due to the sensitiv-
ity of the detection method.  
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4.4.2.4 Nitrate determination 
To monitor the amount of free radicals released by the INS-1E cells and the degree of oxidat-
ive stress in the cells, a nitric oxide assay was performed using Griess’s reagent for nitrate 
(Sigma, SA). Detection of nitrates was performed calorimetrically. To measure the nitrate 
content produced by the cells, 50 µl of medium from the cells was added to 100 µl of 
Griess’s reagent, incubated for 20 minutes at room temperature, followed by recording the 
absorbance in a microtitre plate reader at 540 nm. A nitrate standard curve (0 – 100 nM) was 
constructed (Appendix Figure A4), from which unknown concentrations were determined. 
Nitrates were determined for the conditioned medium obtained from 3T3-L1 cells, C2C12 
muscle cells and Chang liver cells. They were also measured from the INS-1E cells exposed 
to conditioned medium from the above-mentioned cell lines.  
 
4.4.2.5 Statistical analysis  
Data were expressed as the mean ± SEM. Significant differences were reported as p<0.05 or 
p<0.01, where applicable. In this section, two controls were used; a conditioned media 
control and a normal media control.  
 
4.4.3 Results and discussion 
Glucose homœostasis is maintained by controlled insulin release from pancreatic β-cells.  
The β-cells recognise extracellular glucose concentrations and secrete insulin as required at a 
given time. Based on the gene expression experiment completed (Section 4.2) it was 
observed in vivo that the most positive effect of L. leonurus and marrubiin was observed in 
the adipose tissue. This is where the extract and marrubiin had the most anti-diabetic effect. 
In this section, the author established the link between the peripheral tissues and insulin 
release from the pancreatic β-cells. The crosstalk experiment aimed to further explore the 
mechanism of anti-diabetic action of L. leonurus extract and marrubiin. The results obtained 
are represented graphically in the following section. In this section, we compared the insulin 
release by the conditioned media to the insulin release in the normal media (control). Further 
comparison is made within the conditioned media experiments and also within the normal 
media experiments. 
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4.4.3.1 Effect of 3T3-L1 adipocyte-conditioned medium on insulin secretion 
The 3T3-LI conditioned medium enhanced the chronic insulin release significantly (p<0.01) 
in the INS-1E cells at normo- and hyperglycaemic conditions in comparison with the INS-1E 
cells that were not exposed to conditioned medium (Figure 4.15). The CC, MC and EC all in-
creased insulin secretion in both hyper- and normoglycaemic conditions in comparison with 
the treatment of INS-1E cells without conditioned medium. Insulin release was more than 
850 ng/ml for all the conditions after a 48h exposure. Insulin release was significantly eleva-
ted (p<0.01) in marrubiin-treated (Marr) cells in comparison with the normoglycaemic and 
hyperglycaemic control (Cont).  
 
In comparison with the Cont, at normoglycaemic conditions, the Extr showed a significant 
(p<0.01) increase in insulin release. Sul and Marr showed no change relative to the Cont. At 
hyperglycaemic conditions, Sul and Marr showed a significant increase in insulin release 
relative to the Cont (33.3 mM glucose). However, it was also noted that the insulin release 
was higher in normoglycaemic conditions in comparison with hyperglycaemic conditions for 
all the treatments except for the CC from the 3T3-L1 cells. Under hyperglycaemic conditions, 
MC had the most effect on enhancing insulin secretion in the INS-1E cells. Under 
hyperglycaemic conditions, neither the MC nor the EC was able to increase insulin secretion 
above the CC from the 3T3-L1. INS-1E cells receiving direct treatment (no conditioned 
medium) (Figure 4.15) showed low insulin levels in comparison with those receiving 
conditioned medium.  
 
It is known that adiponectin promotes insulin actions through its effects on pancreatic β-cells 
by potentiating insulin secretion, increasing the expression of the insulin gene, preventing cy-
tokine/lipid-induced apoptosis and inducing cell proliferation (Cheng et al., 2013). Numerous 
studies have shown that obesity leads to insulin resistance and the progression to T2D. 
However, the secretory factors of fat do play a major role in cellular function, such as the 
promotion of insulin release and GSIS (Lam et al., 2011a; Lam et al., 2011b). This supports 
the current findings of the 3T3-L1 adipocytes enhancing insulin release in the INS-E cells. 
The effects could possibly be mediated by the adipokine adiponectin, which is known to 
enhance insulin secretion in β-cells. The high glucose concentrations used in the study 
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allowed for the detection of an increase in insulin secretion, while simultaneously simulating 
a diabetic environment.  
 
Figure 4.15. The effect of conditioned medium from 3T3-L1 adipocytes on insulin release in INS-1E. 
A comparison was made with INS-1E cells that did not receive conditioned medium treatment. Data 
was expressed as the mean ± SEM. (n=3). 
#
p <0.01 vs Cont. (11.1mM glucose), *p<0.01 vs Cont. 
(33.3mM glucose). 
 
Thus, it can be summarised that the CM treatment of MC from the 3T3-L1 adipocytes 
enhanced insulin release in the INS-1E cells in comparison with INS-1E cells that did not 
receive CM. However, the treatments under normoglycaemic conditions showed an increase 
in insulin release in comparison with the treatments at hyperglycaemic conditions, suggesting 
that at high glucose concentrations, treatment was not effective at enhancing insulin release. 
The positive control, Sul, also had the same effect. Since the experiment was performed over 
48h, it is likely that the insulin accumulation at normal conditions was higher than that of the 
hyperglycaemic conditions and that the true effect of the treatment was not observed. Also, 
the insulin release in the INS-1E cells over 48h was relatively high as INS-1E cells show an 
improved insulin release in comparison with INS-1 cell lines. It can be recommended that a 
24h sample is taken for comparison.  
 
4.4.3.2 Effect of (C2C12) muscle-conditioned medium on insulin secretion 
Insulin release in INS-1E cells treated with CM from muscle cells showed a decrease in insu-
lin release in comparison with INS-1E cells without conditioned media (control) (Figure 
4.16).  Under normoglycaemic conditions, insulin release from CC, MC and EC were 
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significantly (p<0.01) lower in comparison to Cont. and at hyperglycaemic conditions, the 
CC showed a significant (p<0.01) decrease in insulin release in comparison with the Cont.  
The effect of CM resulted in lower insulin release in comparison with the INS-1E cells 
receiving direct treatment. MC and the EC were able to increase insulin release in the INS-1E 
cells at high glucose conditions in comparison with CC. Comparing this effect with the INS-
1E cells with direct treatment, it was observed that Sul and Marr treatments significantly 
(p<0.05) increased insulin release in relation to the control at hyperglycaemic conditions. At 
normoglycaemic conditions, the extract showed a significant increase relative to the control 
(direct treatment). The extract (Extr) did not increase insulin release under hyperglycaemic 
conditions. 
 
Figure 4.16. The effect of conditioned medium from muscle (C2C12) cells on insulin release in INS-
1E. A comparison was made with INS-1E that did not receive conditioned medium treatment. Data 
represents the mean ± SEM. (n=3). 
*
p <0.01 vs Cont. (11.1mM glucose), 
#
p < 0.01 vs Cont. (33.3mM 
glucose). 
¶
p<0.01 compared with muscle CC (11.1mM glucose), 
$
p<0.01 compared with muscle C2C12 
CC (33.3mM glucose). 
 
Low levels of insulin release in the muscle-conditioned medium were observed in compari-
son with that of the adipocyte-conditioned medium. Adipocytes were cultured with DMEM, 
and muscle and liver cells were both cultured in RPMI-1640 medium. Neither medium 
contains any supplements except for FBS. Thus, the effect of the CM from the adipocytes 
resulted in the increase in insulin release. Within the muscle treatment, however, it was 
observed that CM treatment at hyperglycaemic conditions promoted insulin release in MC 
and CC (p<0.05), when compared with the conditioned medium control (CC). Thus, under 
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hyperglycaemic conditions, the conditioned medium from muscle that was exposed to 
marrubiin and the plant extract caused an increase in insulin release by the INS-1E cells 
(Figure 4.16). Under normal glucose conditions, the conditioned medium from muscle (no 
treatment, CC) increased insulin release in comparison with hyperglycaemic CC (Figure 
4.14).  
 
In summary, the CM from muscle C2C12 enhanced insulin release significantly (p<0.05), with 
MC and EC treatment at hyperglycaemic conditions in comparison with normoglycaemic 
conditions. However, the observed release was significantly lower than the control.  
 
4.4.3.3 Effect of liver-conditioned medium on insulin secretion 
Treatment of INS-1E cells with liver-conditioned medium resulted in a significant increase 
(p<0.05) in insulin release with the MC and EC treatments relative to the control (liver CC) 
under normoglycaemic conditions (Figure 4.17). Under hyperglycaemic conditions, no in-
crease in insulin was observed with the MC and EC in comparison with the CC.  
 
INS-1E cells that did not receive conditioned medium showed a significant (p<0.01) increase 
in insulin release by all the treatments including the Cont under hypoglycaemic conditions 
but not under hyperglycaemic conditions, in comparison with the CC. CM from the control 
liver cells showed an increase in insulin release under hyperglycaemic conditions in 
comparison with normoglycaemic conditions. However, EC treatment on INS-1E showed a 
significant increase (p<0.05) at high glucose concentrations relative to normal glucose levels. 
Thus, the EC treatment increased insulin release in the hyperglycaemic diabetic model 
environment. No other treatments enhanced the uptake at high glucose levels.  
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Figure 4.17. The effect of conditioned medium from Chang liver cells on insulin release in INS-1E 
cells. A comparison is made with INS-1E that did not receive conditioned medium treatment. Data 
represents the mean ± SEM. (n=3). 
#
p < 0.01 vs Cont. (11.1mM glucose), *p <0.01 vs Cont. (33.3mM 
glucose). 
¶
p <0.01 compared with liver Chang CC (11.1mM glucose), 
$
p <0.01 compared with liver 
Chang CC (33.3mM glucose). 
 
In summary, liver cells treated with conditioned medium showed a significant reduction in 
insulin secretion in INS-1E cells when compared with INS-1E cells treated with normal 
medium under normoglycaemic conditions. At high glucose concentrations, the positive 
control and Marr treatment in the normal medium showed a significant (p<0.05) increase in 
insulin release in comparison with all the conditioned medium treatments. Thus, conditioned 
medium from liver cells showed a decrease in insulin release by INS-1E cells in comparison 
with 3T3-L1 adipocytes.  
 
Treatment of the INS-1E cells with Marr, Extr and the positive control, sulfonylurea, showed 
an increase in insulin release when compared with the conditioned medium from muscle and 
liver cell lines, but not adipose cell lines. The secretory protein and cytokines from the mus-
cle and liver did not have a similar effect as that of adipocytes.  
 
Figure 4.18 is a combined graph showing the effect of the CM treatments from adipocytes, 
liver and muscle cells as well as the average insulin secretion in INS-1E cells in response to 
Ext, Marr and Sul treatments. The presence of high glucose concentrations in the medium has 
an effect on normal cellular function of the INS-1E cells. Hyperglycaemic conditions are 
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known to cause insulin resistance (Cryer, 2012). With high glucose concentrations, 
sulfonylurea and marrubiin significantly (p<0.01) increased insulin secretion in cells in 
comparison with the control (Figure 4.18). The L. leonurus extract did not show any increase 
in insulin release under the same conditions. Marrubiin, L. leonurus extract and sulfonylurea 
all enhanced insulin release when exposed to normal glucose concentrations; the plant extract 
was shown to have a significant (p<0.01) increase.  
 
Figure 4.18. A summary of the effect of muscle, liver and fat cell lines conditioned medium on INS-
1E cells. Control conditioned medium: CC, marrubiin conditioned medium: MC, extract conditioned 
medium: EC, marrubiin: Marr, L. leonurus extract: Ext, sulfonylurea: Sul, Control: Cont. Error bars 
represent mean ±SEM, n=3. All the treatment conditions were compared with the Cont. 
#
p<0.01 vs 
Cont (11.1mM glucose), *p<0.01 vs Cont (33.3mM glucose). 
 
In summary, when conditioned medium from differentiated adipose tissue cells was added to 
INS-1E cells, there was an increase in insulin release compared with INS-1E cells treated 
with normal INS-1E medium irrespective of 11.1 or 33.3 mM glucose levels. The muscle and 
liver-conditioned medium did not have a similar effect to the adipocyte CM. The various 
hormones, cytokines and proteins secreted by the adipose tissue could possibly be the link 
between the pancreas and the adipose tissue. The cytokines and growth factors from the 
adipose tissue-conditioned medium could cause cell proliferation as well as sensitising the 
cells to insulin.  
 
The crosstalk effects observed in the in vivo section creates a link for discussion with the 
findings obtained in the in vitro CM experimental work. The adipokines secreted from the 
adipose tissues are known to regulate insulin sensitivity (Dunmore and Brown, 2013). CM 
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from abdominal subcutaneous and visceral omental fat has been used to determine the effect 
of insulin sensitivity of L6 myotubes and the mechanisms involved (Lam et al., 2011b). Sup-
porting the current approach to determining the CM effect from adipocytes in an in vitro 
model, mouse models of increased insulin sensitivity such as the heterozygous PPAR-γ-
deficient mice have been used to screen for molecules secreted by white adipose tissue. It was 
observed that the increased expression of adiponectin seen in these mice is associated with in-
creased insulin sensitivity (Yamauchi et al., 2014). Also, the combination of low adiponectin 
signalling and high insulin resembles an insulin-resistant state which is associated with car-
diovascular disease, fatty liver disease and a decrease in life expectancy (Combs and Marliss, 
2014). To highlight the importance of the adipokines on the insulin secretagogue effect, it is 
possible that having an effective adiponectin signalling could prevent the need for insulin 
treatment in T2D patients (Combs and Marliss, 2014). 
 
Figure 4.19. A summary of the major effects of the plant extract (L. leonurus) and marrubiin (MARR) 
on the various tissues in the in vivo experiment. Marrubiin and the plant extract show their anti-diabet-
ic action mainly in the adipose tissue. The crosstalk of the peripheral tissues with the pancreas (mod-
el) with respect to insulin sensitivity and insulin release is noted in the adipose tissue in vitro experi-
ment. No effect was observed with conditioned medium treatment from the muscle and liver receiving 
marrubiin and L. leonurus treatment. Green arrow shows the positive effect of treatment; red arrow 
shows the negative effect of treatment. The up or down arrows represent significant findings 
observed.  
ADIPOSE 
TISSUE 
MUSCLE 
LIVER 
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The relationship between the peripheral tissues in the in vivo and in vitro experiments is sum-
marised in Figure 4.19, highlighting the effects the extract and marrubiin have on the peri-
pheral tissues (in vivo study) and also the effects the plant extract and marrubiin has on insu-
lin release in cultured cells (in vitro study). The summary shows the significant effects ob-
served in the in vivo study. The plant extract showed promising results by the control of gene 
expression of adiponectin, leptin, PPAR-γ, glucokinase and UCP-2. Marrubiin also showed 
some promising results in the adipose tissue. The treatments did not show promising results 
in the liver and muscle tissue. Thus, the effects of the increase in the adipokines in adipose 
tissues to promote insulin release by INS-1E cells could be correlated with the findings ob-
served in the 3T3-L1 cells. However, adipokine levels in the cells could be determined for 
confirmation.  
 
To conclude, the present study has shown novel findings of the effect of adipose tissue CM 
on insulin release by INS-1E cells. The CM generated from the cell lines served as a model to 
mimic the in vivo effects, thus establishing a crosstalk between the muscle, liver, adipocytes 
and the pancreatic β-cells. The crosstalk findings observed correlated to the in vivo study with 
the treatments having a significant effect in the adipose tissue. This has provided evidence for 
the L. leonurus extract and marrubiin predicting their anti-diabetic effects largely at the level 
of the adipose tissue, both in the in vivo and in vitro models.   
 
4.4.3.4 Nitrate determination 
The presence of NO in the cellular environment presents an important factor in cell metabo-
lism. As discussed previously, the presence of NO in the cell at micromolar concentrations 
gives an indication of cells that are prone to diabetic conditions. The presence of nitrates from 
adipose, liver and muscle conditioned medium were investigated. The results showed that no 
nitrates were detected in the medium samples (data not shown). After constructing a standard 
cure with nitrate concentrations, the nitrates measured from the experimental findings showed 
null values and thus could not be represented graphically. The calibration curve for nitrate de-
termination is shown in Appendix A4. This is, however, a good indication, as the presence of 
nitrates released in the medium gives an indication of cells undergoing stress conditions. Oxi-
dative stress is defined as a disturbance in the balance between the production of ROS (free 
radicals) and antioxidant defences. ROS appear to be produced in larger amounts by islets 
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from T2D patients than by those from non-diabetics (Marchetti et al., 2004). Obesity, as well 
as hyperglycaemia, are associated with ROS production (Liu and Sweeney, 2013).  
 
It has been shown that increased intracellular ROS levels caused by mitochondrial dysfunc-
tion resulted in impairment of insulin action and adiponectin secretion in adipocytes (Liu and 
Liu, 2013). It has been shown that mitochondrial dysfunction-induced ROS overproduction is 
associated with decreased levels of the high molecular weight form of adiponectin in adipose 
tissues of the caveolin-1 knockout mice (Wernstedt Asterholm et al., 2012). Thus, the current 
results may reveal that the low levels of NO indicate normal insulin action as well as possible 
high levels of adiponectin. This is further confirmed by the high insulin release observed in 
the INS-1E cells treated with conditioned medium from the 3T3-L1 cells. Conditioned medi-
um from 3T3-L1 cells treated with marrubiin at the normoglycaemic level resulted in a 
significant increase in insulin release (Figure 4.15).  
 
The mitochondria are the main source of ROS production. Molecular species of ROS include 
superoxide anion (O2•
−
), hydrogen peroxide (H2O2), and the hydroxyl radical (•HO). The 
electron transport chain continually generates small amounts of superoxide anion radicals, 
principally through complexes I and III. Superoxide production increases in obesity and in 
hyperglycaemia. When ROS is generated and not removed, it generates a series of stress-re-
lated pathways (Fariss et al., 2005). Studies have shown that generation of ROS in INS-1 
cells triggers apoptosis, the process involving mitochondrial phospholipid oxidation and cyto-
chrome c release (Zhao et al., 2010).  
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5 CHAPTER 5: NANOFORMULATIONS OF L. LEONURUS EXTRACT 
5.1 Introduction  
The aim of this chapter was to prepare and compare three types of nanoformulations of L. 
leonurus plant extract, i.e. nanocrystals, nanostructured lipid carriers (NLC) and 
nanoemulsions, for in vitro anti-diabetic study and to determine their characteristics. The 
characterisation and properties of these nanoformulations have been discussed in section 1.6. 
The preparation and characteristics as well as physical stability of the formulations were 
investigated. The experimental work in this chapter was conducted at the Freie Universität 
Berlin (Germany), under the supervision of Prof R H Müller and Dr. R Shegokar, as part of 
an Erasmus Mundus exchange programme.  
 
Nanoformulations are known to enhance the solubility of poorly soluble drugs and thereby 
increasing their bioavailability. The NLC and the nanoemulsion formulations of the extract 
were prepared by incorporating lipids. They are therefore referred to as lipid nanoparticles. 
Lipids are known to promote the absorption of many drugs. When lipids are taken orally they 
are dispersed in the gut into fine droplets by bile salts or by mechanical movements. Lipid 
nanoparticles can also be prepared for drugs to be administered dermally, mucosally, using 
intravenous injections or inhalants, as well as ocular delivery (Müller et al., 2011b). Nano-
crystal drugs do not have a lipid base and constitute mainly the drug and a surfactant or an 
excipient.  
 
5.2 Materials and methods 
5.2.1 Production of formulations  
In section 1.6 the properties of SLN and NLC formulations were discussed and it was shown 
that the NLC had many advantages over SLN. Therefore, the NLC formulation was chosen 
and was thus prepared using the L. leonurus extract for the current study.  
 
HPH was used in the preparation of the three different formulations. For smaller volumes of 
the formulations, a B3 high-pressure homogeniser was used (Figure 5.1A). This homogeniser 
accommodates a maximum volume of 3 ml. The heating jacket heats the samples during 
homogenisation which prevent samples containing lipids from solidifying. The LAB 40 
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homogeniser was used for samples with volumes of up to 40 ml (Figure 5.1B). This also has 
a heating jacket, serving the same purpose of heating lipid samples during homogenisation. 
The compositions of the formulations of the NLC, nanoemulsions and nanocrystals are given 
in Tables 5.1, 5.2 and 5.3, respectively. 
  
Figure 5.1. (A) Avastin B3 homogeniser with a batch size ≥3 ml. (B) High-pressure homogeniser 
(LAB-40) working with piston gap technology. Arrows represent heating jackets for homogenisation 
of lipid samples at higher temperatures to ensure that they do not solidify. 
 
The NLC and the nanoemulsions were all prepared in a similar manner. Plant extract was ini-
tially dissolved in hot oil, Miglyol
®
 812 (caprylic/capric triglyceride (Caelo Hilden, 
Germany) at ± 80
°
C, followed by the addition of solid lipid, Cutina
®
 CP (Cognis, Düsseldorf, 
Germany) and a surfactant, Plantacare
®
 2000 (Cognis GmbH, Germany). The rest of the 
samples for the NLC and nanoemulsion preparation were added according to the order in 
Tables 5.1 and 5.2. All additions were performed at ± 80
°
C. Once they were dissolved, a 
short 10-second pre-milling step was performed with an Ultra Turrax T25 homogeniser 
(Janke and Kunkel GmbH, Germany) prior to HPH. The solution was homogenised for five 
cycles at a pressure of 800bar (for NLC preparation) and three cycles at 800 bar (for nano-
emulsion preparation). After homogenisation, the homogenate was immediately added to 
vials, sealed and allowed to cool at room temperature. 
 
Table 5.1. The composition of the reagents used in the preparation of the plant extract nanoemulsion. 
Sample % of product (total = 100%) Theoretical weight (total 
= 30 g) 
Actual weight (total 
= 30 g) 
Plant extract 1 0.3 0.3106 
TagoCare
®
 450 1 0.3 0.3147 
Plantacare 2000 1 0.3 0.3215 
Lipid (Cutina
®
 CP) 8 2.4 2.4452 
Oil (Miglyol
®
 812) 2 0.6 0.6217 
Water  87 26.4 26.56 
A B 
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Table 5.2. Composition of the reagents used in the preparation of the plant extract NLC 
Sample % of product (total = 100%) Theoretical weight (total 
= 30 g) 
Actual weight (total 
= 30 g) 
Plant extract 1 0.3 0.3534 
TagoCare
®
 450 1 0.3 0.3117 
Oil (Miglyol
®
 812) 10 3.0 3.0075 
Plantacare 2000 1 0.3 0.310 
Water 87 26.1 26.269 
 
Table 5.3. Composition of the reagents used in the preparation of the plant extract nanocrystals 
Sample % of product (total = 100%) Theoretical weight (total 
= 3 g) 
Actual weight (total 
= 3 g) 
Plant extract 1 0.03 0.0311 
Plantacere 2000 0.25 0.0075 0.008 
Water 98.75 2.9625 2.9700 
 
Nanocrystals of the plant extract were prepared by initially dissolving the extract in a solvent 
(ethanol, Sigma), followed by the addition of de-ionised water and surfactant (Plantacare
®
 
2000) and immediately homogenised using the Avastin B3 homogeniser for 20 cycles. Parti-
cle size, microscopy and zeta potential measurements were determined immediately after 
homogenisation of the formulations. Double distilled de-ionised water was used in the pre-
paration of all the formulations and all other materials used were of a good analytical grade. 
 
5.2.2 Characterisation of formulations 
Characterisation of the formulations was performed by particle size analysis using PCS and 
LD measurements. PCS measurements were performed using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK), equipped with a red laser (633 nm) and non-invasive back-scat-
tering detection optics. The detector position and configurations allow for the analysis of par-
ticle sizes ranging between 0.6 nm and 6 μm. Before measurements were taken, the prepared 
formulations were diluted (1:10) with de-ionised water. The average particle sizes and poly-
dispersity index (PI) from 30 runs/readings were obtained. For LD measurements, a Beckman 
Coulter LS230 Laser diffractometer (Beckmann-Coulter, Krefeld, Germany) was used. It has 
a measuring range of 40nm to 2 000 μm due to the use of two Fourier lenses and three detect-
ors (low-, mid- and high-angle-detectors) as well as polarization intensity differential scatter-
ing (PIDS) technology. One measurement was completed in 60 sec and the obscuration was 
adjusted to 40-50%. An average of three readings was obtained. Visual characterisation was 
performed using light microscopy at various magnifications (up to 1 000 times magnifica-
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tion), as well as by scanning electron microscopy (SEM). SEM studies were performed using 
a Carl Zeiss Evo MA 15 scanning electron microscope and images were analysed using Vega 
TC software (Tescan digital microscopy imaging).   
 
5.2.3 Short-term stability of nanoformulations 
To determine the physical stability of the formulations during storage, the samples were 
stored in sealed vials at three different temperatures: 4
°
C, room temperature (± 25
°
C) and 
40
°
C. During this period the physical stability was determined up to a maximum of 60 days. 
During this period, particle size measurements, measured by LD and PCS, as well as zeta po-
tential measurements were taken. These readings were taken on the day of production and on 
the third, seventh, 14
th
, 28
th
 and 60
th
 day. 
 
5.3 Results and discussion 
5.3.1 Production of formulations 
The average particle size diameter of the NLC formulation, as measured by PCS, was ob-
tained to confirm that the average particle size was in the nano-range. Particle size (reported 
as z-average diameter) was found to be 250nm after the first cycle of HPH (Figure 5.2A). 
Particle size diameter measurements were recorded after each homogenisation cycle and no 
significant decrease in average particle size diameter was observed after the fifth cycle (parti-
cle size 220.6nm). The decrease in particle size correlated to the decrease in the polydispersi-
ty index with each cycle, and after the fifth cycle, the PI of the NLC formulation was 0.076, 
an indication of a narrow particle size distribution (Figure 5.2A). These production results are 
comparable with NLC formulation drug products prepared by high-pressure homogenisation 
using the LAB-40 (Das et al., 2012; Mitri et al., 2011).  
 
Measurements of the average particle size diameter for the nanoemulsions were also obtained 
using PCS. The initial particle size of the extract nanoemulsion was 182.8 nm in diameter aft-
er HPH (Figure 5.2B). Only three homogenisation steps were performed for the nanoemul-
sions as this was enough to attain a particle size in the nanometre range (Muller and Keck, 
2012). Between the second and the third homogenisation cycles, there was no significant par-
ticle size reduction. The final particle size diameter of the nanoemulsions was 139.1 nm with 
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a PI of 0.08. Particle size diameters of drug nanoemulsions are usually smaller in comparison 
with NLC formulation products. The effect of the lipid matrix composition is a possible cause 
linked to the larger particle size of the NLC in comparison with the nanoemulsions (Mason et 
al., 2006). Also, the effect of the solid lipid, Cutina CP, in the NLC matrix mix is why a 
homogenised solid lipid’s particle size is much larger than that of an oil. The effect of the 
lipid composition on particle size is related to the interaction between the lipid, the stabiliser 
and the crystallisation degree of each lipid. As the oil content in the formulation is increased, 
as in the case of the emulsion, the viscosity of the melted droplets is reduced, easing the 
dispersion to result in smaller particle sizes (Müller et al., 2000). 
 
Due to the small volume of the extract nanocrystals prepared, PCS particle size analysis was 
only attained after the final homogenisation cycle to minimise sample loss. The particle size 
diameter of the plant extract nanocrystal as measured by PCS was 190 nm with a PI of 0.4. 
After the final product, the zeta potential of the formulation, measured in conductivity water, 
was -53.5 mV. Particle size analysis determined using LD was not completed because the 
measurement of any possible microparticles by LD requires larger volumes – up to 2 ml in 
some cases. This was not possible for the nanocrystals as it would result in massive sample 
losses. 
  
Figure 5.2. Average particle size diameter analysis and PI of L. leonurus nanoformulation. (A) L. 
leonurus NLC formulation after the first, second, third, fourth and fifth homogenisation cycles, at 800 
bar at 80°C; (B) L. leonurus nanoemulsion formulation after three homogenisation cycles. 
 
Sample preparation of the NLC and the nanoemulsions was achieved using a blend of solid 
lipids. These are cetyl palmitate, myglyol
®
 812 and Tego® Care 450. Cetyl palmitate is a 
mixture of esters from saturated natural FAs and saturated alcohols, mainly hexadecyl hexa-
decanoate (C32H64O2), an ester of cetyl alcohol and palmitic acid. In addition to palmitic acid, 
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cetyl palmitate may contain myristin acid and stearic acid. Cetyl alcohol may be partly re-
placed by myristyl alcohol or stearyl alcohol. Cetyl palmitate is a white wax which is sup-
plied as pellets or flakes. Pure cetyl palmitate crystallises in two modifications, melting at 
52.4 to 52.9°C and at 53.2 to 53.8°C. According to the composition of the ester mixture, the 
melting point is increased or decreased. Cetyl palmitate is insoluble in water and paraffin, 
whereas it is soluble in chloroform and acetone. For this study cetyl palmitate (Cognis, Düs-
seldorf, Germany) was used and in the subsequent section Cutina
®
 CP was used as a syno-
nym for cetyl palmitate. 
 
Medium chain triglycerides (triglyceride saturate media) are a synonym for Miglyol
®
 812. It 
is produced from the oil which is extracted from the solid and dried part of the endosperms of 
Cocos mucifera L and Elaeis guineensis JACQ. Miglyol
®
 812 consists of a mixture of trigly-
cerides, mainly caprylic acid and capric acid. It consists of at least 95% saturated fatty acids 
with eight or 10 carbon atoms. Miglyol
®
 812 is a colourless light yellowish oily liquid which 
is insoluble in water, but miscible with dichloromethane, ethanol, petroleum ether and fatty 
oils. Miglyol
®
 812 was obtained from Caelo (Hilden, Germany). 
 
Polyglyceryl-3 methyl-glucose di-estearate is a synonym for Tego
®
 Care 450 and is non-ion-
ic. Tego
®
 Care 450 is supplied as amber-coloured pellets. It exhibits a melting point at 55°C. 
At 20°C Tego
®
 Care 450 is insoluble in water and at 60°C approximately 100 g/l can be 
emulsified in water.  
 
Larger particles are not easily detected by PCS as it is a tool used for particle size measure-
ments in the nanometre range (Keck and Müller, 2006). Thus, it is possible for particles lar-
ger than a micrometre to exist in the formulation. To overcome this, LD measurements were 
performed for the detection of any agglomerates or aggregates that might have been formed. 
Figure 5.3 is a summary of the LD volume weighted diameters (d[v] 50%, d[v] 90% and d[v] 
95%) values obtained after each homogenisation cycle for the L. leonurus NLC and nano-
emulsion formulations. For the NLC, a decrease in particle size was observed with an in-
crease in homogenisation cycles, with a major decrease in particle size between the first and 
second homogenisation cycles, as compared with the second to fifth cycles (Figure 5.3). The 
presence of microparticles can thus be excluded from the particle size analysis as the volume-
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weighted diameter d(v) 95%, for the NLC was 452 nm. The final particle sizes for the emul-
sions, as determined by the LD, were 188 nm, 206 nm and 243 nm for the d(v) 50, d(v) 90 
and d(v) 95, respectively (Figure 5.3). These results obtained are in agreement with literature 
findings of particle sizes of NLC and nanoemulsions of other drug nanoformulations (Chen et 
al., 2012; Hunter et al., 2012; Tadros et al., 2004).  
 
Figure 5.3. LD 50, 90, 95 and LD 99 of L. leonurus NLC and nanoemulsion. (A) NLC after the first, 
second, third, fourth and fifth homogenisation cycles, at 800 bar at 80°C; (B) nanoemulsion of L. 
leonurus extract after three homogenisation cycles. 
 
5.3.2 Physical stability determination   
A physical short-term storage study was performed to determine the stability of the formula-
tions prepared at three different temperatures: 4°C, room temperature (± 25°C) and 40°C. The 
stability was measured for a period of 60 days. Stability testing gives information about the 
ideal storage temperature of the formulation as well as the maximum storage duration. During 
this storage period, the particles size (PCS and LD measurements), as well as the zeta poten-
tial, were observed. These sub-sections (PCS, LD and zeta potential) of the stability study 
will be investigated in more detail in the subsequent sections. Nanocrystals of the plant ex-
tract were not stable after ± 4 days in storage. Aggregation of particles began to form within a 
week of preparation (results not shown). However, NLC formulation and nanoemulsions of 
the L. leonurus extract showed good stability over the period of testing.  
 
5.3.2.1 Zeta potential analysis during storage 
The zeta potential measurement determines the physical long-term stability of a formulation 
(Table 5.4).  Zeta potential measurements were measured with a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK), applying a combination of Laser Doppler Anemometry and 
Phase Analysis Light Scattering. Samples were diluted with double-distilled water to ensure 
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effective mixing of the formulation during analysis. It was then adjusted with 0.9% (w/v) so-
dium chloride (B Braun Melsungen AG, Germany) solution to a conductivity of 50 μS.cm-1 
and the pH was adjusted to 6.0. On the day of production, the zeta potential measurement was 
54.8mV and 52.3 mV for the NLC and the nanoemulsion respectively, an indication of good 
physical stability (Table 5.5). With high zeta potential values, particle aggregation is less 
likely to occur due to electrostatic repulsion between the lipid particles (NLC) and the oil 
droplets (nanoemulsion) (Wang et al., 2013b). Moreover, the stabilisers used, TagoCare
®
 and 
lantacare
®
 2000, provided further stabilisation of the formulations. Table 5.5 gives a summa-
ry of the zeta potential results of the formulations for the stability period at 4
°
C, 25
°
C and 
40
°
C. 
Table 5.4. Stability determination of nanoparticles as determined by zeta potential measurement. The 
degree of stability is determined by the high zeta potential (mV) of the nanoparticle(s).  
Zeta potential [mV] Stability behaviour of the colloid 
0 to ± 5 Rapid coagulation or flocculation 
± 10 to ± 30 Incipient instability 
± 30 to ± 40 Moderate stability 
± 40 to ± 60 Good stability 
> ± 61 Excellent stability 
 
Usually, zeta potential measurements are obtained in water and in the original dispersion me-
dium used in the production of the formulation. The values obtained are lower when the ori-
ginal dispersion media is used. This is because the measurement of the zeta potential in the 
original dispersion medium is a measure of the thickness of the diffuse layer. The thinner the 
diffuse layer, the stronger the potential decay and the lower the measured zeta potential at the 
slipping plane (Mitri et al., 2011). Therefore, occasionally the stability in the original disper-
sion medium is also vital for a more accurate representation of the stability of the formu-
lation.  
 
During storage of formulations, it is generally observed that at higher temperatures, the sizes 
of particles grow due to aggregation (Wang et al., 2013b). The zeta potential values are thus 
also lower. The instability at higher storage temperatures is due to stressful factors which 
have a destabilising effect, e.g. reduction of viscosity in stabiliser layers (Moschwitzer, 2013; 
Müller et al., 2011b). In the results obtained, no significant change in particle size was ob-
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served and a good stability was achieved after 60 days of storage. For the NLC preparation, 
the stability of the formulation reported on the day of preparation in comparison with the sta-
bility at day 60 showed a good stability of the formulation. Good stability was observed 
across all the temperatures (Table 5.5). Stability has been reported for other NLC drugs at 
room temperature and at lower temperatures as well. Encapsulation of these drugs also in-
creased their storage duration as well as the stability. This was shown in a study with an NLC 
prepared formulation containing the antifungal agent clotrimazole (Das et al., 2012). The 
NLC and the emulsion were all stable across the various temperatures tested, on the day of 
production and at day 60. If samples are not stable during the storage period, it could be at-
tributed to the fact that there was an alteration in chemical composition, e.g. the decomposi-
tion of a stabiliser (Mitri et al., 2011).  
 
Table 5.5. Zeta potential values of L. leonurus NLC and the nanoemulsion at the day of production 
and after 60 days of storage. Storage conditions were at 5 ± 3°C, 25 ± 2°C and 40 ± 2°C (measured in 
water with 50 μS/cm conductivity). 
Formulation Day 0 [mV] Day 60 [mV] 
4°C 25°C 40°C 
NLC -54.8  -56.7 -54.4 -53.2 
Emulsion -52,3 -63.2 -62.6 -69.5 
 
5.3.2.2 Particle size analysis during storage 
For the stability study, particle sizes were analysed for any aggregates that might have been 
formed with the L. leonurus NLC formulation and nanoemulsion (Figure 5.4A & B). Studies 
conducted by Freitas and Müller (1998) showed that particle sizes (measured by LD) re-
mained stable for more than 180 days when refrigerated during storage. Stability over a one-
year period at high and low temperatures has been reported for many NLCs and nanoemul-
sions. There is, therefore, no general rule to determine the stability duration of most NLC and 
nanoemulsions prepared, based on these results. Thus, each experimental result should be 
analysed independently. 
 
Particle size diameters measured by PCS showed that L. leonurus formulations were stable 
over the 60-day period and a small increase in particle size diameter was observed with sam-
ples stored at 40°C (Figure 5.4). This could possibly be due to aggregation, which is likely to 
occur at higher temperatures (Gao et al., 2013; Wang et al., 2013b).  
140 
 
  
Figure 5.4. Particle size diameters showing the stability of (A) NLC and (B) the nanoemulsion of L. 
leonurus extract over two months. The stability test was performed at 4
°
C, 25
°
C and 40
°
C. Error bars 
represent mean ± standard deviation (n=6).  
 
The LD data were evaluated using the diameter d(v) 50%, d(v) 90% and d(v) 95%. This 
means that 50%, 90% or 95% (volume distribution) of the measured particles are below this 
size. LD measurements were also conducted to determine possible microparticles that might 
be present and the findings observed correlated to those of the PCS results. A summary of the 
LD results is shown in (Table 5.6). On day 28 and 60, however, the d(v) 90% and d(v) 95% 
were above the expected particle size range. This could be due to the instability of the 
particles at that temperature and thus, possible aggregation. 
 
Table 5.6. A summary of the LD results obtained for the NLC and nanoemulsions during the 60-day 
storage study. Particle sizes are micrometres (µm) in diameter. 
Duration Temperature 
Nanoemulsion NLC 
d(v) 50% d(v) 90% d(v) 95% d(v) 50% d(v) 90% d(v) 95% 
day 0 
 
0.200 0.373 0.434 0.198 0.368 0.428 
day 7 
± 25°C 0.186 1.597 4.452 0.186 1.597 4.452 
40°C 0.204 1.257 1.322 0.214 1.275 1.399 
4°C 0.181 1.013 3.069 0.181 1.013 3.069 
day 14 
± 25°C 0.119 0.211 0.251 0.196 0.388 0.457 
40°C 0.118 0.209 0.247 0.195 33.506 62.02 
4°C 0.121 0.233 1.197 0.192 0.376 0.440 
day 28 
± 25°C 0.119 0.219 0.272 0.205 0.420 3.629 
40°C 0.119 0.217 0.260 0.200 0.395 0.464 
4°C 0.119 0.212 0.254 0.230 66.965 91.617 
day 60 
± 25°C 0.125 0.228 0.288 0.246 *25.702 *41.751 
40°C 0.126 0.226 0.298 0.214 0.459 4.049 
4°C 0.932 1.485 1.659 1.122 1.523 1.152 
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The d(v) 50 data showed particle size that was comparable with those of the PCS results. The 
exception was the results obtained from the samples stored at 4
°
C after 60 days of storage as 
it indicated particle sizes in the nanometre range, for the NLC and the nanoemulsion d(v) 50. 
These results are not comparable with those obtained from PCS measurements. A possible 
explanation for this could be the LD instrumental settings. An imaginary refractive index of 0 
was used for the analysis of the samples as there is no known value for the L. leonurus 
extract. It is also known that changes in the optical parameters could have a marked influence 
on the LD results as they change the particle size and size distribution drastically (Keck and 
Müller, 2008). It was found that a trimodal mixture of latex particles, having a mean particle 
size of 845 nm, and mean particle sizes ranging from 284 nm up to 1.005 µm, were obtained 
due to the variation of the optical parameters (Keck and Müller, 2008). During stability 
testing, one of the factors that can cause the particle size to increase with time is an 
insufficiency of stabilisers present in the formulations. This could be the case for the 
instability observed for the nanocrystal formulation. The high values obtained for the zeta 
potential readings are an indication of maximum stability, with reference to Table 5.4. The 
characterisation and stability assessment of nanoformulations, particularly nanoemulsions, is 
strongly associated with particle size and PDI. If both parameters remain largely unchanged 
during a storage period, a formulation is usually considered physically stable (Klang et al., 
2012). 
 
Most studies on drug nanoformulations are performed on purely synthesised or purely iso-
lated drug compounds. Currently, there is little literature available describing the properties 
of nanoformulations of plant extracts. Also, no literature has been reported on the nanoformu-
lation of L. leonurus extract. A freeze-dried L. leonurus extract has been formulated into cap-
sules to enhance its storage efficacy. However, this was not nanoformulated. The author con-
cluded that the capsules of L. leonurus freeze-dried extract were not very stable in storage 
and that the hygroscopic nature or moisture content of the extracts may possibly contribute to 
this instability (Ma, 2006). Thus, nanoformulation of L. leonurus extract offers better stability 
in comparison. However, several plant species have been reported to have been formulated 
into nano-medications by attaching or encapsulating them with suitable nanomaterials. In so 
doing the activity, specificity, bioavailability and therapeutic index are increased. Increased 
therapeutic efficacy of nanoformulated drugs has been reported for the plant-based drug 
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curcumin as well as for paclitaxel (Kumari et al., 2012). These drugs showed improved 
bioavailability with fewer side-effects in comparison with their non-formulated form. 
Various types of formulations were employed for the preparation of the nanoparticles and the 
results obtained clearly confirmed that the lipid nanoparticles were more stable than the nano-
crystals. This could be because for nanocrystal formation, a pure synthetic drug was not used 
for its preparation. The method of nanocrystal preparation (ethanol evaporation) is also not a 
popular method of nanocrystal preparation as it often does not yield desired results, especially 
in the preparation of samples like plant extracts. In addition, the percentage surfactant used 
could have caused its instability during storage (Tiwari and Pathak, 2011; Chingunpitak et 
al., 2008). It is indeed evident that the surfactants, along with the lipids used for the NLC and 
nanoemulsion preparation, contributed largely to the stability of the formulations, as reported 
in literature for many NLC and emulsion products (Miller et al., 2014; Wu et al., 2014; 
Zhang et al., 2014; Gao et al., 2013; Moschwitzer, 2013; Müller et al., 2011a).  
 
5.3.3 Light microscopy 
Light microscopy is a powerful technique for the visualisation of particles and objects of 
about 1µm in size. After homogenisation of the formulations, light microscopy was used as 
the initial tool to check that the homogenisation process was successful. Light microscopy 
was used in this study to investigate the nanoparticles after each homogenisation cycle for 
uniformity in particle size and the presence of micro- and macromolecules, as well as any 
aggregation that might have occurred. The microscopic results of the initial and the final 
homogenisation products of the nanoemulsion and NLC are shown in Figures 5.5 and 5.6 
respectively. Images of the extract nanocrystals are shown in Figure 5.7. The findings from 
the microscopy study showed clear uniformity observed for the final product in comparison 
with the initial cycles of the formulations.  
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First cycle       Last cycle 
Figure 5.5. A 1 000 times magnification of the stages of the cycle steps of L. leonurus nanoemulsion 
using HPH at a pressure of 800 bar. 
 
    
First cycle       Last cycle 
Figure 5.6.  A 1 000 times magnification of the stages of the cycle steps of the plant extract NLC us-
ing HPH at a pressure of 800 bar. 
 
   
5th cycle      Last cycle  
Figure 5.7. A 16 times magnification of the plant extract nanocrystal using HPH at a pressure of 800 
bar. 
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5.3.4 Scanning electron microscopy  
Figure 5.8 represents the SEM images of the L. leonurus extract (A) nanocrystal, (B) NLC 
and (C) nanoemulsion, which demonstrate the particles of the formulations. SEM was used to 
study the topography of solid objects to confirm the light microscopy results. The figure 
shows spherical particle sizes within 0.5 µm and 2 µm for the nanocrystals and the NLC. The 
nanoemulsions showed the particles in the amorphous state (Figure 5.8C). However, particle 
sizes also exist in the non-amorphous state. It is possible that there might be aggregated forms 
in the figure and that this can be seen by the larger particle sizes. Particle aggregation might 
be due to the sticky nature of the lipid present in the formulation. Surface morphology of the 
nanocrystals, the NLC and the emulsion was not clearly visible in the figure.  
  
 
Figure 5.8  SEM micrograph of (A) nanocrystal L. leonurus extract formulation, (B) L. leonurus 
extract NLC formulation and (C) L. leonurus extract nanoemulsion formulation. 
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To conclude, the L. leonurus leaf extract nanoformulation was achieved successfully by 
nanoemulsion, NLC and nanocrystal preparations. All the formulations produced particle 
sizes in the nano-range and the lipid nanoparticles (emulsion and NLC) were stable over a 
period of two months in comparison with the nanocrystal formulation.  The properties of the 
formulations obtained in this study were in accordance with other similar lipid formulations. 
Thus, the current study could serve as a potential product for nanoformulated L. leonurus.  
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6 CHAPTER 6: AN IN VITRO ANTI-DIABETIC EFFECT OF L. LEONURUS 
EXTRACT NANOFORMULATION 
6.1 Introduction 
Prior to further experimentation with the formulations, the stability of the formulations was 
analysed according to their zeta potential measurements. Of all three formulations analysed, 
the NLC was the most stable. Although particle size of the other formulations were all in the 
nanometre range, the NLC was most stable and was therefore taken forward for use for 
further in vitro studies. Since the other formulations were also stable, their cytotoxicity in 
vitro was also determined in Chang liver and INS-1 cell lines. Further in vitro studies on the 
extract NLC was performed to determine its effect on glucose uptake and on chronic insulin 
release in INS-1 cell lines. In the following section, an in vitro study of the formulations was 
undertaken. This section of the work was completed at the Biochemistry and Microbiology 
Department at Nelson Mandela Metropolitan University. 
 
To determine whether the formulated plant extract had retained its anti-diabetic properties 
and had retained its anti-diabetic effect, the glucose uptake and insulin secretion potential 
were investigated in an in vivo cell culture model using the L. leonurus NLC formulation in 
parallel with the L. leonurus extract and marrubiin. The plant extract is insoluble in aqueous 
media, therefore it is often solubilised in organic media, such as dimethylsulfoxide (DMSO). 
The use of DMSO has some disadvantages as it is toxic to the biological system and thus has 
to be used in very low concentration volumes (<0.1% DMSO) to be diluted effectively upon 
administration. The aim of the L. leonurus extract nanoformulation preparation was to 
increase solubility in an aqueous environment without the addition of any toxic chemicals, 
thereby reducing toxicity and in the process increasing their surface area and bioavailability 
in an in vitro and in vivo system. The NLC formulations were tested in an in vitro system 
using insulin secretory cell lines (INS-1) and liver cell lines (Chang liver) for glucose uptake 
efficacy. The cytotoxicity of the formulations was first determined in each of the cell lines, 
prior to the insulin secretory potential being completed using the INS-1 cells, and glucose 
uptake was investigated in the Chang liver cell lines. 
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6.2 Materials and methods 
6.2.1 Chang liver and INS-1 cell culture and maintenance  
Chang liver cells were used for glucose uptake studies. The cell lines were maintained in a 
controlled incubated environment at 37
°
C in 5% CO2 in RPMI-1640 medium (Thermo Fisher 
Scientific, US), supplemented with 10% (v/v) heat-inactivated fœtal bovine serum (FBS) 
(Gibco). Cells were cultured in 10cm culture dishes until confluent and then seeded in 48-
well plates at a density of 50 000 cells per well.  
 
INS-1 cells were routinely maintained using similar conditions as above and RPMI-1640 was 
supplemented with Glutamax
TM
-I (Gibco), 1mM sodium pyruvate, 10 mM HEPES and 
50mM β-mercaptoethanol, as well as 10% FBS. Cells were seeded in 24-well plates at a 
density of 50 000 cells/well. After 24 h incubation period, treatment was commenced and 
lasted for 48 h.  
 
6.2.2 Cytotoxicity study of the nanoformulations in cell lines 
Chang liver cells and INS-1 cells were used to determine the effects on glucose uptake and 
insulin secretion, respectively. It was of interest to investigate the cytotoxic effect of the L. 
leonurus formulations on these cell lines to ensure that no cytotoxicity was present prior to 
further experimentation. In previous studies using L. leonurus plant extract, the IC50 value 
was evaluated (Low Ah Kee et al., 2008). It was established that the cytotoxic level of the 
plant extract was 10 µg/ml. This was the highest concentration of the plant extract that caused 
no cell cytotoxicity. For the current work, the same concentration of the plant extract was 
used, as contained in the formulations. The effects of nanocrystals, NLC, and nanoemulsions 
on cell viability were investigated. 
 
Cell cytotoxicity was analysed using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide), a yellow dye that is reduced to purple formazan in the mitochondria of liv-
ing cells. The MTT assay is often used for cell viability, cytotoxicity, or cell proliferation 
studies (Mossman, 1983). It has been known from literature that the solute of this salt is taken 
up by cells through endocytosis and is reduced to a water-insoluble purple formazan by 
mitochondrial and cytosolic enzymes. The percentage cell viability or proliferation is 
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determined in comparison with the test control samples (Ronicke et al., 2008). The following 
equation was used in calculating the viability: 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑠𝑎𝑚𝑝𝑙𝑒 −  𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑏𝑙𝑎𝑛𝑘
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑏𝑙𝑎𝑛𝑘
× 100 
INS-1 cells were seeded in 24-well plates at a density of 30×10
3
 per well and the Chang liver 
cells were seeded at 2×10
3
/well in 24-well plates. The cells were exposed to the L. leonurus 
NLC formulation at a concentration range of 0.2, 0.5, 1.0, 5.0 and 10 µg/ml, a non-
formulated L. leonurus extract and an NLC blank (formulation prepared with no plant 
extract). Cells that received only medium served as a control. After 48 h exposure, MTT 
(0.5mg/ml) was added and incubated at 37
°
C for 3 h. DMSO was added to solubilise the 
formazan crystals and the absorbance was read at 540 nm in a microtitre plate reader (Biotek 
Powerwave XS microtitre plate reader).  
 
6.2.3 Insulin-stimulated glucose uptake assay in Chang liver cells 
Chang liver cells were seeded in a 24-well plate at a density of 2×10
3
/well and were allowed 
to attach overnight. The same concentration range of the formulation used for the INS-1 cells 
was applied to these cells. Cells exposed to medium with no treatment served as a control and 
metformin (1 µM) was used as a positive control. Treatment was performed in triplicate and 
incubated for 48 h. After 48 h, the medium was replaced with glucose-free medium (RPMI 
1 640) for 1h. Afterwards, the medium was replaced with medium that contained 8mM D-
glucose supplemented with 60 µU/ml insulin. The insulin-stimulated glucose uptake was 
measured after 1h. Measurement of glucose uptake was determined by the addition of a 
fivefold diluted sample. An aliquot of the diluted sample (50 µl) was added to 200 µl of 
glucose oxidase reagent (phenol, 4-aminoantipyridine, ethylenediaminetetraacetic acid 
(EDTA), glucose oxidase and peroxidase, Sigma). Incubation was for 30min at room 
temperature (25°C) and the absorbance was monitored at 492 nm using a Biotek PowerWave 
XS microtitre plate reader. 
 
6.2.4 Insulin secretion in INS-1 cells 
Insulin release was investigated over a 48 h period and was conducted using INS-1 cells. 
Cells (30×10
3
/well) were seeded in 24-well plates. Cells were cultured in both 
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normoglycaemic (11.1 mM glucose) and hyperglycaemic conditions (33.3 mM glucose). The 
NLC drug dose was added to the cells at a range of concentrations between 0.25 to 10 µg/ml 
and treatments were performed for 48 h. The procedure for measuring the insulin content was 
conducted with a RIA kit (Millipore, US), according to the manufacturer’s instructions. This 
can be found at (www.millipore.com). Sulfonylurea (gliclazide) (10 µg/ml) is a drug that is 
used for the treatment of cells to respond to insulin and was used as a positive control for 
insulin release. A standard curve was constructed using commercial insulin (provided by the 
kit) in the concentration range 0.25 to 10 µg/ml (Appendix Figure A3).  
 
6.2.5 Statistical analysis 
Data for this section were expressed as the mean of three experiments ± SEM. Statistical sig-
nificance was achieved using the student t-test. The significance level was compared with the 
untreated control group. The corresponding significant levels were indicated in the figures.  
 
6.2.6 Results and discussion 
6.2.6.1 Cytotoxicity in Chang liver cells 
A concentration range (0.25 to 10 µg/ml) of the three formulations (nanocrystal, NLC and 
nanoemulsion) was used to investigate the cytotoxic effect (Figure 6.1). The results indicate 
that for the nanocrystal and the nanoemulsion formulations (Figure 6.1 A&B), there was no 
significant decrease in the number of viable Chang liver cells in a concentration-dependent 
manner from 0.25 to 10 µg/ml. The findings revealed the NLC extract formulation to be non-
cytotoxic at the highest concentration as it did not show a significant decrease in cell viability 
in comparison with the controls (Figure 6.1B). A decrease in cell viability was observed with 
the nanoemulsion formulation with the concentration range tested. However, a concentration 
dependence decrease was not observed (Figure 6.1C). The lowest level of cell viability 
obtained (80% at 2.5 µg/ml), was not cytotoxic in comparison with the control cells. The 
range of concentrations was tested to determine the cytotoxicity limit of the formulations.  
Metformin, at a concentration of 1 µM, was used in parallel to the experiment to test for cyto-
toxicity, since it would be used for the glucose uptake study. In comparison with the controls, 
there was no cytotoxicity observed (Figure 6.1 A-C). The blank formulations also did not 
show any significant increase or decrease in cell viability, in comparison with the control, the 
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positive control and the formulations at the different concentrations. Thus, the formulation 
had no effect on cell viability and can thus be effectively used as a vehicle for the delivery 
and administration of nanoformulated drugs.  
 
Nanoformulations (nanocrystals, NLC and nanoemulsions) have been prepared for various 
other medicinal drugs. One such drug is tripterine, which was prepared for delivery as an 
NLC drug (Chen et al., 2012). The NLC tripterine showed no cytotoxicity when investigated 
in Caco-2 cell lines. Less cytotoxicity was observed for the NLC tripterine in comparison 
with the non-formulated tripterine, reducing its side-effect in the intestinal cell line model. 
This evidence supports the current finding of less cytotoxicity observed with the three formu-
lations investigated. Since the IC50 for the non-formulated plant extract is known, the current 
concentrations used also showed minimal cytotoxicity in comparison with the formulated ex-
tracts. The decrease in cytotoxicity which is often associated with most nanoformulated drugs 
can be explained by their controlled release once administered to their target tissues (Das et 
al., 2012).  
   
  
Figure 6.1. Cytotoxicity studies of nanoformulations on Chang liver cells. (A) Extract nanocrystal 
cytotoxicity of L. leonurus on Chang liver cells. (B) NLC cytotoxicity, (C) Nanoemulsion 
cytotoxicity. Data are expressed as the mean ± SEM (n=3). Cont, control; L leo, L. leonurus extract 
(10 µg/ml); Met, metformin (1 µM); NLC blank, NLC formulation prepared with no L. leonurus; NE 
blank, nanoemulsion formulation prepared with no L. leonurus extract. No significant difference was 
obtained relative to the control for this data sat.  
0%
20%
40%
60%
80%
100%
120%
Cont. 0.2 0.5 1 5 10 Met L. leo
V
ia
b
le
 c
el
ls
 r
el
at
iv
e 
to
 c
o
n
tr
o
l 
Nanocrystal formulation (µg/mL) 
A 
0%
20%
40%
60%
80%
100%
120%
Cont. NLC
Blank
0.2 0.5 1 5 10 Met L. leo
V
ia
b
le
 c
el
ls
 r
el
at
iv
e 
to
 c
o
n
tr
o
l 
NLC formulation (µg/mL)  
B 
0%
20%
40%
60%
80%
100%
120%
Cont. NE
Blank
0.2 0.5 1 5 10 Met L. leo
V
ia
b
le
 c
el
ls
 r
el
at
iv
e 
to
 c
o
n
tr
o
l 
Nanoemulsion formulation (µg/mL) 
C 
151 
 
6.2.6.2 Cytotoxicity in INS-1 cells 
Cell viability observed for the nanocrystals and NLC formulations on INS-1 cells showed no 
significant difference between the formulations and the control (Figure 6.2 A & B). The 
nanocrystal formulation range tested showed a slight decrease in cell viability from 101 to 
85%, from the lowest to the highest concentration range, respectively. The highest concentra-
tion for the nanocrystal formulation was, however, not cytotoxic. The non-formulated extract 
also showed less cytotoxicity (95%) in comparison with the control. The nanocrystal 
preparation contained mainly the plant extract or the drug, surfactant and water, and it has 
been shown that the surfactant used (Plantacare 2000) was not cytotoxic (Mitri et al., 2011). 
Thus, a blank formulation was not prepared for the extract nanocrystal formulation.  
 
Figure 6.2. Cytotoxicity studies of nanoformulations on INS-1 cells. (A) Nanocrystal cytotoxicity of 
the L. leonurus extract on INS-1 cells, (B) Cytotoxicity of L. leonurus NLC on INS-1 cells, (C) Nano-
emulsion cytotoxicity of the L. leonurus extract on INS-1 cells. Data are expressed as the mean ±SEM 
(n= 3) experiment.*p < 0.05 relative to Cont. Cont, control; L leo, L. leonurus extract (10 µg/ml); 
NLC blank, NLC formulation prepared with no L. leonurus extract; NE blank, nanoemulsion 
formulation prepared with no L. leonurus extract. 
 
In comparison with the nanoemulsion blank (103 %), there was no significant decrease in cell 
viability as compared with 115% for the 0.5 µg/ml of the formulation. However, cell 
proliferation was observed for the control (Figure 6.2C). Cell proliferation was also observed 
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at the concentrations 0.25, 0.5 and 1 µg/ml of the extract nanoemulsion formulation. This 
could be due to the lipids and oils in the formulation having an effect on the proliferation of 
the INS-1 cells.  
 
The results provided a good indication that the composition of the formulations had no cyto-
toxic effect on the Chang liver and INS-1 cells. This was also evident by using the blank for-
mulations, i.e. the formulations prepared without any plant extract. At the highest concentra-
tion of the formulation (10 µg/ml), there was a slight decrease in cell proliferation, in compa-
rison with the control and the “blank formulation”. This decrease could possibly be attributed 
to effects of the components of the plant extract. In vivo and in vitro studies performed with 
nanoparticles and nanosuspensions have been reported in rats and in cell lines respectively, 
and there were no cytotoxic effects observed for the oral administration of the drug nanoparti-
cle to rats (Chiang et al., 2007; Hecq et al., 2006). In vitro studies using hydroxyapatite nano-
crystals on endothelial cell lines are examples of the non-toxic nature of the formulation. The 
nanocrystals were added to the medium at the desired concentration and further exposed to 
the cells for experimentation (Pezzatini et al., 2006). Also, studies on INS-1 cell lines 
(Mnonopi et al., 2012), used similar concentrations of the plant extract and no cytotoxic 
effects were observed, supporting the current findings of the plant extract and the extract 
nanoformulations having no cytotoxic effect in the cell lines investigated.  
 
6.2.6.3 Insulin-stimulated glucose uptake in Chang liver cells 
Based on the findings that NLC was non-cytotoxic and its stability was better when compared 
with the other two formulations, an in vitro glucose uptake study was completed using this 
formulation. An insulin-stimulated glucose uptake study is a good screening indicator to 
determine any abnormalities in the cells and to determine whether the formulation had 
retained its anti-diabetic properties. Glucose uptake was significantly (p<0.05) increased by 
21% after treatment with the NLC extract formulation at 0.25 µg/ml in comparison with the 
control. With an increase in concentration of the formulation, no change in glucose uptake 
was observed. At the highest concentration of the extract NLC formulation (10 µg/ml), 
glucose uptake increased by 18% relative to the control. A similar effect was observed for the 
non-formulated extract. Metformin increased glucose uptake significantly in comparison with 
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the formulations and in comparison with the control (p<0.01) by 51%. The Chang liver cells 
were normalised to 50 000 cells/well using the MTT assay (Figure 6.3).  
 
Figure 6.3. Insulin-stimulated glucose uptake measured on Chang liver cells in the presence of 60 
µU/ml insulin. Metformin (1 µM) was used as a positive control and the L. leonurus extract (10 
µg/ml), was used as a reference treatment in comparison with the formulations. The untreated samples 
only had medium present. Data are expressed as the mean ± SEM (n= 3). *p<0.05 vs control. 
#
p<0.01 
vs control. Ext = L. leonurus, Met = metformin, positive control. 
 
Glucose is an important energy source for most tissues in the body and serves as a metabolic 
substrate for cells. There are some selected types of cell lines which are ideal for studying 
glucose uptake. Some of these cell lines are from muscle, adipose tissue and liver. In muscle 
and adipose tissue, the effect of insulin to acutely stimulate glucose uptake is essential for 
normal glucose homœostasis. Insulin increases glucose transport by facilitating the transfer of 
the glucose transporter, GLUT-4, from an intracellular vesicle pool to the plasma membrane 
(Yamamoto et al., 2011). The results of this study provide novel findings of glucose uptake in 
cell lines by the L. leonurus extract NLC. It can be concluded that the extract NLC was able 
to stimulate glucose uptake in Chang liver cells, possibly facilitated by GLUT-4 
translocation. 
 
6.2.6.4 Insulin secretion in INS-1 cells 
Insulin release in INS-1 cells was investigated with the treatment of the plant extract NLC. 
Previous studies conducted in our laboratory have shown the plant extract to have a positive 
response to insulin secretion in the same cell line (Mnonopi et al., 2012). Under normogly-
caemic conditions, insulin release was significantly (p<0.05) observed for the positive control 
treatment in comparison with the normoglycaemic control (Figure 6.4). No significant 
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increase in insulin release was observed for the extract NLC formulations (0.25 µg/ml to 10 
µg/ml) in comparison with the control under normoglycaemic conditions. The non-
formulated extract at 10 µg/ml also did not show any significant increase in insulin release in 
comparison with the normoglycaemic control. Under hyperglycaemic conditions, however, a 
significant increase was observed with the extract NLC at 10 µg/ml in comparison with the 
hyperglycaemic control. The positive control, as well as the non-formulated extract, also had 
a significant increase in insulin release in comparison with the hyperglycaemic control.  
 
The control cells showed an increase in insulin release at normoglycaemic conditions in 
comparison with hyperglycaemic conditions. However, this was not significant. The extract 
NLC treatments revealed an increase in insulin release when the cells were exposed to hyper-
glycaemic conditions in comparison with normoglycaemic conditions. The concentration 
ranges (0.25 µg/ml to 10 µg/ml) all showed an increase in insulin release under 
hyperglycaemic conditions in comparison with normoglycaemic conditions. The insulin 
increase under hyperglycaemic conditions was significantly observed for the NLC extract at 
0.25 µg/ml in comparison with the normoglycaemic insulin increase. None of the other 
concentrations showed a significant increase. The positive control and the non-formulated 
extract caused INS-1 cells to increase insulin in high glucose conditions in comparison with 
normal glucose levels. The increase was significantly observed for the non-formulated 
extract. Thus, in summary, the NLC formulations, the positive control, and the non-
formulated extract all caused an increase in insulin release under hyperglycaemic conditions 
in comparison with the normoglycaemic environment. However, only the NLC extract at 10 
µg/ml, the positive control, and the non-formulated extract showed a significant increase in 
comparison with the control.  
 
Insulin secretion from β-cells is a very important marker for β-cell dysfunction. Any abnor-
malities in β-cell function could lead to β-cell failure and possibly the onset of T2D as glu-
cose homœostasis cannot be attained (Jhun et al., 2013). In healthy individuals β-cells re-
spond to an increase in blood glucose by secreting insulin into the bloodstream. The insulin 
release triggers peripheral tissues such as skeletal muscle and liver to take up or store glu-
cose. When blood glucose levels rise, β-cells increase their oxidative catabolism of glucose, 
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leading to an increase in the mitochondrial proton motive force and an increase in the cyto-
plasmic ATP/ADP ratio. 
 
Figure 6.4. Chronic insulin release in INS-1 cells completed under normo- and hyperglycaemic condi-
tions for a 48h exposure of the NLC at varying concentrations (0.25 µg/ml to 10 µg/ml).  Data are ex-
pressed as the mean ± SEM (n = 3), 
#
p<0.05 vs control normoglycaemia (11.1mM) treatment, *p<0.05 
vs untreated (Control) hyperglycaemia (33.3mM). Sul; sulfonylurea, positive control. Ext; L. leonurus 
extract 10µg/ml.  
 
An extract from Leonotis sibiricus has also been shown to enhance insulin secretion in INS-
1E cells and also to promote proliferation of the cells (Schmidt et al., 2013). This supports 
the current findings of the effect of other Leonotis species on insulin release. Marrubiin, an 
organic extract from L. leonurus, has been shown to increase insulin secretion in INS-1 cells, 
at both 11.1mM and 33.3mM glucose (Mnonopi et al., 2012), supporting the current results 
with the extract formulation and the non-formulated extract. It is possible that marrubiin or 
other compounds found in the plant extract are responsible for the stimulation of insulin 
secretion (Schmidt et al., 2013). The increase in insulin release by the extract NLC could be 
due to the small particle size and bio-availability of the formulation (Jin et al., 2013), which 
results in an effective cellular uptake to achieve its effect. Subsequently, the solubility, the 
dissolution rate and the bio-adhesion to the cells or tissues are improved (Gao et al., 2013).  
 
To conclude, L. leonurus extract NLC formulation was effective in alleviating diabetic symp-
toms based on the results obtained by the increase in insulin-stimulated glucose uptake of the 
extract NLC in Chang liver cells, as well as an increase in insulin secretion by the INS-1 cells 
under hyperglycaemic conditions when compared with the hyperglycaemic control cells. 
These findings will provide further insight into a new era of an anti-diabetic nano-drug deliv-
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ery system. Thus, the author suggests an NLC formulation of L. leonurus with the potential to 
deliver L. leonurus effectively to peripheral target tissues. 
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7 CHAPTER 7: GENERAL DISCUSSION AND CONCLUSIONS 
The epidemiology of T2D is still of great concern in the world as the numbers affected by 
this epidemic continues to rise. It is no surprise that a lack of physical activity, obesity and a 
sedentary lifestyle, coupled with the intake of high-caloric diets to a large extent, contribute 
to this epidemic. The alarming fact is the number of fatalities associated with T2D. This is 
estimated to be of 595 million by the year 2035 or about 10% of the world population (IDF, 
2013). Medical research has improved during the past decade by providing treatments to 
alleviate the symptoms associated with the metabolic disorders of T2D. Although exercise 
and a strict diet will be very helpful, it is sometimes not enough (Hussey et al., 2012). It is, 
however, easier to tackle early onset diabetes with exercise and diet rather than to wait until 
full-blown T2D prevails. When it is fully developed, there are major complications such as 
macro- and microvascular symptoms that need more medical attention than exercise 
(American diabetes association, 2013).  
 
Traditionally, efforts have been made to alleviate the symptoms of diabetes, or to treat it 
completely. Medicinal plants have over many years, effectively been used for the treatment 
of many ailments and diseases all over the world. Of late, the incorporation of traditional 
medication into modern medicines, as produced and packaged by pharmaceutical companies, 
has been popular. Many medicinal plants are known to be effective in treatments of several 
diseases. However, their mechanisms of action are sometimes unknown or poorly understood. 
Medical research has been conducted on many medicinal plants to identify their mechanisms 
of action and many efforts have succeeded in producing drugs that have single or multiple 
targets for specific abnormalities in glucose metabolism, insulin action and obesity (Tiwari 
and Madhusudanarao, 2002).  
 
L. leonurus is a traditional medicinal plant which has been of interest in the field of diabetes. 
Studies conducted in our research group have focused on medicinal properties related to L. 
leonurus. It was found that the plant possesses anti-diabetic and anti-coagulation effects 
(Mnonopi, 2010). Ojewole (2005) has reported the leaf extract of the plant to have a 
hypoglycaemic effect in rats. L. leonurus contains many chemical components such as sapo-
nins, quinones and labdane diterpenoids, e.g. premarrubiin and marrubiin, with marrubiin be-
ing one of the active components of L. leonurus. Marrubiin can be found in many other plant 
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species other than L. leonurus. It exists in more than 97 other Marrubium spp as reported by 
El-Mohsen et al. (2014). Most anti-diabetic drugs target the inhibition of α-glucosidase, an 
enzyme found in the brush border of the intestine responsible for carbohydrate digestion. 
Marrubiin has been shown to possess anti-diabetic properties inhibiting this enzyme, as 
shown by experiments conducted in vitro and in vivo (El-Mohsen et al., 2014).  
 
Marrubiin is believed to be formed from premarrubiin and solvent removal at 90
°
C is the best 
way of converting premarrubiin into marrubiin (Rodrigues et al., 1998). The biosynthesis of 
marrubiin is reported to proceed through the 1-deoxy-D-xylulose-5-phosphate pathway 
(Piccoli and Bottini, 2008). Marrubiin is known to have many medicinal and therapeutic 
properties. Thus, most of the medicinal properties of the marrubiin-containing plants are due 
to the activity of marrubiin. In the current study, an organic extract from L. leonurus leaves 
was effectively achieved with acetone extraction. Marrubiin in the plant extract was 
analytically identified and quantified in the extract by using RP-HPLC with acetonitrile and 
water as mobile phase (50:50). HPLC analysis has been reported for other Leonotis spp at 
25°C using water (pH 2.8 with formic acid) and methanol as mobile phase. A complete 
separation was achieved of the butanol extract of Leonurus sibiricus after 83 min (Schmidt et 
al., 2013). Thus, the current study provides a novel, alternative separation method which 
could be used for the analysis of plant extracts in a short space of time using readily available 
solvents via PFP chromatography, with improved resolution, as compared with other 
traditional methods of quantification. This RP-HPLC condition was achieved after several 
optimisation experiments. Marrubiin in the extract was identified by comparison with the 
retention time of commercial marrubiin. RP-HPLC of the commercial marrubiin was 
performed under the same chromatographic conditions. The quantification was completed by 
comparison of the retention times (3 min), which was reported for the commercial marrubiin 
and which was also seen in the plant extract. A calibration curve using the peak areas of 
commercial marrubiin at varying concentrations was used for the quantification. RP-HPLC 
analysis of the plant extract has always been a complex procedure due to limited or 
incomplete separation of the components in the extract. This limits the accurate quantification 
of the marrubiin, which sometimes is not isolated as a single peak for accurate analysis. The 
recovery of marrubiin in the plant extract was reported to be 10%, as extrapolated from a 
standard curve. 
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The structure of marrubiin in the plant extract was confirmed by HPLC-MS/MS analysis by 
linking the chromatographic procedure to an MS instrument. HPLC-MS/MS is a tool that 
combines the high capabilities of HPLC, having a high analytical sensitivity, specificity and 
accuracy, to mass spectrometric detection. Structurally, marrubiin was analysed from the L. 
leonurus extract based on HPLC-MS/MS analysis. Marrubiin in the plant extract was identi-
fied at 2.24 min from the MS analysis graph and correlated to the retention time of commer-
cial marrubiin (also 2.24 min). Tandem MS analysis indicated marrubiin to have an m/z value 
of 333.20 and a chemical structure identical to marrubiin, shown in Figure 3.5. Many authors 
have reported the isolation of marrubiin from plant species containing the compound; the 
characterisation process being NMR analysis as well as MS analysis (Agnihotri et al., 2009; 
Kruger and Rivett, 1988; Mangoni et al., 1972; Rivett, 1964). Based on these results, tandem 
MS analysis of marrubiin in this study focused on structural verification, giving further 
evidence of marrubiin in the organic extract of L. leonurus.  
 
The anti-diabetic properties of the extract of L. leonurus and marrubiin were further investi-
gated in vivo using insulin-resistant obese rats. Insulin resistance studies are normally per-
formed in muscle, liver and adipose tissue, where insulin exerts its main metabolic action. 
Thus, this study focused on these three tissues in the obese rat model. Gene expression of se-
lected diabetic biomarkers was investigated to explore gene expression levels on treatment 
with the plant extract and marrubiin, as well as selected controls. The study determined the 
mechanism through which marrubiin and the plant extract delivered their anti-diabetic prop-
erties.  
 
Obtaining a stable reference gene as an internal control for the in vivo gene expression study 
proved difficult due to the number of treatment conditions used. A stable reference gene 
should not show any variation in gene expression across all the treatments to be used in the 
study; i e the cycle threshold value differences generated from the qPCR method should not 
be greater than 2. The reference gene or genes of interest had to be stable across the seven 
different treatments performed on each tissue. Thus, for this study B2M and YWHAZ were 
stable across all the treatments among a variety of reference genes that were investigated. 
These genes showed similar quantification cycles (Cq) for all the treatments and controls. For 
each gene investigated, the PCR amplification efficiency was calculated by means of a 
calibration curve. The calibration curve provided a simple, rapid and reproducible indication 
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of the mean PCR efficiency, the analytical sensitivity, and the robustness of the assay (Bustin 
et al., 2009). All the RNA quality and RIN assays were assessed spectrophotometrically and 
an OD260/280 of between 1.8 and 2.0 was reported for all tissue samples investigated. 
 
Leptin levels are increased in obesity and thus a drug candidate to lower the expression of the 
gene will improve insulin resistance. L. leonurus extract, marrubiin and sulfonylurea all de-
creased the expression of the leptin gene significantly. Adiponectin is known to play a major 
role in the regulation of insulin resistance, and a high expression and circulating level are 
known to restore insulin sensitivity as well as insulin resistance (Al-Suhaimi and Shehzad, 
2013). The plant extract was able to increase the gene expression of the adipokine. Marrubiin 
treatment decreased adiponectin gene expression. It is known that high gene expression of re-
sistin, derived from adipose tissue, can contribute to insulin resistance (Al-Suhaimi and 
Shehzad, 2013). In the current study, it was observed that marrubiin and aspirin reduced the 
gene expression of resistin significantly (p<0.05) in comparison with the obese control rats, 
improving the insulin-resistant state.  
 
Expression of the FAS gene and FAS activity are increased by insulin in cultured human adi-
pocytes, suggesting that insulin sensitivity plays a role in their regulation (Claycombe et al., 
1998). Increased FAS gene expression in adipose tissue has been linked to visceral fat accu-
mulation, impaired insulin sensitivity, increased circulating fasting insulin, IL-6 and leptin, 
suggesting an important role of lipogenic pathways in the causal relationship between conse-
quences of excess energy intake and the development of obesity and T2D (Berndt et al., 
2007). Thus, normal subjects will show low expression of the gene. In adipose tissue, no sig-
nificant effect was observed. In the muscle and liver, the extract caused a significant (p<0.05) 
decrease, but marrubiin caused less of a decrease.  
 
Glucose transporters serve as important mediators for the uptake of glucose into all cells. As 
previously discussed, they are often insulin-stimulated. The affinity of the GLUT isoforms 
for glucose (Km) can be expressed in two ways. The first method involves the over-expres-
sion of GLUT cDNA by specific transfer into a host cell and the second approach is to study 
isolated or cultured cells that are known to express only a single GLUT isoform (Garvey, 
1992). An increase in gene expression of the GLUT isoforms gives an indication of normal 
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cellular functioning of glucose uptake and metabolism. Glucose transporter isoforms were in-
vestigated in this study by means of mRNA expression. GLUT-2 was investigated in the 
liver, where it is mostly expressed. It is known that low insulin and high glucose levels 
increase the expression of GLUT-2 in the liver, suggesting that insulinaemia and glycaemia 
control GLUT-2 gene expression (Leturque et al., 2009). Due to the Fanconi-Bickel 
syndrome, characterised by glycogenesis, GLUT-2 inactivation in humans is detrimental to 
glucose re-absorption by the liver. In the current study, metformin treatment in the obese rats 
was able to restore gene expression of GLUT-2 in the liver. However, it was not significant. 
Marrubiin and L. leonurus extract did not enhance gene expression in the liver. In Zucker 
diabetic fatty (ZDF) and STZ-induced diabetic rats, GLUT-2 gene expression remains 
unchanged in the liver. Preliminary data in humans indicate that liver GLUT-2 content is 
similar in obese individuals with and without T2D, and is elevated twofold in obese 
individuals with impaired glucose tolerance (Fröjdö et al., 2009). GLUT-2 levels are not 
correlated with rates of hepatic glucose output. Glucose uptake in hepatocytes and pancreatic 
β-cells is dependent on a physical association between high-Km GLUT-2 and GK (Garvey, 
1992). In livers from insulin-deficient rats, glucose uptake is reduced in conjunction with a 
reduction in GK activity. Therefore, any alteration in GLUT-2 or transport activity does not 
necessarily contributes to diminished glucose uptake. A reduced uptake could be entirely 
explained by the change in GK (as a potential rate-limiting step), whether or not it is 
complexed with GLUT-2 (Cahill et al., 1958). GK was significantly up-regulated in adipose 
tissue, but not in muscle and liver tissues, suggestive of the effect of GK as a rate-limiting 
step in muscle and liver tissues.  
 
GLUT-4 mRNA expression was investigated in muscle and fat tissues, and in the adipose tis-
sue, the extract and marrubiin showed a non-significant increase in its expression. Metformin 
showed a significant increase, in comparison the obese control rats. In muscle, the low gene 
expression levels of the marrubiin- and L. leonurus-treated rats could be attributed to the rate-
limiting hexokinase, the first enzyme involved in glycolysis. The gene expression for these 
two treatments correlated to that observed in GLUT-4. Metformin and aspirin treatment re-
sulted in an up-regulation of the gene in muscle tissue.  
 
There has been evidence of a low gene expression of the key docking protein, IRS-1, to be 
found in fat cells from T2D subjects, as well as a cohort of non-diabetic but insulin-resistant 
individuals (Fatchiyah et al., 2013). Low cellular IRS-1 gene expression has been linked to 
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insulin resistance and various other markers of the insulin resistance syndrome. It is also 
known that a low cellular IRS-1 expression occurs roughly two- to threefold more frequently 
in individuals with a genetic predisposition for T2D (Dong et al., 2006). IRS-1 expression is 
associated with a marked impairment in downstream insulin signalling, including PI3-K act-
ivation, Ser phosphorylation of PKB/AKT and insulin-stimulated glucose transport 
(Fatchiyah et al., 2013; Zolotnik et al., 2012). Healthy individuals having low IRS-1 gene 
expression could have adipose tissue with diabetic traits in terms of insulin signalling and 
response (Carvalho et al., 2001). It is known from published data that an increase in IRS-1 
gene expression promotes the uptake of glucose, mediated by an increase in GLUT-4 
translocation to the cell surface for glucose uptake. In the adipose tissue of the obese rats, it 
was observed that marrubiin treatment enhanced mRNA expression of IRS-1. This correlated 
to the high GLUT-4 mRNA expression observed in adipose tissue.  
 
If pre-incubated at a glucose concentration of 2.5mM, INS-1E and INS-1 cells are known to 
cause the cells to exhibit a dose-dependent glucose-induced insulin release with a plateau 
phase at 15mM to 20mM and a 50% effective concentration at 10.4mM (Merglen et al., 
2004). It has been shown that extracts of Leonurus sibiricus increase insulin secretion of rat 
INS-1E insulinoma cells that can be explained at least in part by a transiently increased 
electrical activity and elevation of the intracellular calcium concentration (Schmidt et al., 
2013). In the present study for glucose-stimulated insulin release, two strains of INS cell 
types were used. INS-1 cell lines were used for the nanotechnology section (Chapter 5) and 
for the crosstalk section with the peripheral tissues (Chapter 4, Section 4.4), INS-1E cells 
were used. The high passage number of the INS-1 cells at the time of experimentation made 
them less desirable to use as they displayed an impaired insulin release and therefore the 
effect of conditioned medium on INS-1E cells was investigated. Conditioned medium was 
obtained from adipose tissue, muscle and liver cell lines. The conditioned medium from these 
cells contained cytokines and other proteins, which could have an effect on cell growth and 
other cellular functioning upon exposure to a different cell line. Under both hyperglycaemic 
(33.3mM glucose) and normoglycaemic (11.1mM glucose) conditions, conditioned medium 
from fat 3T3-L1 cells caused a significant increase in insulin secretion in INS-1E cells, when 
compared with the control INS-1E cells with no conditioned medium (Figure 4.15). 
Conditioned medium from muscle and liver cell lines had less effect on insulin secretion in 
the INS-1E cells in comparison with control INS-1E cells with no conditioned medium and in 
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comparison with the fat cells’ conditioned medium. Thus, under high glucose conditions, 
mimicking those of the insulin-resistant state, marrubiin and sulfonylurea, as well as 
treatments from fat-conditioned medium, all had a positive effect on insulin release in 
comparison with the hyperglycaemia control. The same treatments increased insulin secretion 
under normoglycaemic conditions, in comparison with the normoglycaemic control.  
 
Insulin promotes glucose transport in adipocytes by inducing the translocation of intracellular 
glucose transporters to the plasma membrane (Wang et al., 2013a). Impaired insulin secretory 
responses to glucose, elevated rates of hepatic glucose output (HGO) and a diminished ability 
of insulin to stimulate glucose uptake into peripheral tissues (insulin resistance) are all hall-
marks of an indication of abnormalities that are developed in T2D patients and mammals 
(Franciosi et al., 2013). The mechanism of the anti-diabetic action of the L. leonurus extract 
was further investigated in an in vitro study. A nanoformulation approach was adopted for the 
plant extract. Marrubiin would have been the molecule of interest for the nanoformulation 
study. However, due to the cost of obtaining pure marrubiin for the study, the formulation 
study was limited to the plant extract. As the name suggests, nanoformulations are small 
particle sizes (in the nanometre range), increasing their surface area at their target tissues, and 
they have been prepared for many medicinal and cosmetic products (Müller et al., 2011b). 
They offer many other advantages such as increased bioavailability and increased solubility 
in aqueous media. Most medicinal drugs have been known to be poorly soluble in water, thus 
making them less bioavailable to exert their action once administered into the body. L. 
leonurus nanoformulations was prepared with this in mind. Lipid nanoparticles in the form of 
NLC and nanoemulsions, as well as nanocrystals, were effectively prepared. As is known, 
lipids enhance the bioavailability of poorly soluble drugs, especially in the nano form 
(Muchow et al., 2008). Nanocrystal preparation of the plant extracts has been difficult 
because plant extracts contain many components that give them properties like pigmentation, 
stickiness, and insolubility in aqueous media. One way of effectively producing plant extract 
nanoparticles is by incorporating them into lipids (e.g. NLC and nanoemulsions), thereby 
preparing lipid nanoparticles. If non-lipid formulations are required, such as in nanocrystal 
production, the plant extract can be dissolved initially in an organic solvent prior to the 
addition of a suitable stabiliser and water before nanocrystal production. The organic solvent 
is evaporated after the plant extract is dissolved prior to homogenisation or nanocrystal 
production.  
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Lipid nanoparticles (nanostructured lipid carriers and nanoemulsions) from the L. leonurus 
plant extract were prepared and characterised successfully. Their particle size diameters after 
production were 220nm and 139nm respectively, as measured by PCS. Nanocrystals were 
also prepared effectively, having a particle size diameter of 190nm after production. Of im-
portance was the stability of these prepared formulations, as this will be an important para-
meter when it comes to storage and shelf life. The lipid nanoparticles exhibited good stability 
during a 30-day period, although longer periods of storage have been reported for lipid nano-
particles (Souto and Muller, 2010; Junghanns and Müller, 2008; Muchow et al., 2008; Mason 
et al., 2006; Shekunov et al., 2006). A solvent precipitation method was used in the prepara-
tion of nanocrystals from the L. leonurus extract. This product did not show good stability as 
particles precipitated out of solution after a short period of time. Stability measurements were 
determined by measuring their zeta potential and particle size diameters over a specified time 
period. Precipitation methods to prepare nanoparticles are usually not favoured due to insta-
bility problems after production, although this can be solved if the product formed is convert-
ed into tablets immediately after production (Junghanns and Müller, 2008).  
 
The plant extract formulation of the NLC, nanoemulsion and the nanocrystals showed no cy-
totoxicity when exposed to INS-1 and Chang liver cells at a concentration of 10 µg/ml (Fig-
ure 6.1 and 6.2). Also, the formulation on its own (without the plant extract) did not result in 
any cytotoxicity in the cells. The non-formulated extract alone at a concentration of 10 µg/ml 
also showed no cytotoxic effects, as previously shown (Low Ah Kee et al., 2008). The NLC 
formulation showed anti-diabetic properties in the insulin-stimulated glucose uptake study in 
Chang liver cells and improved chronic insulin secretion in INS-1 cells during a 48h period. 
Thus, the plant extract formulations (NLC, nanoemulsions and the nanocrystals) were able to 
retain their anti-diabetic properties, with no known cytotoxic effects to the cell lines.  
 
 
 
  
165 
 
8 CHAPTER 8: FUTURE PROSPECTS 
This study focused on the medicinal properties and the mechanism of action of L. leonurus 
and marrubiin. The nanoformulated products enhanced insulin sensitivity and glucose uptake 
in vitro. Conditioned medium from adipose, muscle and liver cells that were treated with 
marrubiin and L. leonurus extract, increased insulin sensitivity in INS-1E cells. However, 
there are still further questions that need to be answered if marrubiin and the organic L. 
leonurus plant extract are to be used for anti-diabetic treatment.  
 
Nanocrystals, NLC and nanoemulsions were prepared for the L. leonurus organic extract. 
Marrubiin has shown anti-diabetic properties. However, it was not used in the formulation 
study as it is expensive to obtain commercially. Marrubiin could be used in future for the de-
velopment of nanoformulations, as there are other methods to produce nanoparticles and 
nanoformulations which could possibly require less starting material. The methods used in 
the nanoformulation production, as discussed in this work, required more than 1g of starting 
material, and this was not easily obtained with regard to marrubiin. Mangoni et al. (1972) 
reported the chemical synthesis of marrubiin. This approach could be further investigated for 
a cost-effective means of marrubiin synthesis. Also, a batch isolation obtained from the L. 
leonurus extract could be a potential source from which marrubiin could be isolated. Further 
physical properties of the nanoformulations of the plant extract and marrubiin, could be 
investigated, i.e. X-ray crystallography, saturation solubility, differential scanning 
calorimetry and a drug release profile in an in vivo and an in vitro system. Also, the 
encapsulation efficiency, as well as tableting of the formulation, could be determined, since 
encapsulation is known to increase the storage period as well as the stability of the 
formulation (Das et al., 2012; Garg and Singh, 2011). 
 
Nanoformulation of other plant medicines indigenous to South Africa could also be investi-
gated. These can include Hypoxis spp and Sutherlandia spp. There are many further 
possibilities for indigenous plants to produce medicines that might be used as nanoformulated 
drugs. Since there is not much information available on this subject, these findings could be 
investigated. It is noted and observed from this study that nanoformulation of a plant extract 
is difficult due to the pigmentation of the extract, tannins present and other chemical compo-
nents in the extract that might result in the instability of the formulations once prepared. This 
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aspect could be dealt with by exploiting the various methods of nanoformulation preparation 
to determine the best method for a stable product. The use of an effective surfactant or excipi-
ent could aid in the physical as well as chemical stability of the formulations prepared over an 
extended period.  
 
Future possibilities in exploring further nanoformulated products of the L. leonurus extract 
and marrubiin will be of major importance in determining the effect on solubility, bioavail-
ability and storage conditions of the drug. The absorption properties of the formulations can 
be conducted in vivo and in vitro. It has been documented that nanoformulations, and espe-
cially lipid nanoformulations, increase the bioavailability of poorly soluble drugs as well as 
rendering them less cytotoxic (Muller and Keck, 2012). It will, however, be important to 
identify and possibly quantify the amount of drug absorbed into the bloodstream. An absorp-
tion study to determine bioavailability and a drug release study could be investigated. This 
could be achieved using CaCo-2 cell lines in vitro and a rat model for the in vivo study. With 
regards to the viability of the cell lines after being exposed to the nanoformulation, other 
methods of viability could be added to support findings, in addition to the MTT assay used. 
Western blot analysis on cell death as well as cell cycle markers for apoptosis could be used 
to reinforce these results. Additionally, the cells can be exposed the cells to diabetogenic 
conditions e.g. cytokines or strptozotocin, thereafter exposed to the plant extract to 
investigate the recovery of the cells in a pro-diabetic stimuli. 
 
The in vivo study with the peripheral tissues could be supported with the genetic analysis of 
selected genes in pancreatic tissue. Insulin expression can be investigated to explore the ef-
fects adipose tissue adipokines, as well as the peripheral tissues, have on insulin sensitivity of 
the pancreatic β-cells. Furthermore, inflammatory markers such as IL-6, TNF-α and IL-1β 
could be investigated in the INS-1E cells, exposed to conditioned medium as well as in the in 
vivo obese, insulin-resistant model after treatment with the extract and marrubiin, since the 
levels of these inflammatory markers are hugely affected in T2D. Blood serum levels, as well 
as genetic analysis of these biomarkers, could provide evidence of the anti-diabetic potential 
of the extract and marrubiin. These findings will further support the anti-diabetic potential of 
the L. leonurus extract and marrubiin. Concurrently, the nanoformulated forms of the extract 
and marrubiin could be investigated in all the aspects mentioned. 
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GSIS is facilitated by glucose uptake and its metabolism, which results in an increase in the 
ratio of ATP/ADP and the closure of the ATP-sensitive K
+
 channels, resulting in depolarising 
the cell membrane potential (Vmem) and the stimulation of insulin exocytosis by Ca
2+
 influx 
through voltage-dependent Ca
2+
 channels (Komatsu et al., 2013; Affourtit et al., 2011). Thus, 
the intracellular Ca
2+
 concentration and the cell membrane potential of the INS-1E cells could 
be investigated with treatment of the CM to assess whether the altered electrical behaviour of 
INS-1E cells with the extract and marrubiin treatment is paralleled by a rise in intracellular 
Ca
2+
 (Schmidt et al., 2013). Also, a GSIS experiment showing the chronic, basal and stimu-
lated insulin levels, as well as the insulin content, could give a true reflection of the insulin 
secretion potential. The result obtained could be further confirmed by the stimulatory index 
of the GSIS experiment.  
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10 APPENDIX  
 
Figure A1. A standard curve of commercial marrubiin obtained from RP-HPLC using 
acetonitrile:water (50:50) as mobile phase. The area underneath the peak of each concentration was 
used to construct the standard curve. Marrubiin concentration (0.025 – 0.25 µg/ml) was used for the 
standard curve. Error bars represents an average of three readings. (r
2
 = 0.983) 
 
Figure A2. An example of a PCR standard curve for the gene of interest. The figure shows primer set 
for resistin mRNA expression. 
 
Figure A3. Insulin standard curve for the determination of an unknown insulin concentrations 
in a sample well (r² = 0.9768). The equation y=1.3846x-1.1838 was used for the calculation 
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of the unknown insulin concentrations secreted by cells. Error bars indicate the SD of n=3 
experiments.  
 
 
Figure A4. Nitrate standard curve for the determination of nitrates. Error bars represents 
standard deviation of n=3 experiments (r² = 0.9988).  The equation y = 0.0043x was used to 
determine the unknown concentrations.  
 
 
Figure A5. A MTT standard curve of Chang liver cells for the normalization of cell numbers 
for glucose uptake experiment (r² = 0.9661).  
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